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Abstract 
Abnormal expression of the eukaryotic translation elongation factor 1A (eEF1A) has 
been implicated in disease states such as motor neuron degeneration and cancer. Two 
variants of eEF1A are found in mammals, named eEF1A1 and eEF1A2. These two 
variants are encoded by different genes, produce proteins which are 92% identical 
but have very different patterns of expression. eEF1A1 is almost ubiquitously 
expressed while eEF1A2 is expressed only in specialised cell types such as motor 
neurons and muscle.  
A spontaneous mutation in eEF1A2 results in the wasted mouse phenotype which 
shows similar characteristics in the mouse to those seen in human motor neuron 
degeneration. This mutation has been shown to be a 15.8kb deletion resulting in the 
complete loss of the promoter region and first non coding exon of eEF1A2 which 
completely abolishes protein expression.  
The main aim of this project was to further investigate the role of eEF1A2 in motor 
neuron degeneration.  
Firstly, although the wasted phenotype is considered to be caused by a recessive 
mutation, I established a cohort of aged heterozygote mice to evaluate whether any 
changes are seen later in life that might model late onset motor neuron degeneration. 
A combination of behavioural tests and pathology was used to compare wild type 
and heterozygous mice up to 21 months of age. Whilst results indicate that there is 
no significant difference between ageing heterozygotes and wildtype controls, there 
is an indication that female heterozygote mice perform slightly worse that wildtype 
controls on the rotarod (a behavioural test for motor function).  
Secondly, I aimed to investigate the primary cause of the wasted pathology by 
generating transgenic wasted mice expressing neuronal eEF1A2 only. This would 
complement previous experiments in the lab which studied transgenic wasted mice 
expressing eEF1A2 in muscle only. Unfortunately the expression of eEF1A2 in the 
transgenic animals was not neuronal specific. However a transgenic line with 
 
     xix 
expression of eEF1A2 in neurons and skeletal muscle but not cardiac muscle has 
been generated which clearly warrants further investigation. 
Thirdly, I wished to assess whether eEF1A2 has any role in human motor neuron 
degeneration. To achieve this, eEF1A2 expression was investigated in spinal cords 
from human motor neuron disease (MND) patients. Preliminary data suggests that 
motor neurons from some MND patients express significantly less eEF1A2 than 
motor neurons of control samples. Further work is required to confirm these findings.   
Finally, I investigated the individual roles of eEF1A1 and eEF1A2 in the heat shock 
response. I used RNAi to ablate each variant separately in cells and subsequently 
measured the ability of each variant individually to mount a heat shock response. 
Results indicate a clear role for eEF1A1 but not eEF1A2 in the induction of heat 
shock. This may explain in part why motor neurons exhibit a poor heat shock 
response as they express eEF1A2 and not eEF1A1.    
These experiments shed light on our understanding of the role of eEF1A2 in motor 
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                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 1: Introduction 1 
1. Chapter 1: Introduction 
1.1.  Eukaryotic Elongation Factor 1A (eEF1A) 
1.1.1.  Translation 
Each stage of protein synthesis is precisely regulated, to produce the correct protein 
in the correct amounts at the correct time. The translation of mRNA into protein 
occurs in three main stages: 1. initiation, which involves the correct placement of the 
RNA within a ribosome, 2. elongation where peptides are sequentially added to a 
growing peptide chain in accordance with the sequence of codons of the mRNA, 
3.termination; denoted by the presence of a stop codon in the mRNA sequence being 
positioned in the peptidyl (P) site of the ribosome thus resulting in the release of the 
mRNA from the ribosome. The reactions at all three stages are promoted by protein 
factors i.e. initiation factors (IFs), elongation factors (EFs) and release factors (RFs). 
 
1.1.2. The elongation factors 
There are known to be three main players in the translation elongation process in 
eukaryotes; eukaryotic elongation factor 1A (eEF1A), eukaryotic elongation factor 
1B (eEF1B) and eukaryotic elongation factor 2 (eEF2). The roles of each have been 
investigated, however eEF1A has been the most heavily studied. Diagramatic 
representation of the role of eEF1A in translation can be seen in figure 1.1. It is 
thought that eEF1A is responsible for the recruitment of amino acyl tRNAs to the 
ribosome acceptor (A) site (Hershey 1991). eEF1A binds guanosine triphosphate 
(GTP) and in this GTP-bound state, interacts with amino acyl transfer RNA (tRNA) 
to recruit it to the ribosome A site (Merrick 2000). The interaction between the 
mRNA codon and anticodon on the tRNA triggers hydrolysis of GTP by the 
ribosome, resulting in  eEF1A bound to guanosine diphosphate (GDP) being released 
from the ribosome (Pape et al., 1998).  eEF1A-GDP is incapable of binding another 
tRNA molecule and so requires a guanine nucleotide exchange factor, which 
exchanges GDP for GTP to regenerate the active eEF1A-GTP. This role is 
undertaken by the elongation factor eEF1B which consists of three subunits: alpha 
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(α), delta (δ) and gamma (γ) (Le Sourd et al., 2006). eEF1Bα and eEF1Bδ are 
thought to fulfil the GTP exchange role while eEF1Bγ is usually considered a 
structural subunit. Following the release of GDP bound eEF1A from the ribosome, 
eEF2 translocates the peptidyl tRNA from the ribosome A-site to the ribosome P-site 
by one codon.  The GTP-dependent step results in the movement of the ribosome 
along the mRNA strand. Like eEF1A, eEF2 bound to GDP is released from the 
ribosome in the inactive state following hydrolysis at the ribosome (Rodnina et al., 
1997).  
Figure 1.1. Diagramatic representation of the role of eEF1A in translation. 
This image is taken from Abbott and Proud 2004 (Abbott and Proud 2004). In brief, 
eEF1A recruits tRNAs to the ribosome in a GTP dependent reaction. eEF1B acts as 
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1.1.3.  eEF1A: a tale of two variants 
Eukaryotic elongation factor 1A (eEF1A, previously called eEF-1α) is the second 
most abundant protein in the cell after actin (Slobin 1980; Derventzi et al., 1993; 
Condeelis 1995), accounting for 3-5% of the cell’s total protein (Lee et al., 1993). 
The crucial role of this elongation factor is highlighted  in yeast, where deletion of 
eEF1A is thought to be lethal (Cottrelle et al., 1985). It is therefore assumed that a 
lack of eEF1A would be incompatible with life in higher organisms.   
eEF1A exists in two variant forms in mammals named eEF1A1 and eEF1A2 
(originally referred to as S1 after its antigenic similarity to statin (Ann et al., 1991)). 
These variants are encoded by different genes on completely separate chromosomes. 
In human, EEF1A1 is found on chromosome 6 at 6p14 while human EEF1A2 is 
found on chromosome 20 at 20q13.3.  In mouse Eef1a1 is located on chromosome 9  
while  Eef1a2 is located on chromosome 2 (Lund et al., 1996). While multiple 
pseudogenes exist for EEF1A1, EEF1A2 appears to exist as a single copy (Lund et 
al., 1996). Both proteins are highly conserved among mammalian species with 
mouse and human eEF1A2 only differing by 1 amino acid (Lee et al., 1994).  
eEF1A2 does however appear to be a specific variant in vertebrates as it has been 
found in all mammals investigated and also in chicken and xenopus but not in 
Drosophila (Lund et al., 1996). 
The separate genes give rise to similar transcript length (1.8-1.9Kb) and encode 
proteins of the same molecular weight (50KDa) that are 92% identical at the amino 
acid level and 98% similar (Knudsen et al., 1993).  While the amino acid sequences 
display a large amount of homology, the same cannot be said for the 5’ and 3’ 
untranslated regions which only share 20% homology (Ann et al., 1991; Lee et al., 
1992). This observation led to the idea that these two genes are differentially 
regulated which was quickly confirmed by mRNA and protein analysis  
At the whole tissue level eEF1A1, which is present throughout development is 
expressed almost ubiquitously with the exception of adult muscle. eEF1A2 in 
contrast is developmentally controlled and is expressed only in the brain, spinal cord 
and in muscle (Lee et al., 1992; Knudsen et al., 1993; Lee et al., 1995). Additionally, 
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in those tissues where eEF1A2 is expressed, eEF1A1 is downregulated postnatally 
(Lee et al., 1993; Lee et al., 1995). It has been shown that in skeletal muscle and 
heart eEF1A1 expression begins to decline around 7 days postnatal until it is 
undetectable by 21 days. In contrast eEF1A2 expression is minimal at birth but 
increases steadily until  at 21 days it is the sole eEF1A variant detectable in muscle 
(Chambers et al., 1998; Khalyfa et al., 2001). eEF1A1 levels remain constant 
throughout development in tissues that don’t express eEF1A2 e.g. liver (Lee et al., 
1993).  
This variant switch can also been seen at the cellular level. In brain tissue a subtle 
decrease in total eEF1A1 is seen following birth, however expression does not totally 
disappear (Pan et al., 2004). This is due to the variety of cell types within the brain, 
as different cells within the central nervous system express different eEF1A variants. 
Motor neurons and Purkinjie cells for example express eEF1A2 while glial cells 
express eEF1A1 (Khalyfa et al., 2001; Newbery et al., 2007). eEF1A2 expression in 
the brain is restricted to mature, terminally differentiated neurons following a switch 
in eEF1A variants (as seen in muscle and heart) (Pan et al., 2004).  Prior to postnatal 
day 7, eEF1A1 is the primary variant expressed in neurons however by postnatal day 
20 eEF1A2 is the primary variant present. eEF1A2 has also more recently been 
found to be expressed in specific cells within other tissues (where expression at the 
whole tissue level is not detected by western blot) e.g. ganglion cells in the retina, 
glucagon expressing cells in the Islets of Langerhaans and enteroendocrine cells in 
the crypts of the small intestine (Newbery et al., 2007). However, the expression of 
eEF1A1 has yet to be investigated in these cells thus the effect of the loss of eEF1A2 
in these cells cannot yet be determined. 
 At the cellular level the two eEF1A variants are almost always exclusively 
expressed. The only occasions when both have been observed within the same cell 
type is during tumorgenesis and in cultured cells.  
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1.1.4. Why two variants? 
The reason for the existence of two variants and the developmental switch in some 
cells is as yet undetermined. The only known difference in their roles in translation 
elongation is that eEF1A2 has a lower GDP disassociation rate than eEF1A1 (Kahns 
et al., 1998) which may slow translation down, resulting in increased translational 
fidelity. Yeast-2-hybrid experiments suggest that while eEF1B binds eEF1A1, 
eEF1A2 has no detectable affinity for eEF1B (Mansilla et al., 2002) and as such 
eEF1B may not in fact be the guanine exchange factor for eEF1A2.  However, to our 
knowledge, this has not been tested in other experimental systems. 
While they have almost indistinguishable roles in elongation, the two isoforms may 
have varying roles in other cellular mechanisms. The observation that the presence of 
eEF1A2 in addition to eEF1A1 can transform cells and give rise to tumours supports 
different functional properties of the two variants (Tomlinson et al., 2005). In 
addition to its role in translation eEF1A1 has been implicated in numerous other 
cellular processes such as cytoskeletal rearrangement (Murray et al., 1996), apoptosis 
(Duttaroy et al., 1998), nuclear transport (Chuang et al., 2005; Khacho et al., 2008), 
proteasomal-mediated degradation (Chuang et al., 2005) and the heat shock response 
(Shamovsky et al., 2006). Whether eEF1A2 has a role in any of these processes has 
yet to be fully established, as many studies don’t distinguish between the two 
variants. This is largely because many commercially available antibodies recognise 
both variants equally.  
The separate roles of eEF1A1 and eEF1A2 in apoptosis however, have been 
investigated. While eEF1A1 has been shown to be pro-apoptotic in cultured 
myotubes, eEF1A2 which is shown to be upregulated during differentiation acts in 
the opposite way by protecting cells from apoptosis (Ruest et al., 2002). Differences 
in their non-canonical functions may therefore account for the presence of two 
variant forms.  
While brain, heart and muscle are very different tissues with different functions, they 
all contain cells with similar properties, which may account for the expression of 
eEF1A2 and not eEF1A1. eEF1A2 mRNA accumulation correlates with the 
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formation of terminally differentiated (i.e. post mitotic) neurons and myocytes during 
in vivo neurogenesis and myogenesis respectively (Lee et al., 1993). It is therefore 
believed that eEF1A2 is switched on once cells complete the terminal differentiation 
process. The requirement for enhanced translational fidelity in these terminally 
differentiated cells (Lee et al., 1992) may be one reason for the specific expression of 
eEF1A2 and not eEF1A1. It has also been shown that eEF1A2 is highly expressed in 
serum starved NIH3T3 cells (which don’t normally express eEF1A2), in the Go stage 
of the cell cycle but on serum stimulation expression of eEF1A2 declines (Ann et al., 
1991). Thus a quiescent state appears also to be a factor for eEF1A2 expression. It 
should also be noted that muscle cells have been shown to express eEF1A1 following 
injury and then revert back to eEF1A2 expression once the repair process is complete 
(Carlson et al., 2002; Khalyfa et al., 2003).  
All three tissues (brain, muscle and heart) contain cells which are fully differentiated 
and non-proliferating, with large cytoplasmic volume and a stable shape. An 
attractive hypothesis would be that eEF1A2 is required in terminally differentiated, 
quiescent cells such as myocytes and motor neurons, to undertake its translational 
role (like eEF1A1) without the additional roles undertaken by eEF1A1 which may be 
detrimental to such cells such as apoptosis or cytoskeletal rearrangement. 
 
1.1.5. Translation factors in disease 
Translation factors have been implicated in a variety of diseases. Mutations in the 
eukaryotic inititation factor 2B (eIF2B) for example have been found to be a 
causative in the neurological condition Leukoenphalopathy with vanishing white 
matter (VWM) (Leegwater et al., 2001). While no mutations of eEF1A1 have been 
implicated in disease, it is overexpressed in some cancers. eEF1A2 has been shown 
to be a proto-oncogene with high levels of eEF1A2 protein being observed in 
approximately 63% of breast tumours (Tomlinson et al., 2005) and 30% of ovarian 
tumors (Anand et al., 2002), tissues that would otherwise show no expression of 
eEF1A2. Interestingly while overexpression is linked to tumorgenesis, a deletion of 
the promoter of eEF1A2 has been shown to cause the wasted phenotype in mice 
(details below) which are studied as a model of motor neuron degeneration. 
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Mutations in mitochondrial elongation factors have also been shown  to cause 
disease such as fatal mitochondrial encephalomyopathy (Smeitink et al., 2006). To 
our knowledge no release factors have been found to have a causative effect in 
disease. 
 
1.1.6. The wasted mouse 
In 1972 the Jackson lab published information on a spontaneous mutation which 
arose in their HRS/J stock. This mutation was named wasted (wst) and was originally 
thought to be a model for ataxia telangiectasia (Shultz et al., 1982). Further 
investigation however has led to the belief that it is in fact a more useful model for 
the early stages of human motor neuron disease (Lutsep and Rodriguez 1989; 
Newbery et al., 2005).   
It has been shown by our lab and others that the mutation is a 15.8kb deletion in the 
promoter region of the gene for the translation elongation factor eEF1A2 (Chambers 
et al., 1998). The deletion completely removes the promoter region and the non 
coding first exon which results in complete loss of eEF1A2 protein. No other gene is 
present in the deleted region, and transgenic experiments have concluded that the 
wasted phenotype is caused purely by the loss of the gene encoding eEF1A2  
(Newbery et al., 2007). 
Mice homozygous for the deletion develop normally until around 21 days of age 
where they start to show progressive neuromuscular decline, including tremors, un-
coordinated gait and severe weight loss (largely attributed to loss of muscle bulk 
(Newbery et al., 2005)) and usually die by 28 days (Shultz et al., 1982). This timing 
is thought to be unaffected by genetic background or environmental changes (Abbott 
et al., 1994). A photo of a wasted mouse can be seen in figure 1.2. 
From a neuropathological perspective, motor neurons in the spinal cord of wasted 
mice show numerous similarities to motor neurons from the early onset stages of 
human motor neuron disease (often referred to as amyotrophic lateral sclerosis 
(ALS)) patients. As in ALS,  neurons in the spinal cord of wasted mice show signs of 
vacuolation, which is accompanied by increased gliosis (indicated by an increase in 
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reactive astrocytes) and neurofilament accumulation in the neuronal cell body. 
Seventeen day old wasted mice show progressive retraction of neurons from motor 
endplates at the thoracic level, extending to the lumbrical level by 23 days of age 
(Newbery et al., 2005). This observation in addition to the weak synaptic 
transmission at 23 days at the thoracic level and 25 days at the lumbrical level shows 
that disease progresses along a rostrocaudal gradient in the spinal cord. In addition, a 
decline in performance on the rotarod is observed from 21 days (Newbery et al., 
2005). In contrast to human disease no motor neuron loss was initially observed in 
wasted mice (Lutsep and Rodriguez 1989), however our  lab have demonstrated that 
vacuolation of motor neurons is common  at disease end stage (Newbery et al., 
2005). As disease progression in wasted mice occurs over a much shorter period of 
time to that of human disease, many later pathological findings of human disease 
may not have manifested in this short time. Wasted mice are therefore a useful model 
for the early pathological stages of motor neuron degeneration.  
Wasted mice also exhibit immunological defects not normally seen in other models 
of motor neuron degeneration such as atrophy of the spleen, thymus and lymph 
nodes (Shultz et al., 1982). The spleen to body weight ratio of wasted mice is less 
than half that of wildtype animals by 28 days (Shultz et al., 1982). No expression of 
eEF1A2 is observed in either rat or mouse spleen (Lee et al., 1992; Chambers et al., 
1998) suggesting that atrophy is likely to be a secondary characteristic of the disease 
in these animals possibly due to stress.   
Symptom onset coincides with the developmental switch in the eEF1A variants. At 
birth muscle tissue expresses high levels of eEF1A1. This declines over time until 
eEF1A1 is eventually replaced by eEF1A2 which gradually increases from 7 days 
postnatal. By approximately 21 days eEF1A2 has taken over from eEF1A1. In 
wasted mice however eEF1A2 is not expressed. Wasted mice retain the genetic 
regulation of eEF1A1 and thus once the levels of eEF1A1 have disappeared there is 
no eEF1A2 to take over, which is presumed to result in no protein synthesis in these 
tissues, although this hasn’t been investigated to our knowledge. This pattern in 
expression is closely linked to the timing of synaptogenesis in the rat (Aghajanian 
and Bloom 1967). It was therefore possible that eEF1A2 either has a role in 
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synaptogenesis or is only required following synaptogenesis. It has recently been 
shown that eEF1A2 is essential for the prevention of pre-synaptic degeneration 
(Murray et al., 2008). 
Investigation of the wasted mouse has therefore improved our understanding of the 

















Figure 1.2. Photograph of a wasted (wst/wst) and wildtype (+/+) mouse. 
A wasted mouse (wst/wst, left) with a wildtype littermate control (+/+, right). Photo 
courtesy of  Dr Helen Newbery.   
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1.1.7. A role for eEF1A in spinal muscular atrophy (SMA) 
Spinal Muscular Atrophies (SMA) are characterised by degeneration of lower motor 
neurons in the anterior horn (Markowitz et al., 2004). Proximal- SMA (usually 
referred to as SMA) is an autosomal recessive condition, caused by deletion of, or 
mutations in the Survival Motor Neuron-1 (SMN1) gene on human chromosome 
5q13 resulting in low level expression of the full length SMN protein (Lefebvre et 
al., 1995; Lefebvre et al., 1997). The SMN1 gene encodes a ubiquitously expressed 
38kDa protein with highest levels of expression found in brain, spinal cord and liver 
(Coovert et al., 1997). While the major cause of SMA is the loss of expression of full 
length SMN, potential modifiers such as the zinc finger protein ZPR1 may also play 
an important role in disease.  
ZPR1, which is expressed at low levels in SMA patients (Helmken et al., 2003), may 
affect the severity of the disease. ZPR1 was identified as a zinc finger protein 
necessary for translocation of SMN to the nucleus (Gangwani et al., 2001). Reduced 
expression of ZPR1 in mice heterozygous for  ZPR1
-/+ 
(generated by disrupting one 
ZPR1 allele) show signs of neurodegeneration including motor neuron degeneration 
and loss in addition to axonal defects  (Doran et al., 2006). Another gene located in 
the same region as SMN1 is SMN2 which expresses a truncated form of SMN protein 
that does not interact with as many factors as the full length protein including ZPR1 
(Gangwani et al., 2001). It is the loss of the full length SMN protein that is the major 
cause of SMA.  
eEF1A has been found in a complex with ZPRI and SMN, however the specific 
variant involved has yet to be determined. It is thought that the interaction of ZPR1 
with eEF1A is essential for cell proliferation (Gangwani et al., 1998). Upon mitogen 
treatment ZPR1 binds directly to eEF1A (Gangwani et al., 1998) and assembles into 
multi protein complexes with SMN (Gangwani et al., 2001). It has also been 
demonstrated that axonal degeneration in wasted mice correlates with a decrease in 
ZPR1 expression (Murray et al., 2008). Investigating the role of this complex and the 
interactions between the proteins within it are therefore potentially important for our 
understanding the role of eEF1A in motor neuron degeneration. 
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1.2.   Motor neuron disease 
1.2.1. Introduction 
Due to their complex nature, neurodegenerative diseases are often poorly understood. 
A classic example of this is the motor neuron (or neurone) diseases, the most 
common of which is amyotrophic lateral sclerosis (ALS) otherwise known as Lou 
Gehrig’s disease (named after a famous baseball player who suffered from the 
condition). ALS, first described by neurologist Jean-Martin Charcot in 1869, is a 
highly complex disorder with a variety of symptoms, age of onset and disease 
progression. The complexity and heterogeneity of ALS has resulted in little progress 
being made in both understanding the disease and in its prevention and treatment. 
The primary hallmark of ALS is the selective degeneration of both upper and lower 
motor neurons, leading to muscle atrophy, weakness and paralysis (Pasinelli and 
Brown 2006). Respiratory failure is typically the cause of death, which usually 
occurs within 5 years of symptom onset. The mean age of onset is between 50 and 65 
years of age, although juvenile forms are also seen. The incidence of disease is 
around 1-2 per 100,000 (Boillee et al., 2006; Pasinelli and Brown 2006) and at any 
given time, approximately 5,000 individuals in the UK and 30,000 in the US are 
affected by the condition (Bruijn et al., 2004). The cause of most cases of ALS is 
unknown and no effective treatments are currently available. 
 
1.2.2. Pathology 
ALS is a progressive neurodegenerative disease involving mainly motor neurons in 
the cerebral cortex, brain stem and spinal cord. The common distinguishing feature 
of ALS is the selective vulnerability of motor neurons, which involves both upper 
motor neurons (run from the brain to the spinal cord) and lower motor neurons (run 
from the spinal cord to muscle). In some motor neuron diseases, such as the 
childhood motor neuron disease spinal musclular atrophy (SMA), only loss of lower 
motor neurons is observed. In ALS loss of motor neurons is accompanied by reactive 
gliosis (Nagy et al., 1994; Fujita et al., 1998), neurofilament accumulation (Munoz et 
al., 1988) in the neuronal cell body and ubiquitinated inclusion within motor neurons 
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(Leigh et al., 1988; Leigh et al., 1991), features often seen in mouse models of the 
disease (discussed below). 
Understanding the selective vulnerability of motor neurons in these diseases is one of 
the great challenges facing researchers in neurodegenerative conditions, especially 
given that many of the genes (described below) involved in ALS are often 
ubiquitously expressed. Distinguishing features of motor neurons include their large 
somatic diameter (approx 50-60µm) and very long axonal processes (some up to a 
meter in length). These features of motor neurons would suggest high energy demand 
and metabolic rate, which may be a contributing factor to their vulnerability (Shaw 
and Eggett 2000).  
Understanding the reason for the selective vulnerability of motor neurons is key to 




Approximately 10% of ALS cases are inherited (often referred to as FALS (Familial 
amyotrophic lateral sclerosis)) and the remaining 90% are of unknown cause (often 
referred to as SALS (Sporadic amyotrophic lateral sclerosis)). In terms of clinical 
and pathological features FALS and SALS are largely indistinguishable.  
Of those cases presenting with FALS, approximately 20% are due to a dominant 
mutation in the Superoxide dismutase 1 (SOD1) gene (Rosen et al., 1993). Until 
recently much of the research on ALS has focused on understanding the pathology of 
SOD1 mutations and developing and analysing transgenic SOD1 models. SOD1 
mutations may only account for a small proportion (approximately 2%) of all ALS 
cases, however given the pathological similarities between FALS and SALS it was 
hypothesised that studying models of FALS may identify pathological mechanisms 
common to both FALS and SALS. In addition to SOD1, family-based linkage studies 
have identified 12 loci and 8 genes for ALS alone, and three loci for ALS with 
frontotemporal dementia (FTD, reviewed by Dion et al (Dion et al., 2009)).  Defects 
in genes such as angiogenin (Greenway et al., 2006), alsin (Hadano et al., 2001; 
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Yang et al., 2001) dynactin (Puls et al., 2003), synataxin (Chen et al., 2004) and 
VAPB (VAMP (vesicle-associated membrane protein) – associated protein B) 
(Nishimura et al., 2004) have been identified as being causative of various forms of 
ALS, but for many years investigating the pathology of SOD1 mutations has 
dominated the motor neuron disease research field. This all changed in 2006 with the 
identification of a new candidate gene in ALS: TDP-43. 
In 2006 the 43kDa Tar (Transactive response) DNA-binding protein TDP-43 was 
found to be a major constituent of ubiquitinated inclusions in patients with FTD and 
ALS (Arai et al., 2006; Neumann et al., 2006). Ubiquitination of misfolded proteins, 
forming aggregates within cells of the central nervous system, is a key hallmark of 
neurodegenerative disease. TDP-43 is a highly conserved, ubiquitously expressed, 
predominantly nuclear protein. It is believed to be involved in RNA processing 
through the repression of transcription and regulation of splicing (Buratti et al., 2001; 
Buratti et al., 2004; Mercado et al., 2005).  
In patients with ALS, TDP-43 is depleted from the nucleus and is instead found 
redistributed in the cytoplasm of affected cells, where it is sequestered in a 
phosphorylated form into insoluble aggregates (Neumann et al., 2006). While TDP-
43 is predominantly expressed in the nucleus, some shuttling between the nucleus 
and cytoplasm has been shown (Ayala et al., 2008). Recent evidence suggests that 
the cytosolic localisation of TDP-43 observed may represent a response to neuronal 
injury, with nuclear localisation being restored following recovery (Moisse et al., 
2009a; Moisse et al., 2009b).  
The discovery of TDP-43 in ubiquitinated inclusions has led to the identification of 
more than 30 dominantly inherited mutations in TDP-43 that so far account for 1-3% 
of all ALS cases (Reviewed in Lagier-Tourenne and Cleaveland (Lagier-Tourenne 
and Cleveland 2009)). The identification of mutations in TDP-43 that result in 
neuronal toxicity supports a pathophysiological role for TDP-43 aggregation in ALS. 
However, abnormal TDP-43 pathology is not observed in all ALS patients. It appears 
that FALS associated with mutant SOD1 do not show abnormal distribution of TDP-
43 (Mackenzie et al., 2007). Consistently with this finding, SOD1 transgenic mice 
also fail to show TDP-43 positive inclusions (Robertson et al., 2007). It is as yet 
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unclear whether it is the loss of normal function of TDP-43, or gain of a toxic 
function, that is causative of disease pathology. 
The discovery of TDP-43 as a major player in ALS led in quick succession to the 
identification of another DNA/RNA binding protein implicated in ALS; FUS (fused 
in sarcoma) or TLS (translocated in liposarcoma) (Kwiatkowski et al., 2009; Vance 
et al., 2009). Normally expressed in the nucleus, FUS/TLS (like TDP-43) is thought 
to be involved in the regulation of transcription and RNA splicing (Ou et al., 1995; 
Yang et al., 1998). Mutations in the gene encoding FUS/TLS results in the 
mislocalisation of FUS/TLS in the cytoplasm, and as with mislocalisation of TDP-
43, FUS/TLS protein is also found to be sequestered into cytoplasmic aggregates 
(Kwiatkowski et al., 2009; Vance et al., 2009).  While the similarities between the 
abnormal expression of TDP-43 and FUS/TLS are clear, FUS/TLS positive 
inclusions are in fact negative for TDP-43 (Vance et al., 2009), implying that the 
FUS/TLS disease pathway may be independent of that of TDP-43.  
Together, the discovery of these key factors in neuronal degeneration highlights 
common pathways in the pathogenesis of ALS, despite the involvement of 
potentially different genes and proteins. The importance of the role of protein 
localisation, aggregate formation and RNA processing have become clear not only in 
ALS but also in other neurodegenerative conditions. The SMN protein, for example, 
has also been shown to have a role in mRNA splicing (Pellizzoni et al., 1998). The 
generation of cellular and animal model systems to identify the precise roles of these 
newly identified players in ALS, will provide further insight into disease progression, 
and may identify possible pathways for therapeutic intervention in the future.  
 
1.2.4. Models of MND 
In additional to the wasted mouse model (described previously in section 1.1.5.1), 
numerous other models of motor neuron degeneration are under investigation, 
including both spontaneous models and those generated by genetic manipulation. 
Investigating multiple models is crucial for understanding common, and often 
fundamental, disease processes. The oldest spontaneous model is the wobbler (wr)  
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mouse where homozygous expression of the mutant wobbler gene wr causes motor 
neuron death in the cervical section of the spinal cord (Mitsumoto and Bradley 
1982). Genetically modified models have been developed for many of the genes 
implicated in ALS, such as ALS2 (Cai et al., 2005) and dynactin (Laird et al., 2008). 
The most heavily studied animal models for ALS are the transgenic superoxide 
dismutase 1 (SOD1) models. Numerous transgenic SOD1 models have been 
generated by the expression of mutant human SOD1. These include the most 
commonly studied G93A (substitution of glycine at position 93 for an alanine) 
(Gurney et al., 1994), A4V (Gurney et al., 1994), G37R (Wong et al., 1995) and 
G85R (Bruijn et al., 1997) mutations. The pathogenesis of each line is subtly 
different (due to different mutations and the level of mutant SOD1 expression), 
however common pathological features include vacuolar degeneration of motor 
neurons, followed by motor neuron loss and gliosis (Dal Canto and Gurney 1995).  
These pathogical features coincide with hind limb weakness, developing to complete 
limb paralysis.  Pathology in these mice closely mimics human disease. 
To date, the majority of ALS research has been focused on the SOD1 transgenic 
models, under the assumption that SALS and SOD1-mutant ALS are pathologically 
similar. However, given the biochemical distinction of mutant SOD1 and non-SOD1 
cases, as highlighted by TDP-43, this now needs to be re-addressed. This may 
explain in part the so far ineffective transfer of therapeutic strategies from ALS 
mouse models to human disease (Ludolph and Sperfeld 2005; DiBernardo and 
Cudkowicz 2006). While mutations in SOD1 and TDP-43 show similar clinical 
phenotypes, different pathways may be being disrupted, but with the same 
conclusion – motor neuron degeneration. Both spontaneous and genetically modified 
models of neurodegeneration should continue to be fully investigated to attempt to 
identify the common pathological pathways in human disease. While not all models 
will be ideal, each may provide new information on common mechanisms that, when 
disrupted, cause damage to motor neurons. Utilising information from multiple 
models will therefore improve our overall understanding of motor neuron biology, 
which is crucial to understanding the pathogenesis of motor neuron disease. 
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1.2.5.  Pathogenesis: A role for RNA processing 
Following the identification of SOD1 as the first familial ALS gene to be identified 
(Rosen et al., 1993), much research has been dedicated to understanding the disease 
mechanisms caused by SOD1 mutations. As a result much of what we know about 
pathogenesis of ALS has stemmed from research on SOD1 models. Many diverse 
processes have now been implicated in ALS, and given the highly variable nature of 
the disease, it is likely that multiple factors and pathways influence disease. Possible 
pathogenic causes include oxidative stress excitotoxicity, disruption in axonal 
transport and mitochondrial dysfunction (reviewed in (Bruijn et al., 2004; Boillee et 
al., 2006; Cozzolino et al., 2008; Tovar et al., 2009)). The identification of disrupted 
TDP-43 and FUS/TLS expression in ALS has now highlighted the important role of 
disrupted RNA processing in ALS. Investigations have shown that many of the genes 
so far implicated in ALS appear to have some role in one or more stages of RNA 
processing, including splicing (TDP-43 (Buratti et al., 2001; Mercado et al., 2005) 
and FUS/TLS (Yang et al., 1998)), RNA transport and stability (TDP-43 (Strong et 
al., 2007), FUS/TLS (Zinszner et al., 1997), SOD1 (Lu et al., 2007; Li et al., 2009)) 
and both transcription (FUS/TLS (Wang et al., 2008b), ANG (Xu et al., 2002), TDP-
43 (Ou et al., 1995)) and translation (ANG (Saxena et al., 1992) , TDP-43(Wang et 
al., 2008a)). It is possible that the vulnerability of motor neurons is therefore partly 
due to susceptibility to RNA processing defects as the central nervous system (CNS) 
is thought to contain more alternatively spliced variants than other tissues (Yeo et al., 
2004).  
 
1.2.6.  Heat Shock in motor neuron degeneration 
The heat shock response is simply a defence mechanism adopted by cells in response 
to a wide variety of cellular insults. Stress stimuli such as significant temperature 
changes or infection result in varying degrees of protein misfolding. The cells 
respond to these stresses by upregulating molecular chaperones known as heat shock 
proteins (HSPs) or stress proteins to try and reduce toxicity. These HSPs act as 
molecular chaperones and are responsible for the refolding of damaged proteins or 
the targeting of severely damaged proteins for degradation (Reviewed by Muchowski 
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and Wacker 2005 (Muchowski and Wacker 2005). The HSP family is a large 
collection of chaperones, some of which are constitutively expressed while others are 
inducible and thus only detectable following stress. HSPs are simply named, based 
on their mass in kilodaltons (KDa) e.g. HSP70 is 70kDa, and have been classified 
into 6 main families HSP100, HSP90, HSP70, HSP60, HSP40 and the small HSPs 
e.g, HSP27.  
The reason for the selective vulnerability of motor neurons to stress is one of the 
great unanswered questions in neurodegenerative disease research. One possible 
cause of their vulnerability could be that motor neurons have a high threshold for 
induction of the heat shock response (Batulan et al., 2003).  The exposure of primary 
spinal cord cultures to heat shock, glutamate excitotoxicity or expression of mutant 
SOD1 does not result in the upregulation of HSP70. Other neuronal cells such as 
cortical neurons and astrocytes however do upregulate HSP70 in response to stress 
(Lowenstein et al., 1991; Bechtold et al., 2000; Batulan et al., 2003).  The impaired 
ability of motor neurons to activate HSPs may lead to an increase in misfolded 
protein. Terminally differentiated neurons are particularly vulnerable to 
accumulation of misfolded proteins as they are unable to dilute the toxic effect by 
cell division. Therefore the disruption of the stress response pathway may lead to 
aggregation of misfolded proteins within cells, a hallmark of some neurodegenerative 
diseases including intracellular neurofibrillary tangles in Alzheimers (Selkoe 2001), 
intracellular α-synuclein positive Lewy bodies in Parkinson’s disease (Spillantini et 
al., 1997),  and TDP-43 positive inclusion in FTD and ALS (Neumann et al., 2006).  
The accumulation of HSPs, such as HSC70, in mutant SOD1 inclusions in ALS and 
in transgenic models has been demonstrated and is thought to contribute to disease 
(Watanabe et al., 2001). Mutations in HSPs have also been implicated in 
neurodegenerative disease e.g. a mutations in the gene encoding HSP27 have been 
shown to cause Charcot-Marie-Tooth (CMT) (Evgrafov et al., 2004) and distal motor 
neuropathy (Irobi et al., 2004). 
Research into HSPs could therefore increase our understanding of the role of 
misfolded proteins in neurodegenerative disease and also may prove a valuable 
resource for therapeutic intervention.    
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1.3. Project aims 
The main aim of this project was to increase our understanding of the role of eEF1A, 
particularly the muscle and motor neuron specific variant eEF1A2, in motor neuron 
degeneration. To achieve this, four separate avenues of research were conducted. 
Firstly, to investigate whether there is a gene dosage effect of eEF1A2, an ageing 
cohort of wasted heterozygotes (+/wst) were examined for signs of motor neuron 
degeneration. Secondly, to further investigate the primary cause of the pathology 
observed in wasted mice, transgenic animals expressing eEF1A2 under the control of 
tissue specific promoters were generated and studied. Thirdly, to observe whether 
eEF1A2 has a role in human motor neuron disease, eEF1A2 expression in spinal 
cords of patients with motor neuron disease were compared to spinal cords from 
control patients. Finally the role of eEF1A1 and eEF1A2 in the heat shock response 
was investigated to address whether they have similar or different roles in the heat 
shock response, which could potentially identify an important functional difference 
between the two variants. Together these projects will improve our understanding of 
the role of eEF1A2 in motor neuron degeneration.  
Recent studies have shifted the research of neurodegenerative disease toward factors 
involved in RNA processing, where eEF1A2 clearly has a role. Its function in 
translation combined with its role in the pathology of a mouse model for motor 
neuron disease, makes it an ideal candidate for further investigation. Understanding 
the biology of eEF1A and the pathogenesis of the wasted mouse will thus improve 
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2. Chapter 2: Materials and Methods 
2.1. Materials 
Unless otherwise stated, all general laboratory chemicals were obtained from Sigma-
Aldrich Ltd or Fisher Scientific Ltd. All polymerase chain reaction (PCR) primers 
were ordered from Sigma-Aldrich and all cell culture reagents were obtained from 
Invitrogen. Unless otherwise stated all dilutions were performed using distilled water 
(dH2O). Recipes for buffers and solutions can be found in table 2.1. 
 
25% AMPS Working stock: 25g of Ammonium Persulphate 




5.5M Betaine  Working stock: 7.43g dissolved in 10mls dH20. 
Stored at        -20
o
C 
Cell freezing media 90% FBS (v/v) and 10% DMSO (v/v), made fresh 
immediately before use.  
Citric Acid 
 
Working solution: 2.1g of citric acid dissolved in 
1L dH2O. pH to 6.0.  
Deoxyribonucleoside 
triphosphates (dNTPs) 
Working mix: was prepared by diluting dATP, 
dCTP,dGTP, dTTPs in equal measure to 2.5mM in 
dH2O.  
10x DNA sample loading 
buffer 
Glycerol (Invitrogen) was diluted to 30% (v/v) in 
dH2O. 100mg of Orange g powder was added per 
50ml of 30% glycerol. 
EDTA 0.5M 186.1g Ethylenediaminetetraacetic acid (BDH 
laboratories) diluted in 1L of dH2O (pH8.0) 
Lithium Carbonate 5g of lithium carbonate dissolved in 1L of dH2O. 
LB (Luria-Bertani) medium 1.0% (w/v) Tryptone, 0.5%(w/v) Yeast Extract, 
1.0% (w/v) NaCl dissolved in dH2O (pH 7.0). 
Autoclaved and stored at 4
o
C. 
LB (Luria-Bertani) agar 
plates 
LB was prepared as above but 15g/L of agar was 




Microinjection Buffer 10mM Tris (pH8) and 0.1mM EDTA. Buffer was 
filter sterilised before use. 
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4% Neutral Buffered 
Formalin (NBF) 
 
For 1 litre of NBF: 108ml 37% formaldehyde 
diluted in 892ml of dH2O. 4g of monobasic sodium 
phosphate (NaH2PO4) and 6.5g disodium hydrogen 
phosphate (Na2HPO4) was then added.  
Peroxidase blocking solution 2ml 30% H2O2, 10% sodium azide, up to 400ml 
dH2O.  
Phosphate Buffered Saline 
(PBS) 
1 Phosphate Buffered Saline (PBS) tablet was 
dissolved in 100mls of distilled water and 
autoclaved. 
Radioimmunoprecipitaion 
assay (RIPA) Buffer 
 
150mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) sodium 
deoxycholate, 0.1% SDS (v/v), 50mM Tris-HCL in 
dH2O (pH8.0) 1 tablet of complete protease 
inhibitors (Roche) per 10ml aliquot. Store at -20
o
C. 
0.32M Sucrose 10.9g in 100mls dH2O. Separated into 10ml 




EDTA) buffer  
242g Tris, 57.1ml glacial acetic acid, 37.22g EDTA 
in 1L dH2O (pH8.0) 
10x TBE (Tris-Borate-
EDTA) buffer  
108g Tris, 55g Boric acid and 9.3g of EDTA in 1L 
of dH2O (pH8.0).   
Tris-EDTA (TE) 10mM Tris-HCl, 1mM EDTA dissolved in dH2O 
(pH8.0). 
0.5M Tris-HCl 3g Tris-HCl, 50ml dH2O (pH 6.8). Stored at 4
o
C. 
1.5M Tris-HCl 9g Tris-HCl, 50ml dH2O, (pH 8.8). Stored at 4
o
C. 
Western Blocking Buffer 5% (w/v) marvel milk powder, 0.2% (v/v) Tween 
20 in PBS. 
Western Running buffer 10x tris-glycine-SDS buffer (Bio-Rad) diluted 1:10 
in dH2O. 
Western Transfer buffer 10x stock: 30g Tris-HCl, 144g Glycine dissolved in 
1L dH2O. Working stock: 100mls 10x stock, 
200mls Methanol, up to 1L dH2O.  
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2.2. Animal work 
2.2.1. Wasted mice  
Mice were housed in the Biomedical Research Facility (BRF) at the University of 
Edinburgh. All mice were maintained in accordance with Home office regulations. 
They were exposed to 12 hour light/12 hour dark cycles with ad libitum access to 
food and water. Their diet consisted of a standard chow diet. Wasted mice are on a 
mixed although predominantly C3H/HeH and C57BL/6J background.  
 
2.2.2. Generating transgenic mice 
Transgenic mice were generated by Emma Murdoch in the Transgenic unit at the 
MRC Genetics Unit, Edinburgh. In brief 4-5 week old female B6CBAF1/J mice were 
superovulated by injection of 5iu (international units) of Pregnant Mare Serum 
(PMS) between 12-2pm, 2 days prior to mating. This was followed by a further 
injection of 2.5iu of human chorionic gonadotrophin (HCG) 48 hours later. 
Following HCG injection the females were placed with B6CBAF1/J stud males for 
mating. The following morning, successful mating was confirmed by the presence of 
a vaginal plug and the female mice were sacrificed. The 0.5dpc (day post coitum) 
fertilised embryos were flushed from the oviducts into a 37
o
C FHM (Hepes 
Medium). The DNA construct (2ng/µl) was then microinjected into a pronucleus 
(usually the male pronucleus) of the embryos until they swelled. Injected embryos 
were cultured overnight in equilibrated KSOM (Potassium Simple Optomized 
Medium) at 37
o
C, 5% CO2. Healthy 2 cell stage embryos were then selected for 
implantation and implanted into the oviduct of 0.5dpc pseudo-pregnant (by mating 
with vasectomised males) CD1 recipient females of around 6 weeks of age (23-30g 
of weight). 
   
2.2.3. Rotarod testing 
The Rotarod (Bioseb) is a rotating wheel where the time taken for a mouse to fall 
from the wheel is recorded. The time to fall is sensed by magnetic switches and 
recorded immediately on impact by the machine and shown on the display. There are 
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two options with the rotarod; constant speed and acceleration. To achieve constant 
speed the switch is set to “Run” and the speed adjusted to the appropriate speed using 
the speed dial. The rotarod will begin to turn immediately following the switch to 
“run”. This rotarod can achieve between 4-40rpm. If acceleration is required: the 
switch on the left must first be switched to accelerate (at which point the spindle will 
begin to turn at 4rpm), then the time over which the rotarod is required to reach a 
maximum speed is set using the speed dial ( in this study, tests were undertaken at an 
acceleration of 4-40rpm over 5 minutes). To begin acceleration the start button was 
pressed.  The rotarod has 5 separate compartments thus 5 mice can be tested at the 
same time. For training the rotarod was set at a constant speed of 4 rpm. Mice are 
trained for 5 minutes. If testing was to follow training, a 30 minute rest period was 
allowed between training and testing. Mice were tested 3 times in every session with 
a 15 minute rest period in between each test. To conduct the test, the rotarod was set 
to stop and the mice placed on the stationary central spindle.  The levers that stop the 
timers when the mouse lands on them were raised. The switch was moved to 
“accelerate” and the start button hit immediately to initiate acceleration.   
 
2.2.4. Grip strength analysis 
A grip strength meter (Bioseb) was used to measure limb muscle strength. For each 
test readings for front limbs only as well as for all four limbs combined were 
recorded. For forelimbs only mice were raised by the tail and lowered vertically onto 
a wire grid until they grasped the metal grid with both front paws. Once gripping, the 
tail was lowered steadily so mice were in a horizontal position and pulled steadily 
from the grid in one fluid movement until the mouse released its grip. For a four limb 
reading mice were again raised by the tail then placed on the grid so that all four 
paws gripped the grid, before the tail was steadily and horizontally pulled away from 
the grid. The maximum force (Newtons (N)) required for the mouse to relinquish  its 
grip was recorded. The readings were normalised to body weight (g). Each mouse 
was subjected to three trials of forelimbs only and three trials for all four limbs (thus 
6 trials in all) with a 1 minute break in between each trial.  
 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 2: Materials and Methods 23 
2.3. RNAi 
2.3.1. Cell culture 
Cells were grown in 37
o
C incubators, at 5% CO2. Cells were generally cultured in 
T75 flasks and split every 2-5 days when cells were approximately 70-80% 
confluent. Baby Hamster Kidney (BHK) cells were cultured in a 1:1 mixture of 
Dulbecco’s Modified Eagle Medium (DMEM) and Ham’s F12 media supplemented 
with 10% Foetal Bovine Serum (FBS). NSC-34 cells (a hybrid: motor 
neuron/neuroblastoma cell line (Cashman et al., 1992) were cultured in DMEM 
supplemented with 10% FBS. To passage cells, media was first aspirated from the 
cells before washing briefly with PBS.  TrypLE (a trypsin-like enzyme) was added (5 
mls for a T75 flask) and cells returned to 37
o
C for 5 minutes or until cells had 
dissociated from the flask. Following complete cell disassociation, prewarmed 
growth media (equal to the volume of TrypLE used) was added to the cells. The cell 
suspensions were then removed from the flask and centrifuged at 1200rpm for 5 
minutes. The supernatant was removed and the cell pellets were resuspended in fresh 
pre-warmed (37
o
C) cell culture media.  An appropriate volume was then removed 
and added to a fresh flask of pre-warmed media.  Cells were moved to larger flasks 
(T175) when large numbers of cells were required e.g. for RNAi. Cells were tested 
for mycoplasma infection on a monthly basis. Cells were cultured (as required) until 
passage 15 at which point cells were discarded.  
 
2.3.2. Cryostat preservation of cell lines 
Cell stocks were stored long term in liquid nitrogen. To freeze cells for storage they 
were first disassociated from the flasks and centrifuged, as described for passaging 
cells (section 2.3.1). Following centrifugation, supernatant was removed and 
discarded. Cell pellets were resuspended in cell freezing media (Table 2.1) and 
dispensed into 1ml aliquots for freezing. The volume of freezing media used to 
resuspend the pellet was dependent on the size of the flask. For a T75 flask 10ml of 
freezing media was used i.e. 10x1ml stocks could be stored. Samples were then kept 
overnight at -80
o
C before transfer to liquid nitrogen for storage.  
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2.3.3. siRNAs 
All small interfering RNAs (siRNAs) were custom made by Invitrogen. siRNAs 
were designed by copying the relevant eEF1A1 and eEF1A2 sequence into the 
BLOCK-iT RNAi designer software (Invitrogen) and were ranked based on likely 
effectiveness. siRNAs were selected based on their ranking and also on the number 
of base pair differences between eEF1A1 and eEF1A2 at the target site (to ensure 
specificity for one variant). A table of siRNAs used in this study can be seen below 
(Table 2.2). siRNAs were resuspended to a concentration of 100µM and aliquoted 
before storage at -20
o
C, to avoid repeat freeze-thaw cycles. Three different controls 
were used in each experiment; a mock transfection (no siRNA), a non-targetting 
scrambled siRNA (Stealth RNAi negative control duplexes (Invitrogen)) and  
untreated cells. 
Target siRNA name Sequence (sense) 
Hamster eEF1A1 Ha1A1-1 UUUACUUCUGUUACGUUGACUG 
Hamster eEF1A1 Ha1A1-2 AAGAAGCUGGAAGAUGGCCCUAAAU 
Mouse eEF1A1 m1A1-a UGACAAUCCAGAACAGGAGCGUAGC 
Mouse eEF1A1 m1A1-b AAGUGGAGGGUAGUCAGAGAAGCUC 
Mouse eEF1A2 m1A2-a UUAACGGACACAUUCUUCACAUUGA 
Mouse eEF1A2 m1A2-b CAAUCUUGUACACAUCCUGCAGAGG 
Table 2.2. siRNAs used in this study.  
 
2.3.4. Nucleofection 
A nucleofector system (Amaxa) was used to transfect the cells with siRNAs. Kit V 
(Amaxa/Lonzo) was used for NSC-34 cells and Kit L for BHK cells, following the 
manufacturer’s instructions. In brief, cells were cultured in flasks to around 80% 
confluency on the day of transfection. 100µl of cell suspension was added to 9.9 mls 
of Isotone before counting cells using a Coulter Counter Z (Beckman coulter). 1x10
6 
cells per well were centrifuged at 1200rpm for 5 minutes. Cell pellets were then 
resuspended in nucleofector reagent (100µl per well). 100µl of cell suspension 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 2: Materials and Methods 25 
together with 2µg of siRNA were moved to a cuvette (supplied with the kit). The 
cuvette was placed in the nucleofector and the selected programme was initiated. The 
programme used for BHK cells was A031. Multiple programmes were tested for 
NSC-34 cells, none of which were deemed effective. Immediately following 
electroporation the cuvette was removed from the machine, and 500µl of pre-warmed 
(37
o
C) media was added to the cells. The entire cell suspension was then moved to 
the appropriate well on a 6 well plate, containing 2.5ml of pre-warmed media. Plates 
were mixed by gentle rocking and then incubated at 37
o
C overnight before heat 
shock was performed.  
 
2.3.5. siLentFect 
siLentFect (Bio-Rad) reagent was used for the transfection of siRNAs into NSC-34 
cells, following the manufacturer’s instructions. Unlike nucleofection, siLentFect 
transfection was performed in the plates the cells were grown in. In brief cells were 
plated in 12 well plates to approximately 50-70% on the day of transfection. Growth 
media was aspirated, and replaced with fresh media prior to transfection. siRNAs 
were diluted in serum free media and mixed with siLentFect (also diluted in serum 
free media) so that the final concentration of siRNA in each well would be 10nM. 
Following a 20 minute incubation at room temperature the siRNA/siLentFect 
mixture was added directly to the cells and mixed by gentle rocking. Cells were 
incubated overnight at 37
o
C before heat shock.  
 
2.3.6. Heat Shock 
Prior to heat shock, growth media was aspirated and replaced with fresh media. All 
cells were moved to a separate incubator for heat shock, followed by a recovery 
period in a 37
o
C incubator for 16 hours (overnight). BHK cells were heat shocked for 
2hrs at 42
o
C and NSC-34 cells for 2 hrs at 43
o
C unless otherwise stated. Following 
recovery, cells were disassociated from the wells as previously described (section 
2.3.1) and centrifuged at 1200rpm for 5 minutes.  The pellets were then stored at        
–20
o
C until required for Western blotting.  
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2.4. Western Blotting 
2.4.1. Protein extraction from cells 
Protein was either extracted from cell pellets immediately following centrifugation of 
the cells (section 2.3.1) or, pellets were stored at -20
o
C and protein was extracted at a 
later time. Cell pellets were resuspended in RIPA buffer (table 2.1) containing 
protease inhibitors. For a sample from a 6 well plate 80µl of RIPA was used for  
pellet resuspension. Volumes were adjusted according to well size. The samples were 
then placed on a rotating wheel at 4
o
C for 30 minutes to completely resuspend the 
pellets. Samples were then centrifuged for 30 minutes at 13,000 rpm at 4
o
C. 





2.4.2. Protein extraction from tissue 
Mouse tissues were dissected, and immediately flash frozen in liquid nitrogen before 
storage at -70
o
C. For protein extraction, the appropriate amount of tissue was excised 
and weighed before being placed in a homogenisation tube (Peqlab) with 0.32M 
Sucrose (table 2.1, 100µl per 10µg of tissue). Tissues were homogenised in a 
Precellys 24 Homogeniser (Precellys). Tubes were then briefly centrifuged to gather 
all the sample at the bottom of the tube and the homogenised tissue was moved into a 




2.4.3. Protein quantification 
The concentration of protein samples were quantified using the DC Protein Assay 
(Bio-Rad), following the manufacturer’s instructions. Samples were measured 
against a standard curve produced by serial dilution of BSA (between 4mg/ml – 
0.1mg/ml) in RIPA buffer (for measuring protein from cell pellets) of 0.32M sucrose 
(for measuring protein from tissue). The absorbance (at 750nM) of the standard 
curve samples and protein samples were measured simultaneously on a microplate. 
5µl of each sample was added to an appropriate well on a 96 well plate in triplicate. 
An appropriate volume of solution A1 was made by adding 20µl of solution S per ml 
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of solution A required. 20µl of solution A1 was then added to each well, followed by 
200µl of solution B. Plates were incubated for 15 minutes at room temperature  
before absorbance was measured using a Microplate reader (BioTek) and the Gen5 
software (BioTek). The absorbance of each BSA standard sample was plotted against 
the known protein concentration to generate a standard curve. The concentration of 
the protein samples in each well was then calculated against the standard curve on 
that plate. Once proteins were quantified they were diluted to a concentration of 
2µg/µl with the appropriate solution (RIPA for cells and 0.32M sucrose for tissue). 
10µl of protein was then added to 10µl of Laemmli loading dye (Bio-Rad) with 
added β-mercaptoethanol, resulting in a final concentration of 1µg/µl. Proteins were 
denatured by heating to 100
o
C for 10minutes before cooling on ice. Samples were 
then ready for loading on a Western blot. 
 
2.4.4. Protein separation 
Proteins were separated on a SDS-PAGE gel using the BioRad Mini PROTEAN 3 
gel apparatus, following the manufacturer’s instructions. Firstly a 10% separating gel 
comprised of the following reagents was made (volumes shown are sufficient for 2 
gels). 
30% Acrylamide   5.2 ml    
1.5M Tris pH 8.8   4 ml    
dH2O     6.68 ml   
20% SDS    80 µl    
TEMED    10 µl    
25% AMPS     40 µl    
 
The reagents were mixed briefly and poured between 2 glass plates (BioRad) to set, 
leaving a 1-2cm gap for the subsequent stacking gel. The gels were then covered in 
dH2O while they set (to prevent them drying out). Once the separating gels had set 
(approximately 45 minutes) a 4.3% stacking gel was prepared as shown below. The 
water covering the separating gel was poured off before the stacking gel solution was 
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added. Combs (BioRad) of the required size were placed in the stacking gel once 
poured. 
30% Acrylamide   1.45 ml   
0.5M Tris-HCl pH 6.8  2.5 ml    
dH2O     5.95 ml   
20% SDS    50 µl    
TEMED    10 µl    
25% AMPS    50 µl  
   
Once the stacking gel was set (approximately 30 minutes), gels were removed from 
the apparatus and moved to a mini TransBlot cell (BioRad) which was then filled 
with Western running buffer (table 2.1). The combs were removed and the wells 
were flushed gently with running buffer using a syringe and needle to remove any 
residual acrylamide that could block the wells. Protein samples (with added loading 
dye) were then added to the wells. The protein samples were run through the gels at 
100v until the loading dye had migrated completely through the gel (approximately 
90 minutes). A protein full range ladder (GE healthcare) was used as a size marker. 
Once the loading dye had run off the bottom of the gel the current was stopped and 
the gels could be removed.  
 
2.4.5. Membrane transfer 
To prepare for membrane transfer, the gels were removed from the tank and placed 
in a container filled with Western transfer buffer (table 2.1). Also placed in this 
buffer were pieces of filter paper (4 per gel (Whatman)), sponges (2 per gel) and a 
piece of Hybond P PVDF membrane (Amersham) per gel of the required size to 
cover the area of interest. Membranes required brief pre-soaking in 100% methanol 
to allow them to absorb the transfer buffer. Following 15 minutes of soaking in 
transfer buffer the gels, membrane, filter paper and sponges were stacked (following 
the manufacturer’s guidelines) and moved to the transfer apparatus filled with 
transfer buffer. Proteins were transferred at 100v (no more than 400mA) for 1 hour at 
4
o
C. Following sufficient protein transfer (indicated by the visible transfer of the 
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ladder on to the membrane) the membranes were removed from the transfer 





2.4.6.  Immunoblotting 
Following blocking, membranes were incubated at room temperature in primary 
antibody, diluted in freshly made Western blocking buffer (optimal concentration of 
antibody and length of incubation can be found in table 2.3). Membranes were then 
washed in PBS (4 x 5minutes) before incubation in the appropriate Horse Radish 
Peroxidase (HRP) conjugated secondary antibody for 1 hour (optimal concentration 
of antibody can be found in table 2.4). Following the secondary antibody incubation, 
membranes were again washed in PBS (4x 5 minutes). Proteins were detected using 
the enhanced chemiluminescence (ECL) detection kit (Amersham Biosciences) and 
exposed to  X-ray film (Scientific laboratory supplies) which was developed using a 
Curix 60 developer (AGFA). 
 
Table 2.3. Optimal dilution and incubation times of primary antibodies used for 
Western blot. 
 
Table 2.4. Optimal dilution of secondary antibodies used for Western Blot. 
Primary antibody Species Supplier Dilution Incubation time 
eEF1A1-1 Sheep Helen Newbery 
(Newbery 2003) 
1:1000 2 hours 
eEF1A2-3 Sheep Helen Newbery 
(Newbery 2003) 
1:2000 2 hours 
HSP70 (HSP72) Mouse Stressgen SPA-810 1:1000 1.5 hours 
GAPDH Mouse Chemicon MAB374 1:30,000 1 hour 
Secondary Antibody Supplier Dilution 
Polyclonal Rabbit anti goat immunoglobulins/HRP DAKO 1:500 
Polyclonal Rabbit anti mouse immunoglobulins/HRP DAKO 1:1000 
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2.4.7.  Re-probing membranes 
Following detection of the protein of interest, GAPDH antibody was almost always 
used on the same membrane as a loading control  Prior to addition of another 
antibody, membranes were blocked again overnight in blocking buffer and then 
blotted as previously described (section 2.4.6). eEF1A1 and eEF1A2 antibodies were 
sensitive to re-probing and as such were always probed first on a membrane. 
GAPDH was always probed last. 
 
2.4.8. Quantification of Westerns 
If quantification was required this was measured using a GeneGnome (Syngene Bio 
Imaging) system. The films resulting from shortest exposure for a given experiment 
were scanned using GeneSnap software (Syngene) and the signal intensity of the 
bands measured using GeneTools software. Readings from the bands of the antibody 
of interest were normalised to readings from the bands of the GAPDH antibody 
(loading control) from the same blot.  
 
2.5. Immunohistochemistry 
2.5.1. Human tissue 
Slides mounted with paraffin embedded human spinal cord sections (4µm thick) 
were received from the Edinburgh Brain bank (courtesy of Dr Colin Smith).  
 
2.5.2. Mouse tissue 
Tissue sections were dissected from mice and transferred to 10x volume of 4% 
neutral buffered formalin (NBF, Table 2.1). All tissues excluding spinal columns 
were stored in NBF for 2-3 days before processing by the Pathology Histology 
service. Following 2 days in NBF, spinal columns were decalcified by placing in   
0.5M EDTA for 5 days, with movement to fresh EDTA being conducted every day. 
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Columns were then moved into fresh NBF for a minimum of 3 days before sending 
for processing by the Pathology Histology service (University of Edinburgh), using a 
Leica tissue processor ASP 300S. Paraffin embedded tissue were then sectioned by 
the Pathology Histology service into 4µm sections and mounted on Superfrost plus 
slides in preparation for immunohistochemistry. Whole brains and spinal columns 
from SOD1 mice were received in NBF (Dr Abraham Acevedo, MRC Mammalian 
Genetics Unit, Hawell.) and treated as above.  
    
2.5.3. Paraffin removal and rehydration of sections 
All paraffin embedded mouse and human tissues were first deparaffinised with 
xylene (2 x 5 minutes) and then rehydrated through an ethanol series: 2 x 5 minutes 
in absolute ethanol followed by 2 x 5 minutes in 70% ethanol. Samples were then 
treated with picric acid (for further removal of residual paraffin) for 15 minutes and 
washed gently in running water for a minimum of 5 minutes. 
 
2.5.4. Antigen retrival 
Antigen retrival was performed by microwave treatment of slides in citric acid (table 
2.1). A single rack of slides would be placed in 1 litre of citric acid and placed in the 
designated microwave. The samples were heated in a microwave for 15 minutes on 
high power. Following this period samples remained in the microwave for another 15 
minutes to cool. Samples were then washed in running water for 5 minutes.  
 
2.5.5. Antibody incubations 
Two methods for the next stages of immunhistochemistry are described below. The 
EnVision system and the Polink system were both used in this project. The method 
used is indicated in the appropriate figure legends in the results chapters. The reason 
for the use of two methods is simply that at the start of the project the EnVision 
system was the system in use in the laboratory. However later in the project the 
EnVision system had been replaced by the Polink system.    
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2.5.6. The EnVision method: DAKO EnVision detection kit  
Following antigen retrival, samples were washed in cold water and loaded with 
Sequenza cover plates into the Sequenza apparatus (Thermo Shandon). Samples were 
washed in PBS for 5 minutes, incubated with 100µl peroxidise blocking solution 
(table 2.1) for 10 minutes to block endogenous peroxidise activity and washed again 
in PBS for 5 minutes. Samples were then treated with goat serum (diluted 1:5 with 
PBS) and incubated in primary antibody diluted in PBS (optimal concentration and 
incubation period for each antibody can be found in table 2.5). Samples were then 
washed in PBS and incubated in 3 drops (100µl) of EnVision Reagent (HRP Rabbit 
& Mouse (DAKO)) before a final wash in PBS (5 minutes). 
 
2.5.7. The Polink method:  POLINK-2 HRP detection system  
Following antigen retrieval, samples were washed in cold water and incubated in 3% 
hydrogen peroxide for 10 minutes on a rocker. Samples were then washed again in 
running water and loaded with Sequenza cover plates into the Sequenza apparatus 
(Thermo Shandon). Samples were then treated with goat serum (diluted 1:5 with 
PBS) for 10 minutes and incubated in primary antibody diluted in PBS (optimal 
concentration and incubation period for each antibody can be found in table 2.5). 
Samples were then washed in PBS (2x 5minutes) and incubated in 100µl of Polink 
Broad Antibody Enhancer (GBI-inc) for 10 minutes. Samples were washed again in 
PBS (2x 5 minutes) before a 10 minute incubation in POLINK Polymer-HRP for 
rabbit and mouse. This final incubation was followed by 2 x 5 minute washes in 
PBS, before visualisation.  
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Table 2.5. Optimal concentration and incubation times of primary antibodies 
used for immunohistochemistry 
 
2.5.8. Visualisation of staining 
For antibody visualisation, a Diaminobenzidne (DAB) kit (Vector) was used. 
Samples were removed from the Sequenza apparatus, sections were covered and 
treated for 2 minutes with DAB and washed in running water. Samples were 
counterstained in haematoxylin for 20 seconds, washed in running water and 
differentiated in lithium carbonate for 10 seconds. A final wash step in water was 
performed before dehydrating slides through an ethanol series (10 seconds in 70% 
ethanol, 10 seconds in absolute ethanol) followed by 3 x 10 second incubations in 
xylene. Slides were mounted with coverslips using pertex and allowed to dry before 
visualisation under a Olympus BX60 light microscope. Images were captured using 
the Cell^D software (Olympus). 
Antibody  Species Supplier Dilution Incubation time 
eEF1A2-3 Rabbit Helen Newbery 
(Newbery 2003) 
1:10 Overnight 
eEF1B-Delta Rabbit Proteintech 
(10630-1-AP) 
1:100 30 minutes 




30 minutes  
GFAP  Rabbit Dako Z0334 1:1000 30 minutes 
GRP78 Rabbit Santa Cruz   
SC-13968 
1:50 30 minutes 
Neurofilament Mouse Dako M0762 1:80 30 minutes 





TDP-43  Rabbit Proteintech 
(10782-2-AP) 
1:200 30 minutes 
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2.6.  Molecular Biology 
2.6.1. Genomic DNA extraction from ear notches 
For identification and genotyping, mice were ear notched at no earlier than 14 days 
of age. Two methods were used for the extraction of genomic DNA from ear 
notches: the sodium hydroxide method and the DNeasy kit (Qiagen) method. 
 
2.6.1.1. Sodium Hydroxide (NaOH) method 
This method was preferred for extraction in non-transgenic studies i.e. for 
genotyping of the Eef1a2 alleles only.  Ear notches were immersed in 300µl of 
50mM Sodium hydroxide (NaOH) and heated at 95
o
C for 10 minutes. 50µl of 1M 
Tris-HCl was then added and the samples were centrifuged at 13,000rpm for 6 
minutes. The supernatant was removed and stored at -20
o
C. 1µl of supernatant was 
used in the genotyping PCR  (shown below). 
 
2.6.1.2. Qiagen DNeasy Blood and Tissue kit method 
For identification of the transgenes, DNA extraction using the DNeasy Blood and 
Tissue kit (Qiagen), was performed following the manufacturer’s instructions.  In 
brief samples were lysed overnight in lysis buffer (Buffer ATL)  and proteinase K at 
56
o
C. The following day, DNA was mixed with buffer AL (with Ethanol) to optimise 
binding conditions before centrifugation and binding to a column. Remaining 
contaminants were removed by two wash steps (buffers AW1 and AW2 containing 
ethanol). DNA was eluted in 100µl of elution buffer (AE buffer). 1µl of each sample 
was used in subsequence PCRs. 
 
2.6.2. Genotyping PCR  
Genotyping PCRs were set up as shown below. For the Eef1a2 alleles, two sets of 
primers were used to target the wildtype (Khalyfa et al., 2001)  and wasted (Newbery 
2003) alleles separately. For transgenic studies, two additional sets of primers were 
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designed to target the transgene and used separately for each sample (TG1 and TG2). 
PCR products were visualised on a 2% (w/v) agarose gel. 
 
Target  Primer Sequence (5’-3’) Product size 
Wildtype 
Eef1a2  
Forward:TAGTGGCTCCTTGGAACAG    
Reverse: CTACTCTCCCTGAATGCCTT 
452bp 













Table 2.6. Genotyping primers and expected product sizes.  
 
 50mM Forward primer  2.5µl  
 50mM Reverse primer   2.5µl  
2.5 mM dNTPs   2.0µl  
Sigma taq buffer   2.5µl 
5.5M Betaine     6.75µl  
dH20     7.25µl 
Sigma Taq    0.5µl 
DNA     1.0µl 
The thermal cycler programme was as follows: Initial denaturation of DNA at 95
o
C 
for 3 minutes followed by 30 cycles of 94
o
C for 1 minute, 57
o
C for 1 minute, and 
72
o
C for 1 minute, followed by a final extension step at 72
o
C for 10 minutes. 
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2.6.3. Genomic DNA extraction from cell pellets  
Genomic DNA (gDNA) was extracted from RAT2 cell pellets (kindly donated by Dr 
Justyna Janikiewicz) using the Qiagen DNeasy blood and tissue kit (Qiagen) 
following the manufacturers instructions (previously described in section 2.6.3 
above). The optional Ribonuclease A (RNAse A) step was completed to increase the 
purity of the sample. Samples were eluted in 100µl of elution buffer and 1µl of this 
was used in subsequent PCRs.  
 
2.6.4. Phusion PCR 
For amplification of the NSE promoter region (from RAT2 cells) for insertion into 
the transgenic construct, and also for colony PCR for the construct the Phusion PCR 
kit (Finnzymes) was used, following the manufacturers instructions. The Phusion kit 
contained all required elements excluding the primers. Primer sequences can be 
found in table 2.6.  PCRs were set up as outlined below and run on a thermocylcer.  
 
Master mix   10µl 
DMSO    0.6µl 
H2O    6.4µl 
Forward primer  1µl 
Reverse primer  1µl 
DNA    1µl 
 
The thermocycler programme was as follows; Initial denaturation of DNA at 98
o
C 
for 30 seconds followed by 30 cycles of 94
o
C for 1 minute, 60
o
C for 1 minute, and 
72
o
C for 1 minute, followed by a final extension step at 72
o
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Primer Target Sequence 5’-3’ 
5’ end of NSE promoter ATCGTAAGCTTGAAACCACAGAGTTTTGGAA 
3’ end of NSE promoter ATCGTACCGGTTCGAGGACTGCAGACTCAG 
5’end of NSE promoter 
with flanking HindIII site 
CTGATGCACAATCGTAAGCTTGAAACCA 
3’ end of NSE promoter 
with flanking AgeI site 
CTGATGCACAATCGTACCGGTTCGAGG 
Table 2.7. Primer sequences for amplifying the NSE promoter.  
Red sequence indicates the restriction site (HindIII: AAGCTT, AgeI: ACCGGT), 
green sequence indictates the NSE sequence, blue sequence indicates the additional 
random nucleotides added. 
 
2.6.5. PCR Purification 
To purify PCR products and to remove residual PCR components that may interfere 
with future applications, the Qiagen QIAquick Spin protocol (Qiagen) was used, 
following the manufacturers instructions. In brief the binding buffer PB was added to 
the PCR reaction (5x the volume of the PCR reaction) and mixed. The mixture was 
then added to a QIAquick column and centrifuged for 1 minute at 13,000rpm to bind 
the DNA to the column. The flow through was discarded and the column washed 
with buffer PE (containing ethanol) and centrifuged for 1 minute at 13,000rpm to 
remove residual contaminants. The DNA was then eluted with 30µl of elution buffer 
(Buffer EB: 10mM Tris-HCl pH8.5) and stored at -20
o
C until required.  
 
2.6.6. Agarose gel electrophoresis  
0.6-2.5% w/v agarose (Invitrogen) was melted in 1xTBE buffer in a microwave. Gels 
were cooled slightly before SYBR Safe (Invitrogen) was added (diluted 1:10,000). 
Gels were then cast into gel trays and combs inserted to create wells in which to load 
the DNA. Once set, gels were moved to an electrophoresis tank and immersed in 
1xTBE buffer before removing the combs. DNA loading dye was added to samples 
(10% of the final volume to be loaded) before loading. The volume loaded into the 
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gel was dependent on the size of the well. Voltage and time required for 
electrophoresis is dependent on expected product size and gel percentage. Product 
sizes were estimated using either a lambda DNA ladder (Invitrogen) or a 1Kb DNA 
ladder (Bioline).  
 
2.6.7. Sequencing 
Prior to sequencing, 5µl of PCR product was purified with 1µl of ExoSap 
(Affymetrix). The samples were then incubated at 37
o
C for 15minutes followed by 
80
o
C for 15 minutes. This was done immediately prior to sequencing and thus only 
the required volume of PCR product for the sequencing reaction was treated with 
ExoSap at any one time. To confirm the sequencing of the NSE-EEF1A2 construct, 
the promoter region and each of the exons were first amplified by Phusion PCR 
before sequencing. The primers used to amplify and sequence regions of interest can 
be found in table 2.8. Primers were designed with the aid of Primer 3 software 
(www.frodo.wi.mit.edu/primer3/).  
Primer name Primer target Primer sequence 5’-3’ 
pUC19/NSE F1 Puc19 → NSE ATGCTTCCGGCTCGTAT 
pUC19/NSE F2 Puc19 → NSE TGTGGAATTGTGAGCGGATA 
pUC19/NSE F3 Puc19 → NSE GAGTCAGTGAGCGAGGAAGC 
NSE/Puc19 R1 NSE → Puc19  TAAATGCCGTGCAATGTGTT 
NSE/Puc19 R2 NSE → Puc19 TGTGTCAGCCATACCACCAT 
NSE/Puc19 R3 NSE → Puc19 AGGGGTTAACGCAGGAAAAT 
NSE FA NSE TGCAGATGGCACACCTAGAG 
NSE FB NSE ATCTGAAGCTGGGGAGAACA 
NSE FC NSE GGCTGGTGGTATAGGAGGA 
NSE FD NSE CTGCAGCTCTTGACTCATCG 
NSE RA NSE CCTTCCTGCCATCACCTTT 
NSE RB NSE CCAGTCTGGGACAAAAAGGA 
NSE RC NSE ACCTCCTCGGCTCTTCTCTC 
NSE RD NSE GAGCAGAGGAGGAGCTCAGA 
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eEF1A2/NSE R1 eEF1A2 → NSE  ACCACGATGTTGATGTG 
eEF1A2/NSE R2 eEF1A2 → NSE  TTTTGCTGGGAGTGTGAGG 
eEF1A2/NSE R3 eEF1A2 → NSE  CTCAACATGGCAGAGTTCCA 
NSE/eEF1A2 F1 NSE → eEF1A2 CTGCAGCTCTTGACTCATCG 
NSE/eEF1A2 F2 NSE → eEF1A2 GGCTGGACAAGGTTATGAGC 
NSE/eEF1A2 F3 NSE → eEF1A2 GAGAGAAGAGCCGAGGAGGT 
eEF1A2 Exon 2 F eEF1A2 intron 1 CCTCACACTCCCAGCAAAAT 
eEF1A2 Exon 2 R eEF1A2 intron 2 AGTTGGGGGTTCCTTCTCAG 
* eEF1A2 Exon 3 F eEF1A2 intron 2 CTGTAACAAGCAGCTCGCAC 
* eEF1A2 Exon 3 R eEF1A2 intron 3 GAGCCAGACTGGGTGAGGG 
* eEF1A2 Exon 4 F eEF1A2 intron 3 GGAGAGGCCTGGAGTGAG 
* eEF1A2 Exon 4 R eEF1A2 intron 4 GTGCCACCTGCCGGTGCCTCG 
* eEF1A2 Exon 5 F eEF1A2 intron 4 AGCAGTACTCCTGGAAGCA 
* eEF1A2 Exon 5 R eEF1A2 intron 5 AGAGATTGGAGACAGCCC 
* eEF1A2 Exon 6 F eEF1A2 intron 5 CTTTGTTGGTTTCCAGGCTC 
* eEF1A2 Exon 6 R eEF1A2 intron 6 GACAGTCCTGCTGCTGTCC 
* eEF1A2 Exon 7 F eEF1A2 intron 6 CCTCCAGTCAGCACTCCGG 
* eEF1A2 Exon 7 R eEF1A2 intron 7 CTGCCATGCTCTGGGCCAAGC 
Table 2.8. Primers for sequencing the NSE-EEF1A2 transgenic construct. 
 * Indicates primers as used in Dr Permphan Dharmasaroja’s thesis (Dharmasaroja 
2007).  
 
The sequencing reagent used was the BigDye terminator ready reaction mix v3.1 
system (Applied Biosciences). Reactions were set up in 96 well plates as follows: 
Template DNA    3µl 
 Primer (forward or reverse)   1.µl  
 Big Dye      1.0µl  
 5x Big Dye Buffer    1.5µl 
 H2O      3µl 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 2: Materials and Methods 40 
Pre-sequencing PCRs were placed in a thermocycler and run on the following 
programme: 96
o
C for 1 minute followed by 24 cycles of 96
o
C for 30 seconds, 50
o
C 
for 15 seconds, and 64
o
C for 4 minutes. Following the sequencing reaction, samples 
were allowed to cool to 10
o
C before removing from the thermocycler. 2.5µl of 
125mM EDTA and 30µl absolute ethanol was added to each well. Plates were sealed 
and inverted 4 times to mix before a 15 minute incubation at room temperature. 
Plates were then centrifuged at 3000rpm for 30 minutes then removed from the 
centrifuge. Seals were removed and the plates were then inverted over a paper towel 
and placed (with the paper towel) in a centrifuge and briefly spun at 1000rpm to 
remove all traces of liquid. 30µl of 70% ethanol was then added to each well. Sealed 
plates were centrifuged again at 3000rpm for 15 minutes. Plates were once again 
inverted over a paper towel and centrifuged (while inverted over a paper towel) to 
remove all traces of ethanol. Once ensuring the wells were dry, plates were sealed 
with adhesive film before being stored at -20
o
C. The samples were then taken to the 
sequencing service at the MRC Human Genetics Unit, University of Edinburgh 
where the process was completed.  Sequencing was analysed using the BioEdit (Hall 
1999) software and alignments checked using ClustalW (Thompson et al., 1994).  
 
2.6.8. Cloning 
Plasmids and constructs were stored in glycerol at -80
o
C. This included the pUC19-
eEF1A2 plasmid (kindly provided by Julia Boyd) and the HSA-eEF1A2 transgenic 
construct prepared by Dr Permphan Dharmasaroja.  
 
2.6.9. Preparation of LB plates 
LB agar (table 2.1) stored at 4
o
C was melted in a microwave until no residual solid 
agar could be seen. The bottle was then cooled to 56
o
C for 30 minutes. Once cooled 
ampicillin was added (100µg/ml) and the LB poured into petri dishes and allowed to 
set at room temperature. A final drying stage in a 37
o
C incubator for 20 minutes was 
performed before plates were ready for use (or storage at 4
o
C). Stored plates were 
pre-warmed for an hour at 37
o
C before use. 
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2.6.10. Bacterial culture 
For production of large quantities of DNA, constructs were taken from already 
transformed E.Coli stored in glycerol at -80
o
C. A spreading loop was flamed, dipped 
into the glycerol stock and streaked on a LB plate with ampicillin (100µg/ml). The 
plate was placed at 37
o
C for approximately 16 hours (overnight) to allow colonies to 
grow. Plates with colonies were stored at 4
o
C for up to 1 month. 
 
2.6.11. Minipreps 
If small quantities of DNA were required e.g. to test the construct, a mini-prep was 
conducted using the Sigma Gene-elute kit (Sigma). Colonies were picked from the 
appropriate plate and grown in 5mls of LB media overnight in a shaker at 200rpm 
and 37
o
C. The following morning the mini-prep could then be conducted following 
the manufacturers instructions. In brief cultures were centrifuged at 13,000rpm for 1 
minute and the supernatant discarded. The pellets were resuspended (resuspension 
solution, with added RNAseA) and mixed well. Cells were then lysed (lysis buffer) 
for up to 5 minutes. Cell debris was precipitated (Neutralisation buffer) and pelleted 
by centrifugation at 13,000rpm for 10 minutes. The DNA (supernatant) was then 
centrifuged through a column (at 13,000rpm for 1 minute), washed (Wash solution to 
remove residual contaminants) and eluted (100µl of Elution Solution). DNA 
concentration (µg/µl) was measured using a Nanodrop (Thermo Scientific). If 
required storing transformed bacterial colonies was achieved by mixing 500µl of 
bacterial culture (from the overnight incubation) with 500µl of 80% glycerol. 
Samples were moved immediately to -80
o
C for storage. 
 
2.6.12. Maxipreps 
If larger volumes of DNA was required e.g. in preparation for microinjection, a 
Qiagen plasmid Maxi-prep kit was used. Colonies were picked from the appropriate 
plate and grown for 5-6 hrs in 5mls of LB media containing ampicillin (100µg/ml) in 
a shaker at 200rpm at 37
o
C. Following this initial incubation, the samples were then 
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diluted 1:1000 into a larger volume, typically 200 mls and left to shake overnight 
(~16hrs) at 200rpm at 37
o
C. The following morning the samples were removed from 
the shaker and the maxi-prep could then be conducted following the manufacturer’s 
instructions. In brief, bacterial cultures were centrifuged at 8000rpm for 15 minutes 
at 4
o
C and the supernatant discarded. Pellets were resuspended (Buffer P1: 50mM 
Tris-HCl (pH8.0) and lysed (Buffer P2: 200mM NaOH, 1% SDS). The sample was 
then neutralized and cell debris precipitated (chilled buffer P3: 3.0M potassium 
acetate pH5.0). Lysates were then purified through a Qiafilter cartridge and bound to 
resin in a Maxi tip. The resin bound DNA was then washed (Buffer QC; 1.0MNaCl, 
50mM MOPS pH7.0, 15%(v/v) isopropanol) and eluted (Buffer QF; 1.25M NaCl, 
50mM Tris-HCl pH8.5, 15% (v/v) isopropanol). DNA was concentrated by 
precipitation with isopropanol and filtered through a Qiaprecipitator. A final wash of 
the Qiaprecipitator with 70% ethanol was conducted before final elution of the 
purified DNA in TE buffer. DNA concentration (µg/µl) was measured using a 
Nanodrop (Thermo Scientific). If required storing transformed bacterial colonies was 
achieved by mixing 500µl of bacterial culture (from the overnight incubation) with 
500µl of 80% glycerol. Samples were moved immediately to -80oC for storage.  
 
2.6.13. Restriction enzyme digests 
DNA digests were carried out at 37
o
C using site specific restriction enzymes. 1 unit 
of each enzyme was used to digest 1µg of DNA for 1 hour with the appropriate 
enzyme buffer (as designated by the supplier). HindIII, KpnI, AgeI (NEB) were used 
in varying combinations. Single enzyme digests were incubated for 1 hour at 37
o
C. 
For double digests, the appropriate buffer was selected based on its compatibility 
with both enzymes. A one hour digest at 37
o
C was conducted initially with one 
enzyme followed by the addition of the second enzyme (and additional buffer and 
dH2O as required) and incubation for another hour at 37
o
C. Enzymes were heat 
inactivated at 72
o
C for 20 minutes immediately following digestion. DNA loading 
dye was added to samples before running on a 0.6% (w/v) agarose gel to assess 
whether the correct products were present. For preparation of the transgenic 
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constructs for microinjection, 50µg of DNA was required. As this is a large volume, 





Ligation was achieved using T4 DNA ligase (Invitrogen) following the 
manufacturer’s instructions. In brief, a ligation reaction was set up which comprised 
of the digested eEF1A2 vector, the digested NSE promoter, T4 DNA ligase (0.1unit) 
and 1X reaction buffer. It was found that the optimal conditions for the ligation 
reaction was to incubate the reaction at 4
o
C overnight using a 4:1 promoter:vector 
ratio. Ligation reactions were then diluted 1:5 in TE buffer prior to transformation. 
 
2.6.15. Transforming competent cells 
DNA constructs were transformed into OneShot TOP10 cells (Invitrogen) following 
the manufacturer’s instructions. In brief 50µl aliquots of competent cells were 
thawed on ice. 4µl of ligation reaction was added directly to the cells and mixed 
gently. Cells were then incubated on ice for 30minutes followed by heat shock at 
42
o
C for 30 seconds. Following heat shock samples were immediately transferred to 
ice for 2 minutes. 250µl of room temperature SOC medium was added to each vial 
and the vials were moved to a shaker set at 37
o
C, 225rpm for 2 hours. Following 
transformation, the cells were plated on LB plates in varying volumes and incubated 
at 37
o
C overnight to allow colonies to grow. Colonies were then screened for the 
presence of the insert.  
 
2.6.16. Colony screening 
To test for the presence of the correct construct in the correct orientation, colony 
PCRs were performed. Colonies were picked from the appropriate plate using a non-
filtered gilson pipette tip, streaked onto a gridded new plate (so that the colony is 
maintained) and then the pipette tip was placed into a PCR in a 96 well plate. Its 
position in the 96 well plate corresponded to its position on the new gridded plate 
(thus each PCR can be easily traced back to its original colony). The primers used to 
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identify colonies containing the entire construct in the correct orientation were 
designed so that they crossed the promoter/gene boundary thus eliminating any non-
ligated products (the same as used for identifying the presence of the transgene – 
table 2.6). Colony screens were performed using the Phusion PCR method (section 
2.6.6).  
 
2.6.17. Construct purification  
To purify constructs for microinjection, the digested 50µg of construct was purified 
by electroelution using the Elutrap apparatus (Whatman) following the 
manufacturers instructions. Following restriction digest, a small amount of construct 
was run on an agarose gel (0.6%) to confirm the digest had worked effectively. A 1% 
Seakem GTG agarose gel (Cambrex bio-science) was then set using 1xTAE buffer 
(diluted with miliQ water) and ethidium bromide (final concentration 0.5µg/ml) for 
visualisation under ultra violet (UV) light. All the remaining construct from the 50µg 
digest was loaded into a single well on the gel and the gel was run at 100V for 2-3 
hours. The gel was viewed by UV light to confirm the construct had separated from 
the plasmid backbone. The construct was then excised from the gel with a scalpel 
and loaded into the elutrap apparatus following the manufacturers instructions. In 
brief, gel slices are placed in the centre of the apparatus, which is then placed 
horizontally in a standard electrophoresis chamber and covered in 1xTAE buffer so 
that the gel slice is completely immersed. On electrophoresis the DNA migrates from 
the gel into a trap area formed by two membranes. Electrophoresis was performed 
overnight at 60V. Following electrophoresis the buffer from the trap area now 
containing the DNA was removed to a fresh tube. The DNA was precipitated in 
sodium acetate (10% of the total volume of the buffer containing the DNA) and 
absolute ethanol (twice the volume of the buffer containing the DNA) on dry ice for 
2 hours. The DNA was then centrifuged at 13,000rpm for 30 minutes at 4
o
C. The 
supernatant was discarded and the pellet washed with 70% ethanol before 
centrifugation for another 5 minutes. The pellet was then resuspended with 
microinjection buffer (table 2.1) and the concentration checked by nanodrop and 
confirmed on an agarose gel. The construct was then diluted to 2ng/µl in 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 2: Materials and Methods 45 
microinjection buffer and purified through a column (Spinex). The construct was 
then ready for microinjection. The preparation of the constructs was completed with 
the aid of Dr Laura Lettice at the MRC Human Genetics Unit (HGU), University of 
Edinburgh.     
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3. Aim Chapter 3: Investigating ageing wasted 
heterozygotes (+/wst) as a possible model for 
motor neuron degeneration. 
3.1. AIm 
The aim of this project was to determine if there is a gene dosage effect of eEF1A2 
in ageing heterozygote wasted mice and whether wasted heterozygote mice develop 
any signs of age related motor neuron degeneration.  To assess if wasted 
heterozygotes could be a model for late onset motor neuron degeneration, a 
combination of behavioural testing and pathological analysis was conducted to look 
for any differences between wildtype and heterozygote animals of greater than one 
year old. These experiments are important for increasing our understanding of the 
wasted mutation and have clear implications for our understanding of the role of 
eEF1A2 in motor neurons, as well as the possibility of providing a new model for 
late onset motor neuron degeneration.  
 
3.2. Introduction 
3.2.1. Why wasted heterozygotes?  
In 2006, Doran et al (Doran et al., 2006) published a study in which they 
investigated 1 year old ZPR1 heterozygous mice for signs of neurodegeneration. The 
results showed that ageing heterozygous mice displayed gradual loss of ZPR1 in the 
brain and degeneration of motor neurons at 12 months of age, indicating that ZPR1 
deficiency causes motor neuron degeneration in ZPR1 heterozygous mice. This 
suggests that these animals could be used as a model for late onset motor neuron 
disease. This coupled with the knowledge that ZPR1 has been shown to interact with 
eEF1A (Gangwani et al., 1998) and survival motor neuron (SMN) proteins 
(Gangwani et al., 2001) (mutations of which are the major cause of spinal muscular 
atrophy) led us to believe that older wasted heterozygote (+/wst) mice should also be 
investigated as a possible model for late onset motor neuron degeneration.   
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To date, wasted heterozygotes have generally been characterised as phenotypically 
normal and have often been used as littermate controls in experiments characterizing 
wasted mice. Due to the early death of wasted mice the eldest wasted and 
heterozygous mice that have been studied are generally less than 1 month old.   
Shown here is the first study examining differences both in behaviour and in 
pathology between wasted heterozygote mice and wild type control mice of greater 
than 1 year old to assess whether wasted heterozygotes may be useful as a model of 
late onset motor neuron disease.  
 
3.2.2. Wasted mice: Behavioural analysis 
A paper published by our group in 2005 (Newbery et al., 2005) involved in-depth 
characterization of the wasted model which included analysis of motor impairment in 
wasted (wst/wst) mice using the accelerating rotarod. Results showed that wasted 
mice performed significantly worse on the rotarod than their littermate controls from 
21 days of age. This coincides with the timing of the developmental switch in eEF1A 
variants and is the age at which symptoms of neuromuscular disease become evident. 
This combined with the fact that the rotarod is viewed as the gold standard for 
detecting motor function deficiencies made it the primary candidate assay for 
assessing behavioural differences between older heterozygote animals and wildtype 
controls. Whereas the rotarod is a test of motor co-ordination another significant 
symptom of wasted mice (and also human motor neuron disease) is progressive 
skeletal muscle atrophy. A test of limb-strength was therefore investigated in this 
study. Although there are multiple ways to measure limb-strength the mechanical 
grip strength meter provides ease of use and no training of mice is required. At the 
beginning of this study grip strength data was collected from wasted mice and 
littermate controls using a grip strength meter to assess the time-point at which any 
difference between wasted mice and controls could first be detected. 
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3.2.3. Wasted mice: Pathological analysis 
The choice of markers to investigate the pathology of wasted heterozygotes came 
from current knowledge of the pathology of wasted mice and more importantly from 
knowledge of pathological changes seen in ALS. Newbery et al (Newbery et al., 
2005) describe the upregulation of  glial fibrillary acidic protein (GFAP) in glial cells 
and also the accumulation of neurofilaments in neuronal cell bodies as hallmarks of 
the pathology in wasted mice. Reactive gliosis, which is characterised by the 
upregulation of GFAP is generally seen in response to neurological disease and has 
been observed in brain and spinal cord of ALS patients (Nagy et al., 1994; Fujita et 
al., 1998). Accumulation of phosphorylated neurofilaments in the perikarya of motor 
neurons has also been reported in ALS patients (Munoz et al., 1988). Antibodies to 
GFAP and neurofilament show distinguishable staining patterns between wasted 
mice and controls therefore these two markers were used in this study to look for any 
signs of motor neuron degeneration in ageing heterozygous mice.  
 
3.3. Results 
3.3.1. Wasted limb strength 
Mice were tested for muscle strength in forelimbs only and then in all four limbs. 
Mice were tested on 1 day only, thus eliminating any potential disadvantage from 
multiple testing. Body weight has to be considered when measuring grip strength. To 
account for this variable all grip strength readings (measured in Newtons) were 
normalised to body weight (measured in grams). Results show that a significant 
difference between wasted mice and controls is observable from 20 days in the 
forelimbs only (figure 3.1 and table 3.1) and in all four limbs (figure 3.2 and table 
3.2).  These results validate the grip strength meter as a useful test for distinguishing 
wasted mice from their littermate controls and thus it was considered a valuable test 
to look for differences between older heterozygotes and wildtypes in the ageing 
cohort.  
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Figure 3.1. Forelimb grip strength analysis of wasted mice 
Mean forelimb grip strength of wasted mice (wst/wst) and both wildtype (+/+) and 
heterozygote (+/wst) littermate controls between 16-25 days old. The daily grip 
strength reading of 3 tests (measured in Newtons) were normalised to body weight 
(grams). P values were calculated comparing wasted mice with controls (+/+ and 
+/wst combined). * indicates a P value<0.05, *** indicates a P value <0.001. 
 
Age Mean +/+ Mean +/wst Mean wst/wst P value 
16 days 0.031 (n=8) 0.034 (n=13) 0.032 (n=3) 0.7737 
17 days 0.034 (n=5) 0.032 (n=9) 0.034 (n=3) 0.7726 
18 days 0.034 (n=6) 0.035 (n=22) 0.035 (n=6) 0.9526 
19 days 0.047 (n=4) 0.052 (n=10) 0.04689 (n=9) 0.1364 
20 days 0.046 (n=13) 0.044 (n=26) 0.034 (n=11) 0.0003 
21 days 0.049 (n=10) 0.048 (n=13) 0.043 (n=9) 0.0221 
22 days 0.055 (n=11) 0.052 (n=25) 0.039 (n=9) 0.0002 
23 days 0.049 (n=13) 0.050 (n=18) 0.037 (n=15) 0.0002 
24 days 0.046 (n=10) 0.050 (n=17) 0.025 (n=8) <0.001 
25 days 0.047 (n=14) 0.050 (n=14) 0.024 (n=10) <0.001 
Table 3.1. Forelimb grip strength analysis of wasted mice.  
Mean forelimb grip strength of wasted mice (wst/wst) and both wildtype (+/+) and 
heterozygote (+/wst) littermate controls between 16-25 days old. The daily grip 
strength reading of 3 tests (measured in Newtons) were normalised to body weight 
(measured in grams). P values were calculated between the wasted group and 
controls (+/+ and +/wst combined) using a t-test.  
Forelimbs only
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Mean grip strength of all four limbs of wasted mice (wst/wst) and both wildtype 
(+/+) and heterozygote (+/wst) littermate controls between 16-25 days old. The 
daily grip strength reading of 3 tests (measured in Newtons) were normalised to 
body weight (measured in grams). P values were calculated between the wasted 










Figure 3.2. Four limb grip strength analysis of wasted mice.  
Mean grip strength from all four limbs of wasted mice (wst/wst) and both wildtype 
(+/+) and heterozygote (+/wst) littermate controls between 16-25 days old. The daily 
grip strength reading of 3 tests (measured in Newtons) were normalised to body 
weight (grams). P values were calculated comparing wasted mice with controls (+/+ 
and +/wst combined). ** indicates a P value<0.01, *** indicates a P value <0.001 
   
Age Mean +/+ Mean +/wst Mean wst/wst P value 
16 days 0.053 (n=8) 0.054 (n=13) 0.059 (n=3) 0.3153 
17 days 0.053 (n=5) 0.058 (n=9) 0.064 (n=3) 0.1383 
18 days 0.051 (n=6) 0.060 (n=22) 0.062 (n=6) 0.4943 
19 days 0.063 (n=4) 0.070 (n=10) 0.062 (n=9) 0.1079 
20 days 0.070 (n=13) 0.065 (n=26) 0.056 (n=11) 0.0080 
21 days 0.074 (n=10) 0.068 (n=13) 0.068 (n=9) 0.6720 
22 days 0.076 (n=11) 0.075 (n=25) 0.062 (n=9) 0.0009 
23 days 0.073 (n=13) 0.076 (n=18) 0.060 (n=15) 0.0004 
24 days 0.079 (n=10) 0.070 (n=17) 0.047 (n=8) <0.0001 
25 days 0.075 (n=14) 0.073 (n=14) 0.043 (n=10) <0.0001 
Table 3.2. Four limb grip strength analysis of wasted mice.  
All four limbs
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3.3.2. The ageing study 
3.3.2.1. Pilot studies 
This project was initially started by Antonia Churchhouse in our laboratory.  Antonia 
tested groups of 1 year old heterozygote males and females (+/wst) and female 
wildtype control mice (+/+) for differences in rotarod performance as an indicator of 
loss of motor function. She showed that at 12 months of age, female heterozygotes 
demonstrated a significant decrease in rotarod performance compared to both 
wildtype females and heterozygote males (data not shown). Unfortunately at the time 
of Antonias project no male wildtype controls were available. Therefore at the start 
of this project, male heterozygote mice and male wildtype mice were tested 
following the same protocol as the previous study. These two data sets combined 
showed that while female heterozygotes showed a significant decrease in rotarod 
performance at 12 months of age when compared to wildtype females, male 
heterozygotes did not differ from wildtype males in rotarod performance at this age.  
The males were then tested again at 15 months of age and at this time, a significant 
difference was observed between male heterozygotes and wild types (data not 
shown). Although poor rotarod performance can be attributable to many factors, 
preliminary immunohistochemistry data (conducted by Antonia) of motor neuron 
numbers in the anterior horn of the spinal cord of these same animals showed a  
decrease in the number of motor neurons in the female +/wst compared to both male 
+/wst and female controls at 12 months of age. This is the first account of any 
observable abnormality in wasted heterozygous mice and therefore warranted further 
investigation. 
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3.3.2.2. The ageing cohort 
As there was never a complete set of suitable mice (male wildtypes, male 
heterozygotes, female wildtypes and female heterozygotes) at any one time, a new 
cohort of ageing male and female heterozygous mice as well as both male and female 
wildtype controls were established.  Four groups of 8 animals were bred (male 
wildtype, female wildtype, male heterozygotes, female heterozygotes) from 3 
breeding pairs. Genotyping data can be seen in figure 3.3.  Mice were selected from 
the first two litters of each breeding pair, thus there were slight differences in age of 
some of the litters but this was no greater than 1 month. For testing purposes the tests 
were conducted when the youngest mice were of the required age. All animals were 
housed in single sex cages but all cages were a mixture of both wildtypes and 
heterozygotes with 2-3 animals in each cage. This was to eliminate any stress that 
may occur in single housed animals. The entire cohort was tested on the same days 
and all tests were carried out in the morning to eliminate any variables that may be 
caused by time of day. Initially these animals were to be tested at tri-monthly 
intervals for motor function using an accelerating rotarod and also for limb strength 
using the grip strength meter. The tri-monthly intervals (at 3,6,9,12,15 and 18 months 
of age) would allow identification of the starting point of any difference between 
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Figure 3.3. Ageing study mouse genotypes. 
Agarose gels (2%) showing genotyping PCR results from all mice in the ageing 
cohort. The top panel shows wildtype animals (+/+) while the bottom panel shows 
heterozygote animals (+/wst). Gels (a) and (b) in both panels show results from 
PCRs of the wildtype (WT) allele (expected size of product: 452bp). Gels (c) and (d) 
in both panels show results from PCRs of the wasted (WST) allele (expected size 
200bp). L indicates a size ladder, +/+ indicates a wildtype control sample, +/wst 
indicates a heterozygous control sample, wst/wst indicates a wasted control sample 
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3.3.2.3. Rotarod testing strategy 
The rotarod is one of the most commonly used tests for motor co-ordination in mice. 
Mice are placed on a rotating beam and their latency in falling from the beam is 
recorded. The rotarod may rotate at a fixed speed or at an accelerating speed. For this 
study, mice were trained for 5 minutes at a constant speed of 4rpm, followed by a 30 
minute rest period, followed by 3 tests at accelerating speed (4-40rpm over 5 
minutes) with 15 minute recovery periods in between each test. Mice were tested on 
alternate days over a fortnight. Test days were Monday, Wednesday and Friday 
during week one then Monday and Wednesday during week two. Thus mice had at 
least 1 day to recover between test days. On purchase of a new rotarod at the 
beginning of this study all mice were unable to walk for even a few seconds without 
slipping from the beam. This is believed to be due to the material from which the 
beam was made having little grip and not due to any neuromuscular problem as our 
mice had no problem performing the task on the previous rotarod. To counteract this 
problem it was deemed necessary to coat the rod in dolls house carpet (kindly 
donated by Prof. Cathy Abbott, purchased from Hamleys). Thus all tests on all 
animals in this study were conducted on the carpeted rotarod. To ensure animals did 
not require extensive re-training at the start of each testing month, between testing 
periods mice were trained once a week for 5 minutes on the rotarod set to a constant 
speed of 4rpm to maintain familiarity with the procedure. To eliminate problems 
with reproducibility between investigators, all rotarod data was collected blind by 
myself however weekly training session were conducted by our technician Jennifer 
Doig.  At the start of each testing session mice were monitored for several minutes 
and weighted to check for any obvious mobility or other health problems. Once mice 
were deemed healthy the training could commence. If however a mouse showed any 
signs of illness they were immediately removed from the study and all data for that 
animal for that given month was excluded. 
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3.3.2.4. Ageing Rotarod Results 
The results on the following pages show all data collected at each of the tri-monthly 
time points up until 15 months of age. As males and females perform differently in 
some behavioural tasks such as the rotarod, and given the data from the pilot study it 
was deemed necessary to separate the data by genotype and also by gender. Figure 
3.4 displays the mean daily fall times for each group while figure 3.5 shows the mean 
monthly fall times for the groups at each tri-monthly time point. As can be seen from 
the graphs in figure 3.5 no significant difference was observed between wildtypes 
and heterozygotes of either gender between the ages of 3-15 months of age. The 
Students t-test was used to confirm this.  As the body weight of the animals could 
potentially affect their rotarod performance, the data were also analysed by 
normalising the mean daily times to body weight (data not shown) although these 
data also showed no significant difference between groups.   
To summarise, no statistically significant difference was observed on the rotarod in 
any of these groups by 15 months of age. However as can be observed from both the 
12 month and 15 month time point graph in figure 3.5 it appears that female 
heterozygotes perform slightly worse than the other 3 groups.  
All data from the first 15 months of the study combined to show overall rotarod 
performance of the group over the initial 15 month period is shown in figure 3.6. As 
can be seen in the graphs, the performance of all four groups appears to decline with 




                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 3: Investigating ageing wasted heterozygotes (+/wst) as a possible 
























Figure 3.4. Daily rotarod data from the ageing study.  
Males: 3 months















































































































































































































































Mean daily times of latency to fall from the rotarod. Left panels show male data 
while right panels show female data. +/+ indicates wildtype animals, +/wst indicates 
heterozygote animals. Error bars represent the standard error of the mean. 
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Figure 3.5. Tri-monthly rotarod data from the ageing study.  
Mean monthly times of latency to fall from the rotarod for each group in the ageing 
study. +/+ indicates wildtype animals, +/wst indicates heterozygote animals. Error 
bars represent the standard error of the mean. 
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 Figure 3.6. Rotarod data between 3-15 months of the ageing study. 
 Mean times of latency to fall from the rotarod over the first 15 months of the ageing 
study. +/+ indicates wildtype animals, +/wst indicates heterozygote animals. The 
upper graph shows data from the male groups and the lower graph shows data from 
the female groups. Error bars represent the standard error of the mean. 
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Due to the nature of animal work, some mice died over the course of the study from 
non-motor neuron related conditions such as cervical prolapse, fighting and tumours. 
This appeared to occur at random in both wildtypes and heterozygotes and thus was 
not considered to be caused directly by differences in eEF1A2 expression. By 15 
months of age only 7 wildtype males, 7 heterozygous males, 5 wild type females and 
5 heterozygous females remained.  
At this stage it had to be decided whether to terminate all animals immediately and 
carry out the histological analysis or to continue the behavioural experiments for 
another few months. To address this issue the spinal cords of the mice that had 
already been removed from the study were analysed to examine whether there was 
any evidence of a difference between groups at the histological level. Given the 
limited number of samples available this analysis was unfortunately inconclusive 
(data not shown).  
As female heterozygotes were beginning to show a decrease in performance 
compared to the other groups at 12 months of age it was decided behavioural 
analysis should continue and that the mice would be kept alive for a few more 
months and analysed on a monthly basis instead of tri-monthly. This would ensure 
that the number of animals in each group would remain sufficient for accurate 
pathological analysis i.e. to minimize the risk of reaching the 18 month time point 
and not having enough animals in any given group for sufficient pathological 
analysis. If the number of animals in any group had fallen to 3 the study would have 
been terminated and pathological analysis undertaken at that time point. This was not 
the case and sufficient numbers survived to 18months. Rotarod analysis was 
therefore carried out at 16, 17 and 18 months of age on the remaining mice. The 
mean daily performance of each group can be seen in figure 3.7 while the mean 
monthly data can be seen in figure 3.8.  
As can be observed in figure 3.8. the rotarod data from 16, 17 and 18 months of age 
showed no statistically significant difference between heterozygotes and wildtypes of 
either gender. However once again it does appear that female heterozygotes perform 
worse than the other three groups at 18 and 21 months, but as before this is not 
statistically significant.  
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Interestingly, when the data for the entire study is combined (figure 3.9) the data 
indicates that during the tri-monthly testing period mice generally perform worse 
with age. However when the behavioural testing becomes more frequent (monthly) 
rotarod performance in all four groups improves (figure 3.9). Learning behaviour 
and/or exercise clearly plays a role in the mice’s performance on the rotarod. The 
weekly five minute training session between the tri-monthly tests are clearly not as 
effective as monthly testing for maintaining the mouse’s ability to perform to their 
maximum ability on the rotarod. This interesting observation combined with the fact 
that female heterozygotes were continuing to perform slightly worse than the 
controls led to the decision to keep the animals alive (under close observation) for 
another three months for one more testing period at 21 months of age. As can be seen 
in figure 3.8 at 21 months, female heterozygotes appear to be performing worse than 
the other groups but similarly this is not statistically significant. Interestingly the 3 
month break from the rotarod halted the increase in rotarod performance seen 
between 15-18 months. In fact it appears that this break has now caused a decline in 
the animals performance (figure 3.9). The mean monthly data for each group at each 
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Figure 3.7. Daily rotarod data from the ageing study at 16-21 months of age.  
Mean daily times of latency to fall from the rotarod. Left panels show male data 
while right panels show female data. +/+ indicates wildtype animals, +/wst indicates 
heterozygote animals. Error bars represent the standard error of the mean. 
Males: 16 months























Females:  16 months
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Figure 3.8. Monthly rotarod data from 16-21 months of the ageing study.  
Mean monthly fall times from the rotarod for each group in the ageing study between 
16 and 21 months of age. +/+ indicates wildtype animals, +/wst indicates 
heterozygote animals. Error bars represent the standard error of the mean. 
 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 3: Investigating ageing wasted heterozygotes (+/wst) as a possible 






















Figure 3.9. Rotarod data over the entire course of the ageing study.  
Mean times of latency to fall from the rotarod over the whole 21 months of the 
ageing study. +/+ indicates wildtype animals, +/wst indicates heterozygote animals. 
The upper graph shows data from the male groups and the lower graph shows data 
from the female groups. Error bars represent the standard error of the mean. 
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a. Male wildtype data 
Age N Mean Min Max S.D S.E.M 
3 months 8 96.23 35.73 160.20 40.89 14.46 
6 months 8 66.01 29.20 140.27 35.06 12.39 
9 months 8 52.93 19.60 133.47 37.38 13.22 
12 months 8 46.32 18.47 109.20 29.40 10.40 
15 months 7 48.37 25.93 128.33 36.48 13.79 
16 months 7 41.78 20.78 109.56 31.40 11.87 
17 months 7 74.13 38.78 97.00 21.58 8.16 
18 months 7 78.63 60.47 112.27 20.52 7.76 
21 months 5 53.40 28.80 110.27 33.54 15.00 
 
b. Male heterozygote data 
Age N Mean Min Max S.D S.E.M 
3 months 8 106.92 41.00 184.87 54.05 19.11 
6 months 8 73.60 26.47 187.27 57.24 20.24 
9 months 8 65.31 25.40 130.73 35.87 12.68 
12 months 8 47.38 19.07 91.00 22.86 8.08 
15 months 8 47.36 21.67 87.13 23.98 8.48 
16 months 8 47.53 19.00 118.00 31.22 11.04 
17 months 7 69.37 49.11 93.78 16.67 6.30 
18 months 7 85.73 39.53 146.33 39.46 14.91 
21 months 6 72.39 37.40 125.60 38.00 15.51 
Table 3.3. Male rotarod data from the ageing study.  
Mean latency to fall (seconds) from the rotarod for both male groups (wildtypes 
(table a) and heterozygotes (table b)) from all time points of the ageing study. N 
indicates the number of animals in the group at any given timepoint, Mean is the 
average fall time of the group over the month, Min is the minimum fall time of an 
individual in the group, Max is the maximum fall time for an individual in the group, 
S.D indicates the standard deviation across the group and S.E.M is a measure of the 
standard error of the mean.  
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a. Female wildtype data 
Age N Mean Min Max S.D S.E.M 
3 months 8 89.12 53.87 179.73 42.21 14.92 
6 months 8 68.67 33.67 153.13 39.15 13.84 
9 months 8 53.61 25.07 133.40 34.17 12.08 
12 months 8 48.40 19.27 90.80 23.54 8.32 
15 months 8 43.13 28.67 65.33 13.92 4.92 
16 months 7 31.57 22.22 48.67 8.65 3.27 
17 months 6 59.44 35.67 112.11 28.47 11.62 
18 months 5 67.95 45.93 126.13 33.48 14.97 
21 months 4 68.18 40.53 115.47 32.66 16.33 
 
b. Female heterozygote data 
Age N Mean Min Max S.D S.E.M 
3 months 8 85.13 54.80 123.47 23.00 8.13 
6 months 8 63.41 40.33 125.07 28.70 10.15 
9 months 8 50.06 24.13 76.27 17.33 6.13 
12 months 7 40.52 25.27 64.00 12.58 4.76 
15 months 5 34.57 30.20 43.27 5.27 2.36 
16 months 5 27.07 19.00 36.22 6.11 2.73 
17 months 5 61.51 51.22 75.56 9.49 4.25 
18 months 5 56.88 46.53 67.67 8.29 3.71 
21 months 3 53.42 42.20 68.33 13.45 7.77 
 
Table 3.4. Female rotarod data from the ageing study.  
Mean latency to fall (seconds) from the rotarod for both female groups (Wildtypes 
(table a) and Heterozygotes (table b)) from all time points of the ageing study. N 
indicates the number of animals in the group at any given timepoint, Mean is the 
average fall time of the group over the month, Min is the minimum fall time of an 
individual in the group, Max is the maximum fall time for an individual in the group, 
S.D indicates the standard deviation across the group and S.E.M is a measure of the 
standard error of the mean.  
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3.3.2.5. Grip strength 
 As a grip strength meter is thought to provide accurate readings of limb strength and 
is also able to accurately detect difference between wasted animals and wildtype 
controls, it was selected as another test for this ageing cohort.   
Mice were tested tri-monthly from 3 months of age to 21 months of age. Readings 
from forelimbs only were taken as well as for all four limbs combined. On a single 
test day three readings were taken from forelimbs only and 3 readings were taken 
from all four limbs. In any given testing month these tests were carried out on the 
Friday of week two of the rotarod test period i.e. two days after the last rotarod test 
day.   
Figure 3.10 (forelimbs only) and 3.11 (all four limbs combined) show the grip 
strength test results of each testing month separately. Mean data for each animal was 
normalised to its body weight before combining the group data. There was no 
significant difference between any of the groups at any time point over the course of 
the study. This was confirmed statistically using the Students t-test. However at 21 
months it appears that female heterozygotes are performing slightly worse than the 
other 3 groups in the forelimb test only.  As can be observed from the combined data 
in figure 3.12 (and also in tables 3.5 and 3.6) up until 15 months age appears to have 
no effect on performance. Between 16-18 months of age however there appears to be 
an increase in performance in all groups. This is most likely due to the increase in 
exercise the animals received during this time period when the frequency of rotarod 
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Figure 3.10. Monthly forelimb grip strength data from the ageing study.  
Mean monthly grip strength from the forelimbs only of the animals in the ageing 
study between 3 and 21 months of age. +/+ indicates wildtype animals, +/wst 
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Figure 3.11. Monthly grip strength data from all four limbs combined from the 
ageing study.  
Mean monthly grip strength from the forelimbs only of the animals in the ageing 
study between 3 and 21 months of age. +/+ indicates wildtype animals, +/wst 
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Forelimb grip strength: males
























Forelimb grip strength: females
























Four limb grip strength: males























Four limb grip strength: females
































Figure 3.12. All grip strength data from the ageing study.  
Collated grip strength data for the entire ageing study. Graphs on the left display 
male data and graphs on the right display female data. Top graphs display forelimb 
data only and the bottom 2 graphs display data from all four limbs. +/+ indicates 
wildtype animals, +/wst indicates heterozygote animals. Error bars represent the 
standard error of the mean. 
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a Male Wildtypes +/+ Male Heterozygotes +/wst 
Age N Mean Min Max S.D S.E.M N Mean Min Max S.D S.E.M 
3 8 0.035 0.031 0.044 0.004 0.001 8 0.035 0.028 0.047 0.006 0.002 
6 8 0.034 0.028 0.040 0.004 0.002 8 0.036 0.028 0.046 0.007 0.003 
9 8 0.036 0.030 0.042 0.004 0.001 8 0.035 0.024 0.045 0.008 0.003 
12 8 0.033 0.025 0.047 0.008 0.003 8 0.036 0.029 0.046 0.008 0.003 
15 7 0.033 0.023 0.040 0.006 0.002 8 0.032 0.027 0.038 0.003 0.001 
18 7 0.033 0.027 0.041 0.007 0.003 7 0.037 0.032 0.042 0.005 0.002 
21 5 0.034 0.026 0.046 0.008 0.004 6 0.033 0.024 0.044 0.008 0.003 
 
b Female Wildtypes +/+ Female Heterozygotes +/wst 
Age N Mean Min Max S.D S.E.M N Mean Min Max S.D S.E.M 
3 8 0.035 0.028 0.046 0.007 0.002 8 0.033 0.019 0.042 0.008 0.003 
6 8 0.037 0.029 0.056 0.008 0.003 8 0.037 0.024 0.057 0.010 0.004 
9 8 0.037 0.029 0.049 0.007 0.002 8 0.031 0.025 0.036 0.004 0.002 
12 8 0.033 0.023 0.045 0.007 0.003 7 0.036 0.023 0.043 0.007 0.003 
15 8 0.031 0.025 0.049 0.008 0.003 5 0.032 0.025 0.038 0.005 0.002 
18 5 0.034 0.030 0.041 0.005 0.002 5 0.031 0.026 0.036 0.005 0.002 
21 4 0.036 0.028 0.048 0.009 0.004 3 0.028 0.027 0.029 0.001 0.001 
Table 3.5. Forelimb grip strength data from the ageing study normalised to 
body weight.   
Forelimb grip strength data from all time points of the ageing study normalised to 
body weight. Table (a) shows data from male groups and table (b) shows data from 
female groups. N= number of animals in the group, Mean = average of group, Min = 
minimum reading of group, max= maximum reading of group, S.D = standard 
deviation, S.E.M = standard error of the mean. 
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a Male Wildtypes +/+ Male Heterozygotes +/wst 
 N Mean Min  Max S.D S.E.M N Mean Min  Max S.D S.E.M 
3 8 0.047 0.040 0.060 0.006 0.002 8 0.049 0.036 0.063 0.008 0.003 
6 8 0.051 0.036 0.058 0.005 0.002 8 0.053 0.035 0.063 0.007 0.003 
9 8 0.048 0.040 0.060 0.006 0.002 8 0.048 0.040 0.066 0.008 0.003 
12 8 0.053 0.042 0.067 0.008 0.003 8 0.055 0.038 0.063 0.007 0.002 
15 7 0.047 0.040 0.061 0.010 0.004 7 0.047 0.040 0.061 0.010 0.004 
18 7 0.061 0.054 0.077 0.010 0.004 7 0.066 0.046 0.082 0.011 0.004 
21 5 0.061 0.051 0.075 0.010 0.005 6 0.056 0.042 0.076 0.014 0.006 
 
b Female Wildtypes +/+ Female Heterozygotes +/wst 
 N Mean Min  Max S.D S.E.M N Mean Min  Max S.D S.E.M 
3 8 0.048 0.035 0.060 0.009 0.003 8 0.049 0.043 0.062 0.007 0.002 
6 8 0.058 0.044 0.082 0.013 0.005 8 0.054 0.041 0.074 0.010 0.004 
9 8 0.051 0.038 0.067 0.010 0.003 8 0.056 0.045 0.073 0.009 0.003 
12 8 0.053 0.045 0.068 0.008 0.003 7 0.056 0.046 0.079 0.011 0.004 
15 8 0.052 0.040 0.060 0.006 0.002 8 0.052 0.043 0.066 0.008 0.003 
18 5 0.063 0.052 0.089 0.016 0.007 5 0.063 0.061 0.065 0.002 0.001 
21 4 0.061 0.049 0.090 0.020 0.010 3 0.059 0.055 0.063 0.004 0.002 
Table 3.6. Four limb grip strength data from the ageing study normalised to 
body weight.  
All four limb grip strength data from all time points of the ageing study normalised 
to body weight. Table (a) shows data from male groups and table (b) shows data 
from female groups. N= number of animals in the group, Mean = average of group, 
Min = minimum reading of group, max= maximum reading of group, S.D = standard 
deviation, S.E.M = standard error of the mean. 
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3.3.2.6. Pathology 
At 21 months the behavioural study was terminated and pathological analysis was 
undertaken on the animals.  
 
Western Blotting 
Protein levels of eEF1A2 in brain, spinal cord and muscle were examined by 
Western blot as seen in figure 3.13. Three examples of each of the four groups were 
selected at random for analysis. All of these animals were from the end stage of the 
study i.e. 21 months of age. As can be seen in figure 3.13 expression of eEF1A2 is 
decreased in heterozygote animals (both males and females) compared to the 
wildtype controls in all three tissue types. The graphs in figure 3.14 show this 
decrease normalised to GAPDH protein as a loading control. In brain male 
heteozygotes express 7.5% of  eEF1A2 compared to wildtype males and female 
heterozygotes express 36% compared to wildtype females. In spinal cord males 
express 45.5% of the level of wildtype males, while female heterozygotes express 
38% of wildtype females. Finally in muscle male heterozygotes express 59% of 
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Figure 3.13. eEF1A2 protein expression in tissues from the ageing cohort. 
Western blots showing protein expression of eEF1A2 and GAPDH (as a loading 
control) of animals from the ageing cohort. Three 21month old animals from each 
group are shown. +/+ indicates wildtype animals, +/wst indicates heterozygous 
animals, M indicates a muscle sample (as an eEF1A2 positive control) and L 





WT Male WT Female   Het Female Het Male M    L 
Male +/+     Male +/wst     Female +/+    Female +/wst 
   Male +/+         Male +/wst       Female +/+      Female +/wst 





WT Male  WT Female    Het Female Het Male 
M    L 
Male +/+     Male +/wst     Female +/+    Female +/wst 
Male +/+     Male +/wst               Female +/+   Female +/wst 
M    L 
a. Brain 
M    L 
GAPDH 37KDa 
eEF1A2 50KDa 
WT Male  WT Female    Het Female Het Male Male +/+     Male +/wst     Female +/+    Female +/wst 
Male +/+     Male +/wst      Female +/+   Female +/wst     L 
1 2 50KDa 
PDH 37KDa 
b. Spinal Cord 
 




                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 3: Investigating ageing wasted heterozygotes (+/wst) as a possible 





Figure 3.14. eEF1A2 protein expression in tissues from the ageing cohort. 
Expression of eEF1A2 protein normalised to GAPDH. +/+ indicates wildtype 
animals, +/wst indicates heterozygote animals. Error bars represent the standard error 
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Immunohistochemistry 
To address whether there may be any differences in the pathology of the spinal cord 
between heterozygotes and wildtype controls, spinal cord sections were examined by 
immunohistochemistry. These experiments were undertaken by James Ding under 
my supervision.  
Sections were stained with an antibody for glial fibrillary acidic protein (GFAP) as a 
marker of gliosis. In wasted mice reactive gliosis is the earliest observable 
abnormality in the spinal cord (Newbery et al., 2005) and an example is shown in 
figure 3.15 panel b. No observable differences were seen in GFAP staining between 
wildtypes and heterozygotes of the ageing study. Examples of each of the 4 groups 
can be seen in figure 3.15 (panels c-f). Unlike younger wildtype animals (figure 3.15 
panel a), these older wildtypes display a significant level of reactive gliosis 
characterised by numerous GFAP positive foci in the grey matter of the spinal cord 
(figure 3.14 c and d). In wasted mice there is a rostrocaudal gradient of gliosis within 
the spinal cord. The cervical region displays increased gliosis compared to the 
thoracic and lumbar levels. Cervical, thoracic and lumbar regions of the spinal cord 
were all examined in this study. However due to the heavy staining in all sections it 
proved difficult to establish any difference between regions of the spinal cord.   
Sections were also stained with an antibody that recognises phosphorylated 
neurofilaments (both light and heavy chain). Typically young wildtype mice show 
little or no staining in neuronal cytoplasm (figure 3.16 panel a), whereas 64-100% of 
motor neurons in the spinal cord of wasted animals show staining of neuronal 
cytoplasm (Newbery et al., 2005) (figure 3.16 panel b). The same level of staining 
was not observed in the heterozygote animals from the ageing study. Occasionally 1 
or 2 neurons were observed that had neurofilament staining (as seen in the female 
heteozygote section in figure 3.16 panel f) but this occurred in both wildtypes and 
heterozygotes. This supports the findings of Newberry et al (Newbery et al., 2005) 
which showed occasional staining of neuronal cytoplasm in control animals. In 
conclusion, no significant differences were observed in the pathology of the spinal 
cords from wildtype and heterozygote animals from the ageing study. 
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Figure 3.15. GFAP expression in the spinal cord of animals from the ageing 
study. Cervical spinal cord sections from animals from the ageing study stained with 
an antibody recognising glial fibrillary acidic protein (GFAP). Section (a) is a section 
from a 24 day old wildtype animal, (b) is a section from a 24 day old wasted animal 
as a positive control. (c-e) show examples of each of the four groups of the ageing 
study all of which show characteristic staining of reactive astrocytes throughout the 
grey matter of the spinal cord (arrowed) The larger panels are at 4x magnification 
showing the entire spinal cord section while the smaller panels are a x20 
magnification of anterior horn section.  These results were obtained using the 
POLINK method.  
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 3: Investigating ageing wasted heterozygotes (+/wst) as a possible 
model for motor neuron degeneration 77 
 
Figure 3.16. Phosphorylated neurofilament expression in the spinal cord of 
animals from the ageing study.  
Cervical spinal cord sections from animals from the ageing study stained with an 
antibody recognising phosphorylated neurofilaments. Section (a) is from a 24 day old 
wildtype (+/+), (b) is a section from a 24 day old wasted (wst/wst) animal as a 
positive control. (c-e) show examples of each of the four groups of the ageing 
cohorts. The larger panels are at 4x magnification showing the entire spinal cord 
section while the smaller panels are at x40 magnification of anterior horn section.  
These results were obtained using the POLINK method. 
←
←
a. +/+  
c. Male +/+ 
e. Male +/wst f. Female +/wst 
d. Female +/+ 
b. wst/wst 
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Spinal cord sections were stained with an antibody recognising eEF1A2 to crudely 
count the motor neurons of the anterior horn section of the spinal cord.  Figure 3.17 
shows examples of spinal cord staining with the eEF1A2 specific antibody. No 
significant difference was observed in eEF1A2 staining between wildtypes and 
heterozygotes of either sex in these sections.  
The motor neuron counts were conducted blind by 2 separate individuals each with 
some experience of examining sections of spinal cord.  When counting, the 
investigators marked on images which cells were counted as motor neurons so any 
discrepancies could be checked. An example of one such image is shown in figure 
3.18. The anterior horn section was divided by drawing a straight line from the 
central canal to the most central anterior point of the spinal cord. Another line was 
then drawn perpendicular to this.  Motor neurons were counted in the area between 
these lines as shown in figure 3.18. This region is defined as in Fischer et al (Fischer 
et al., 2004). The images for this analysis were prepared by James Ding under my 
supervision. No significant differences were observed in motor neuron numbers 
between wildtypes and heterozygotes at any region of the spinal cord (table 3.7). The 
graphs (figure 3.19) do show however that heterozygotes (both male and female) 
show slightly reduced numbers of motor neurons in the thoracic and lumbar regions 
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Figure 3.17. eEF1A2 expression in the spinal cord of animals from the ageing 
study.  
Cervical spinal cord sections from animals from the ageing study stained with an 
antibody recognising eEF1A2. Section (a) is a section from a 24 day old wildtype 
animal, (b) is a section from a 24 day old wasted animal as a negative control. (c-f) 
show examples of each of the four groups of the ageing study. The larger panels are 
at 4x magnification showing the entire spinal cord section while the smaller panels 
are a x20 magnification of anterior horn section (except for sample (a) where the 
smaller panel is at x10).  These results were obtained using the EnVision method. 
f. Female +/wst 
d. Female +/+ 
e. Male +/wst 
c. Male +/+ 
b. wst/wst a. +/+  
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Figure 3.18. An example of a motor neuron count.   
An example of how counts were conducted for the motor neuron counts. Counts 
were conducted in one anterior horn of each section. Each motor neuron was marked 
with a red dot as seen in the image.  The black arrow shows the position of the 
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Figure 3.19. Motor neuron numbers from the spinal cords of the ageing cohort. 
Mean motor neuron counts from spinal cord sections from the ageing cohort. +/+ 
indicates wildtype animals, +/wst indicates heterozygote animals, Error bars 
represent the standard error of the mean. 
 
Table 3.7: Motor neuron numbers from the spinal cords of the ageing cohort. 
 
Group Section     N Mean Min Max SD SEM 
MALE +/+ Cervical 6 30.25 17 45 9.42 3.85 
 Thoracic 6 33.25 16 49 12.62 5.15 
 Lumbar 4 26.25 19 38 8.43 4.22 
MALE +/wst Cervical 5 32.6 29 37 3.83 1.71 
 Thoracic 6 29.1 25.5 37.5 4.55 1.86 
 Lumbar 4 14.4 10 32 9.64 4.82 
FEMALE +/+ Cervical 2 26 21 31 7.07 5.00 
 Thoracic 3 36.7 38 56.5 9.57 5.53 
 Lumbar 1 29 29 29 N/A N/A 
FEMALE +/wst Cervical 2 30.5 29.5 31.5 1.41 1.00 
 Thoracic 2 33 32.5 33.5 0.71 0.50 
 Lumbar 1 15 15 15 N/A N/A 
Mean motor neuron counts from spinal cord sections from the ageing cohort. +/+ 
indicates wildtype animals, +/wst indicates heterozygote animals N= number of animals 
in the group, Mean = average of group, Min = minimum reading of group, max= 
maximum reading of group, S.D = standard deviation, S.E.M = standard error of the 
mean. 
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3.3.3. The second ageing study 
A possible explanation for the fact that no significant difference was observed in the 
ageing cohort could be that the repeated exposure to the behavioural test was 
somehow masking any difference. This is discussed further in the discussion section 
of this chapter.  
A second cohort of animals was therefore tested. These animals had not been 
exposed to the any tests in the past. An 18 month old cohort consisting of 3 wildtype 
males, 3 heterozygous males, 3 wildtype females and 4 heterozygote females were 
tested on the rotarod and with the grip strength meter. These animals were tested as 
in the ageing study with 5 rotarod tests over a fortnight, with tests being conducted 
on alternate days.  
Female heterozygote animals appear to perform worse than the controls on both the 
rotarod (figure 3.20) and the grip strength meter (figure 3.21). This difference 
however, is not statistically significant.  
A 12 month old cohort of females was also tested (no males of the correct age were 
available). This cohort consisted of 2 wildtype females and 5 heterozygote females.  
Heterozygote females again appear to perform worse than wildtype females on the 
rotarod (figure 3.22) and on the grip strength meter (figure 3.23) but once again this 
difference is not statistically significant.  
The rotarod data from this most recent 12 month old female cohort was combined 
with the data from Antonia’s pilot study. As different rotarod were used in these 2 
studies the data was initially expressed as the mean difference between wildtypes and 
heterozygotes before combining the two data sets (figure 3.24). These combined 
results show that heterozygote females at 12 months show a 33% decreased 
performance compared to wildtype females. 
 
 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 3: Investigating ageing wasted heterozygotes (+/wst) as a possible 
model for motor neuron degeneration 83 
Females: 12 months


























































Figure 3.20. Rotarod data from 12 month old cohort.  
Left graph shows mean daily times of latency to fall from the rotarod. Right graph 
shows mean monthly latency to fall times. +/+ indicates wildtype animals, +/wst 
indicates heterozygote animals. Error bars represent the standard error of the mean. 
 
Table 3.8. Rotarod data from the 12 month old cohort.  
Number of animals (N), average latency to fall time (Mean), group minimum (Min) 
and maximum (Max) latency to fall, standard deviation (S.D) and standard error of 
the mean (SEM) are shown. +/+ indicates wildtype animals, +/wst indicates 







Group N Mean Min Max S.D S.E.M 
Female +/+ 2 80.67 51.6 109.7 41.11 29.07 
Female +/wst 5 56.87 38.8 95.07 21.96 9.821 
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Figure 3.21. Grip strength data from the 12 month old cohort.  
Left graph shows mean forelimb grip strength of cohort. Right graph shows mean 
grip strength for all four limbs. +/+ indicates wildtype animals, +/wst indicates 
heterozygote animals. Error bars represent the standard error of the mean. 
 
a. Forelimbs 
Group N Mean Min Max S.D S.E.M 
Female +/+ 2 0.032 0.029 0.036 0.005 0.004 
Female +/wst 5 0.035 0.026 0.044 0.007 0.003 
 
b. All four limbs 
Group N Mean Min Max S.D S.E.M 
Female +/+ 2 0.060 0.056 0.063 0.005 0.003 
Female +/wst 5 0.066 0.058 0.076 0.007 0.003 
Table 3.9: Grip strength data from the 12 month old cohort.  
Table (a) shows forelimb grip strength only and table (b) shows grip strength data 
from all four limbs. Number of animals (N), average latency to fall time (Mean), 
group minimum (Min) and maximum (Max) latency to fall, standard deviation (S.D) 
and standard error of the mean (SEM) are shown. +/+ indicates wildtype animals, 
+/wst indicates heterozygote animals group. 
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Figure 3.22. Rotarod data from the 18 month old cohort.  
Upper graphs shows mean daily times of latency to fall from the rotarod. Lower 
graph shows mean monthly latency to fall times. +/+ indicates wildtype animals, 
+/wst indicates heterozygote animals. Error bars represent the standard error of the 
mean. 
 
Group N Mean Min Max S.D S.E.M 
Male +/+ 3 60.89 54 65.56 6.09 3.516 
Male +/wst 3 59.33 40.89 82.78 21.39 12.35 
Female +/+ 3 73.37 58.56 97.56 21.12 12.19 
Female +/wst 4 47.61 23.78 79.67 24.05 12.03 
Table 3.10. Rotarod data from the 18 month old cohort.  
Number of animals (N), average latency to fall time (Mean), group minimum (Min) 
and maximum (Max) latency to fall, standard deviation (S.D) and standard error of 
the mean (SEM) are shown. +/+ indicates wildtype animals, +/wst indicates 
heterozygote animals. 
Males 18 months
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Figure 3.23. Grip strength data from the 18 month old cohort.  
Left graph shows mean daily forelimb grip strength of cohort. Right graph shows 
mean grip strength for all four limbs. +/+ indicates wildtype animals, +/wst indicates 
heterozygote animals. Error bars represent the standard error of the mean. 
 
a. Forelimbs 
Group N Mean Min Max S.D S.E.M 
Male +/+ 3 0.038 0.032 0.042 0.005 0.003 
Male +/wst 3 0.036 0.027 0.042 0.008 0.005 
Female +/+ 3 0.035 0.028 0.039 0.006 0.003 
Female +/wst 3 0.026 0.023 0.031 0.004 0.003 
b. All four limbs 
Group N Mean Min Max S.D S.E.M 
Male +/+ 3 0.053 0.049 0.059 0.005 0.003 
Male +/wst 3 0.057 0.045 0.069 0.012 0.007 
Female +/+ 3 0.057 0.050 0.064 0.007 0.004 
Female +/wst 3 0.049 0.039 0.063 0.012 0.007 
Table 3.11. Grip strength data from the 18 month old cohort.  
Table (a) shows forelimb grip strength data only and table (b) shows grip strength 
data from all four limbs. Number of animals (N), average latency to fall time (Mean), 
group minimum (Min) and maximum (Max) latency to fall, standard deviation (S.D) 
and standard error of the mean (SEM) are shown. +/+ indicates wildtype animals, 
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Figure 3.24. Rotarod data from the 12 month old cohort combined with the 12 
month old pilot study.  
Mean times of latency to fall from the rotarod of wildtype and heterozygote animals 
normalised to wildtypes. +/+ indicates wildtype animals, +/wst indicates 
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3.4. Discussion 
In this project, ageing wasted heterozygote (+/wst) animals were investigated for 
signs of late onset motor neuron degeneration. 
The rotarod was used as the primary behavioural test in this study. This easily 
quantifiable task is thought of as the gold standard for detection of motor 
impairment. It has been shown previously that wasted mice perform significantly 
worse than wildtype controls on the accelerating rotarod from 21 days (Newbery et 
al., 2005). The grip strength meter was investigated to establish if this test could 
categorize wasted mice earlier than the rotarod. Newbery et al (Newbery et al., 2005) 
showed that the sequence of events in wasted mice begins with gliosis in the spinal 
cord, followed by retraction of motor nerve terminals in muscle and finally motor 
neuron pathology and death. As retraction of motor nerve terminals precedes motor 
neuron pathology in wasted mice it would be possible that the grip strength meter 
may detect any deficit before the rotarod.  In the test of forelimbs only and all four 
limbs combined, wasted mice had significantly lower grip strength than controls by 
20 days. This is a day earlier than detection by rotarod. The difference between 
groups was more significant when analysing forelimbs only compared to all four 
limbs. This supports previous data from our group (Newbery et al., 2005) which 
indicated that the disease severity of spinal cord pathology shows a rostrocaudal 
gradient. To complete this data it would be interesting to see the results of measuring 
hindlimbs only however this proved too difficult to conduct. 
The results of the first ageing study show no statistically significant differences 
between wildtype and heterozygote animals of either gender in either rotarod 
performance or grip-strength. However, female heterozygotes from around 12 
months of age do perform slightly worse than wildtype controls on the rotarod.  The 
study was limited by numerous factors and presents many possible avenues for future 
investigations. 
Firstly the tests themselves have limitations. A common problem with the rotarod 
test is that mice may cling to the beam and rotate instead of falling when they lose 
balance. If this occurred in this study, mice were permitted to rotate 360
o
 while 
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clinging to the beam only once. If they then began to walk again the test was allowed 
to continue. If however the mouse rotated more than once the test was terminated and 
the time measurement taken immediately following the first rotation. Another factor 
that can affect rotarod performance is weight, with smaller, lighter mice performing 
better than overweight animals. To account for this variable, data was also analysed 
with normalisation to body weight (data not shown).  No significant differences were 
observed in either data set. Finally, susceptibility to fatigue may contribute to poor 
performance. A maximum time on the rotarod was set to 180 seconds as in Barneoud 
et al (Barneoud et al., 1997) to try and limit fatigue that could be caused by allowing 
mice to continue indefinitely. Significant breaks were also given between tests on a 
given day to minimize this, and tests were not conducted on consecutive days to 
allow sufficient recovery time.  It is possible that higher rotation rates at a fixed 
speed in future tests may ensure that falls are attributable to motor coordination and 
less to fatigue. Despite these problems the rotorod still remains the gold standard for 
measuring motor function in mice and so is still believed to be the best test for this 
study and future studies of this kind.   
The grip strength meter has less confounding variables. The only variable that must 
be taken into account is weight, thus normalising the meter reading to body weight is 
required and was conducted in this study 
Other tests could be considered in future studies. In some studies such as Barneoud et 
al (Barneoud et al., 1997), the balance beam has shown to detect deficits in mouse 
models of neurodegeneration prior to the age at which motor neuron death is 
observed. Mice are trained to cross an elevated beam and the time taken to cross 
and/or the number of rear foot slips are recorded.  This test that challenges fine motor 
balance and coordination was attempted in this study, however all mice (wildtypes 
and heterozygotes) performed  poorly and thus it was deemed unsuitable. Mice 
displayed “hind limb dragging” where their abdomen were flattened against the 
upper surface of the beam and their hind limbs and tail were wrapped around the 
beam. They would therefore use their forelimbs to drag themselves across the beam 
instead of walking therefore measuring foot slips became an impossible task. 
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In future studies, further tests where training is not required could be used, such as 
gait abnormality using footprint tests, although previous attempts of this method in 
our lab have been problematic and often inconclusive. In a recent study  
Knippenberg et al  compared several behavioural assessments to select the most 
appropriate methods for detecting motor symptom onset in the G93A SOD1 mouse 
model (Knippenberg et al., 2010). This study states that deficits were observed first 
by rotarod and around a week later, by step length analyses. They concluded that 
while the rotarod detected the earliest signs of disease, the footprint test has the 
major advantages of being far less time consuming and costly and also is less 
stressful to the animals. Thus both assays should perhaps be considered for future 
studies.  In the Barneoud et al study an inclined plane test was the first to detect any 
deficit in the G1H SOD1 transgenic mice (Barneoud et al., 1997). Mice were scored 






There are many options for further behavioural analysis of these animals in future 
however as previously mentioned the rotarod is known as the gold standard for this 
type of study and therefore should continue to be used in future studies. Other test 
could also be beneficial but mostly to further untangle the behavioural aspect of 
disease, not to replace the rotarod.  
The more important issue that needs to be addressed for future studies is to 
understand why there was a statistically significant difference between heterozygotes 
and wildtypes in the pilot study but not in this ageing study.  
There were some differences between these studies. The first of these was that the 
pilot mice had not been subjected to the rotarod repeatedly throughout their lives (as 
in the first ageing study described here). The difference in results could therefore be 
explained in terms of learning capability or differences in the amount of exercise the 
animals received during the course of the study. In a study comparing various 
behaviour testing methods in G1H mutant SOD1 transgenic mice, it was noted that 
the age at which animals are first tested was important in determining the age at 
which significant deficits could be observed (Barneoud et al., 1997). This may be 
due to the differing abilities of the groups to learn and habituate to a given task. In 
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these studies both wildtypes and heterozygotes demonstrated learning behaviour in 
the rotarod test as when they only had 1 month between tests, performance in all 
groups increased compared to when tests were conducted every 3 months. This was 
also true of the Barneoud study(Barneoud et al., 1997), in that both wildtypes and 
transgenics showed evidence of learning. Kirkinezos et al  published a studying 
showing the beneficial effects of exercise on the G93A model of ALS (Kirkinezos et 
al., 2003). Regular treadmill exercise over a 10 week period significantly expanded 
the lifespan of the diseased animals. Another study demonstrated that exercise 
delayed the onset of disease in females but not in males and had no affect on lifespan 
of either sex (Veldink et al., 2003). This data suggested that regular exercise could 
potentially mask any differences between the wildtypes and heterozygotes in this 
study and therefore may explain why the pilot study showed statistical difference 
whereas the ageing cohort didn’t. The affect of exercise on ALS patients has always 
been controversial with numerous studies implicating various exercise activities as 
risk factors in ALS and others identifying exercise as beneficial resulting in 
increased quality of life. Dalbello-Haas et al  review current data on the subject and 
conclude that current data is inconclusive due to the small numbers of subjects in the 
studies (Dalbello-Haas et al., 2008). In the United States, ALS is referred to as Lou 
Gehrigs disease after the famous baseball player who succumbed to the disease in the 
late 1930s. Numerous other famous athletes including  boxer Ezzard Charles, 
baseball player Jim Hunter and the more local Don Levie of Leicester city football 
club to name a few who all suffered with the disease. While so many cases of 
athletes with the disease may suggest exercise as a risk factor many specific 
neurological advantages to exercise have also been identified. These include 
increasing neurogenesis (van Praag et al., 1999) and hindering age-related neuronal 
loss (Larsen et al., 2000) (which is of particularly relevance here).  
Exercise and learning behaviour could certainly explain the differing results between 
the pilot study and first ageing study. A new pilot study cohort of ageing mice was 
then gathered which had not been exposed to behavioural tests in the past. Limited 
animals were available for this study.  An 18 month old cohort of male and female 
wildtypes and heterozygotes were analysed but no statistically significant differences 
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were observed between any of these groups. A 12 month cohort of females also 
showed no significant difference between wildtypes and heterozygotes. However 
there is a definite trend for females heterozygotes to perform worse than wildtype 
females.  The mean difference between female wildtypes and heterozygotes appears 
more dramatic in the pilot study and in the 12 month old female cohort described 
here  than in the larger ageing cohort. This supports the theory that exercise may be 
masking any difference in the ageing cohort. The next study to be undertaken should 
include larger groups of animals that should be tested once at 18 months of age.  
Another interesting avenue for future investigations is to address what is happening 
at 12 months that causes this decline in female heterozygotes but not in males. The 
importance of gender differentiation when analysing behaviour data is becoming 
increasingly recognised. As such analysing animals separately by gender has been 
recommended in the recently updated guidelines for preclinical animal research in 
ALS (Ludolph et al., 2010) 
Studies of SOD1 G93A transgenic mice have shown that disease onset is 
significantly earlier in males than in females (Veldink et al., 2003; Choi et al., 2008).  
Studies have also shown that overactomy accelerates the progression of motor 
neuron disease symptoms in female SOD1 G93A transgenic animals suggesting that 
female sex hormones are neuroprotective (Groeneveld et al., 2004; Choi et al., 
2008). 17β-estradiol treatment of these ovarectomised females also reversed the 
reduced survival rate. These studies suggest that oestrogen is a key player in the 
female advantage of lifespan in these animals. Up until menopause oestrogen may be 
providing a selective advantage to females but when they reach the age of 
menopause they lose this advantage.  Interestingly the age of onset of menopause for 
mice is thought to be between 12-14 months of age (Silver 1995). This coincides 
with the age at which a difference is first observed between female wildtypes and 
heterozygotes. Therefore it is possible that on approaching menopause the decline in 
oestrogen normally associated with menopause could account for the increased 
difference between the female groups in this project. Investigating ovarectomised 
females would be an interesting tactic for investigating the apparent difference 
between males and females in this study. Veldink et al also demonstrated that 
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exercising female hSOD1 mice had a higher uterus weight and less irregular estrous 
cycles than non-exercising females which they conclude to mean that exercising 
females have a higher exposure to oestrogen (Veldink et al., 2003). This supports the 
results of this project in that a smaller difference is observed between female groups 
when animals received regular exercise. A possible hypothesis could be that the 
poorer performance observed in female heteorzygotes could be attributed to lower 
eEF1A2 expression combined with an additional effect caused by menopause (such 
as a change in oestrogen level). This may account for why female heterozygotes and 
not male heterozygotes show a decrease in rotaord performance (compared to 
wildtypes controls) even though male heterozygotes show a greater reduction in 
eEF1A2 expression by western blot.    
Another consideration for future work will be the genetic background of the animals 
as this could have an effect on both behavioural testing and on any disease 
phenotype. Whilst the onset of wasted disease is unaffected by genetic background 
(unpublished observations described in Abbott et al (Abbott et al., 1994)) genetic 
background has been shown to influence disease onset in transgenic mouse models. 
Studies have shown that crossing the SOD1 transgenic mice onto different 
backgrounds resulted in differences in disease severity (Kunst et al., 2000; Heiman-
Patterson et al., 2005). The degree of difference between survival of males and 
females was also affected by different genetic backgrounds (Heiman-Patterson et al., 
2005). Messer et al demonstrated that outcrossing of motor neuron degeneration 
(mnd/mnd) mice from a C57BL/6J genetic background to a AKR/J background 
advances symptom onset (Messer et al., 1999). Modifier genes in different genetic 
backgrounds must therefore play an important role in disease pathology and thus 
genetic background should certainly be a consideration in any future studies. 
Although in this study all mice were of the same stock, genetic background was 
mixed and so could possibly lead to difference between groups and certainly between 
individuals. Furthermore some wildtype C56BL/6J males were also tested during the 
pilot study. These males far outperformed all of the mice (wildtypes included) from 
the wasted stock (data not shown). Perhaps breeding the mice onto a purer C57BL/6J 
background might result in wildtypes reaching 100% performance more quickly and 
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thus maybe any difference between wildtypes and heterozygotes may become more 
evident.  
Behavioural differences between groups can be attributable to many things and  
thorough pathological analysis is therefore crucial in studies such as this. In this 
study no significant differences were seen in the spinal cord pathology between any 
of the groups examined using GFAP and neurofilament antibodies as markers of 
neurodegeneration.  Levels of GFAP in the mouse CNS have been shown to increase 
with age (O'Callaghan and Miller 1991; Kohama et al., 1995; Mouton et al., 2002; 
Hartman et al., 2007)  and therefore may explain the high level of staining in older 
wildtypes that made analysis difficult. Moulton et al also demonstrated that aged 
females have an increased number of microglia and astrocytes compared to males of 
the same age (Mouton et al., 2002). The heavy staining in the samples made this 
difficult to ascertain in this study. Motor neuron counts also demonstrated no 
significant difference between groups, however the small number of animals at the 
endpoint of the study combined with the crude counting method could account for 
this. Furthermore the choice of marker may not have been ideal given the difference 
in expression of eEF1A2 the spinal cord of wildtype and heterozygous animals. In 
future more sophisticated methods should be adopted for this such as the fractionator 
method and image analysis software used in Fishcer et al (Fischer et al., 2004) and 
Weber et al (Weber et al., 1997). It would also been useful to measure neuron size as 
12 months old ZPR1 heterozygotes show decreased neuron size compared to 
wildtypes (Doran et al., 2006).   
Gene dosage has a direct effect on ZPR1 causing decreased ZPR1 protein levels in 
heterozygous ZPR1 mice compared to wildtype controls (Doran et al., 2006). This 
decrease became more extensive with age. Whilst 6 week old heterozygote mice 
showed no marked decrease in motor neuron number compared to wild type controls, 
by 12 months of age heterozygote mice displayed reduced cell density and loss of 
anterior horn motor neurons compared to wildtypes. This correlates directly with the 
decrease in ZPR1 protein with age. ZPR1 has been shown to preferentially bind to 
GDP bound eEF1A (Mishra et al., 2007). As eEF1A2 has a slower disassociation 
rate than eEF1A1 it is possible that ZPR1 preferentially binds eEF1A2. It is therefore 
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plausible that in ageing wasted heterozygotes the reduced levels of eEF1A2 result in 
insufficient ZPR1-eEF1A complexes which may decrease motor neuron viability. An 
interesting avenue for future work would be to examine whether any changes occur 
in the levels or localization of ZPR1 and SMN in older heterozygote animals, which 
would contribute to further our understanding of the interaction between these three 
proteins.  
By examining eEF1A2 protein levels in various tissues it became apparent that while 
heterozygotes would be expected to have approximately 50% of eEF1A2 protein of 
wildtypes (Newbery 2003) this is not always the case for older animals. It appears 
that with age the amount of eEF1A2 in brain, spinal cord and muscle of 
heterozygotes decreases. These data also suggest that in brain tissue the decrease is 
more dramatic in males than in females. This result must be viewed with caution as 
ensuring the exact region of the brain is taken in each sample was very difficult. 
Analysing eEF1A2 expression in tissues from mice of varying ages would be 
interesting to identify when any decrease in protein expression first appears. 
This information is extremely useful as in this study it shows that 26% of eEF1A2 
protein in muscle for example is sufficient for normal motor function. Having a 
reduction to only a quarter of wildtype eEF1A2 expression does not result in a 
significant behavioural deficits or pathology. This information is essential if eEF1A2 
were ever used for gene therapy, for example.  
3.5. Conclusion 
The aim of this study was to assess whether wasted heterozygotes develop any signs 
of motor neuron degeneration later in life. The results of the project are still 
inconclusive to some extent. Given that the pilot study showed statistically 
significant difference in the performance of wildtypes and heterozygotes on the 
rotarod and the same pattern appears in both of these ageing studies they do provide 
an interesting model for future investigation. As there is little evidence of any 
pathological differences between heterozygotes and wildtypes their value as a model 
for motor neuron degeneration however is limited.  
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4. Chapter 4: Investigating the primary cause of the 
pathology in wasted mice 
4.1. Aim 
The main aim of this study was to investigate the primary cause of  the pathology of 
wasted mice. To address this aim, transgenic animals expressing eEF1A2 under the 
control of a neuronal specific promoter were generated to attempt to investigate the 




The wasted mouse model (wst) arose from the spontaneous  deletion of the promoter 
region and first non-coding exon of eEF1A2. This 15.8kb  deletion completely 
abolishes eEF1A2 protein expression (Chambers et al., 1998). Mice homozygous for 
this deletion develop symptoms of neuromuscular disease such as weight loss 
(largely attributed to loss of muscle bulk), tremors and gait abnormalities from 21 
days of age. Mice deteriorate rapidly from this point resulting in death by 28 days 
(Shultz et al., 1982). The onset of these neuromuscular symptoms in wasted mice 
coincides with a developmental switch in eEF1A variants in muscle. eEF1A1 
expression is normally highly expressed in muscle at birth and then gradually 
declines to become undetectable by 21 days. By this point in wildtype animals, 
eEF1A2 expression would normally have taken over (Khalyfa et al., 2001). A similar 
expression pattern of eEF1A variants is also seen in motor neurons (Newbery et al., 
2005; Newbery et al., 2007). Wasted mice at 21 days therefore have neither eEF1A1 
or eEF1A2 expression in muscle or motor neurons. Motor neuron pathology similar 
to that seen in human motor neuron degeneration is also observed in wasted mice 
from around 21 days (Chambers et al., 1998; Newbery et al., 2005) 
Previous transgenic studies in our lab imply that Eef1a2 is the only gene responsible 
for the wasted phenotype (Loh 2003; Newbery et al., 2007). However it is currently 
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unknown whether the muscle degeneration in wasted mice is a primary myopathy 
due to the loss of eEF1A2 in muscle or is due to denervation atrophy caused by the 
loss of eEF1A2 in the motor neurons.  
This question was previously approached by generating transgenic animals 
expressing eEF1A2 under the control of the human specific actin promoter (HSA 
(Dharmasaroja 2007)). Homozygous wasted mice (wst/wst) carrying the muscle-
specific transgene died at the same age as those without the transgene, despite 
significant levels of eEF1A2 protein expression in muscle. The muscle specific 
transgene therefore failed to rescue the wasted phenotype.  These results suggest that 
the loss of eEF1A2 in neurons is the primary cause of the muscle pathology, but it is 
critical to test this experimentally, especially given that only one line expressing 
eEF1A2 under the control of the HSA promoter was generated in the previous study. 
In this project a construct containing the human EEF1A2 gene under the control of 
the rat Neuronal Specific Enolase (NSE) promoter was generated to test this. A 1.8kb 
fragment of the promoter region of NSE has been previously shown to contain all the 
regulatory elements required for driving neuronal specific expression in transgenic 
mice (Forss-Petter et al., 1990). Numerous studies have demonstrated neuronal 
specific transgene expression using this promoter region (Maddatu et al., 2004; de 
Luca et al., 2005) and this was therefore the reason for its use in this study.   
These experiments will aid in our understanding of the pathology of wasted mice in 
addition to improving our understanding of motor neuron degeneration.  
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4.3. Results 
4.3.1. The NSE-EEF1A2 construct 
To meet the aim of this study a construct containing the human EEF1A2 gene under 
the control of the rat neuronal specific promoter Neuronal Specific Enolase (NSE) 
was generated.  
 
4.3.1.1. eEF1A2 
A pUC19-EEF1A2 plasmid was created by subcloning the 18,891bp human EEF1A2 
gene from the P1-derived artificial chromosome (PAC) previously constructed by 
Dawn Loh (Loh 2003). The gene (including its promoter) was cloned into the 
multiple cloning site of the pUC19 plasmid, between the HindIII and KpnI sites by 
Dr Julia Boyd.  Thie pUC19-EEF1A2 was used for the generation of the transgenic 
construct. 
An AgeI site located 102bp upstream of the second exon (the first coding exon) of 
EEF1A2 was identified as a suitable unique site for insertion of the new promoter 
(Dharmasaroja 2007). The aim was to remove the promoter region of EEF1A2 by 
digestion with HindIII and AgeI. The NSE promoter (flagged with HindIII and AgeI 
sites) could then be inserted into this site.   
 
4.3.1.2. The Promoter 
A 1946bp fragment from the Rat NSE promoter region was amplified by polymerase 
chain reaction (PCR) from a cell pellet from the RAT2 cell line. Primers were 
designed to span the required region and also to attach restriction sites to the ends of 
the fragment. Nested PCR was then performed with primers targeting the newly 
added restriction sites, resulting in the correct product flanked with the desired 
restriction sites. The 5’ end of the promoter contained a HindIII site and the 3’ end 
contained an AgeI site. The use of different restriction sites decreased the probability 
of the promoter being inserted in the incorrect orientation.  
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4.3.1.3. Cloning 
Following PCR amplification of the promoter region, a double restriction digest was 
performed with HindIII and AgeI restriction enzymes on the nested PCR promoter 
product (flanked with HindIII and AgeI restriction sites). Simultaneously, a 
restriction digest was also performed on the pUC19-EEF1A2 vector which removed 
the 7.7kb promoter region of EEF1A2. Attempts were made to gel extract the 
required fragment of EEF1A2 (and eliminate the unrequired EEF1A2 promoter 
region) however the gel extraction purification seemed to hinder ligation. The 
digested promoter and vector were therefore purified by a PCR purification kit 
(Qiagen) and ligated with a T4 ligase. Diagramatic representation of the cloning 
strategy can be seen in figure 4.1. Ligation was optimally achieved at 25
o
C for four 
hours using a 4:1 promoter:vector ratio. Ligated products were then transformed into 
TOP10 competent cells (Invitrogen).  Positive colonies were screened by colony 
PCR using primers which would produce a product that bridged the 3’ end of the 
NSE promoter and the 5’ of the EEF1A2 gene (this ensured that the original EEF1A2 
promoter had not re-ligated into the backbone vector). Details of the primers used 
can be seen in Chapter 2: Materials and Methods. A Maxi-prep kit (Qiagen) was used 
to prepare large scale preparations of the NSE-EEF1A2 construct. Restriction digests 
were performed on these preparations to ensure the correct construct was present 
(figure 4.2, table 4.1). Further PCR analysis was also performed using multiple 
primer pairs to confirm the correct orientation of the promoter.  The NSE promoter 
region, exons 2-7 of EEF1A2 and the region between the promoter and exon 2 of 
EEF1A2 were sequenced to check for any mutations. No mutations were found in 
any of these regions. As such the construct was deemed suitable for microinjection. 
The 13Kb construct was excised from the vector by a double restriction digest with 
HindIII and KpnI, separated from the plasmid backbone on a gel and purified by 
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Figure 4.1. NSE-EEF1A2 
Diagramatic representation of the generation of the NSE-EEF1A2 construct. H 
indicates a HindIII restriction site, A indicates an AgeI restriction site and K indicates 
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Figure 4.2. Restriction digests of NSE-EEF1A2  
Agarose gel (0.6%) showing restriction digest products from pUC19-EEF1A2 and 
NSE-EEF1A2 construct. Single digests with HindIII (H), AgeI (A) and KpnI (K) are 
shown which all linearise the plasmid. A double digest with AgeI and HindIII (A/H) 
removes the promoter region and a double digest with KpnI and HindIII (K/H) 
removes the entire construct from the vector. Expected product sizes can be seen in 
table 4.1 below.  
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Table 4.1. Expected product sizes from restriction digests of NSE-EEF1A2  






4.3.2. Generating NSE-EEF1A2 transgenic mice 
Microinjection of the NSE-EEF1A2 construct into fertilised embryos, and 
subsequent embryo transfer into pseudo-pregnant females was performed by Emma 
Murdoch. Ninety seven embryos at the two cell stage were transplanted across three 
pseudo-pregnant females of which thirty six live pups were born. Positive offspring 
were identified by PCR of genomic DNA extracted using the DNeasy extraction kit 
(Qiagen). Two primer pairs (as shown in figure 4.3) were used; the forward primers 
were both located within the NSE promoter region and the reverse primers located 
within the EEF1A2 gene. Three animals were identified that were positive for the 





Enzyme/s pUC19-EEF1A2 NSE-EEF1A2 
Hind III 21528bp 15,729bp 
AgeI 21528bp 15,729bp 
KpnI 21528bp 15,729bp 
Hind III & KpnI 18,881bp, 2647bp 13082bp, 2647bp 
Hind III & AgeI 13,783bp, 7745bp 13,783bp, 1946bp 
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Figure 4.3. Location of transgenic primers.  
Target regions of primers used to identify the presence of the NSE-EEF1A2 
transgene in mice. Two primer pairs were used: NSE-EEF1A2 F1 paired with NSE-
EEF1A2 R1 results in a PCR product with an expected size of 671bp, NSE-EEF1A2 
F2 paired with NSE-EEF1A2 R2 results in a PCR product with an expected size of 
387bp. The AgeI site is also highlighted (pink), which marks the end of the NSE 
promoter region and the beginning of the EEF1A2 gene. Underlined text denotes the 
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NSE-EEF1A2 F1 → 
NSE-EEF1A2 R1 → 




















NSE-EEF1A2 F2 → 
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4.3.3. Maintaining transgenic lines 
The three founders were separately mated to wasted heterozygote mice (+/wst). All 
three founders transmitted the transgene through the germline resulting in transgenic 
offspring. The three separate lines were then designated NSE-EEF1A2-A, NSE-
EEF1A2-B and NSE-EEF1A2-C. Lines containing wasted homozygous animals 
carrying the NSE-EEF1A2 transgene (+/tg, wst/wst), were generated by mating 
wasted heterozygote animals carrying the NSE-EEF1A2 transgene (+/tg, +/wst) with 
heterozygote animals without the transgene (+/+,+/wst,). All transgenic mice were 
therefore hemizyous for the transgene. The strategy for generating wasted 
homozygous animals carrying the NSE-EEF1A2 transgene (+/tg, wst/wst) is shown 
in figure 4.4. 
Wasted homozygous animals carrying the NSE-EEF1A2 transgene (+/tg, wst/wst) 
were identified by genoptyping with four primer sets. Genotyping primers routinely 
used to identify the wildtype Eef1a2 allele and separately the wasted Eef1a2 allele  
were used as well as two separate primer pairs to identify the NSE-EEF1A2 
transgene. Further details of the genotyping assay for the wasted mutation can be 
found in Chapter 2: Materials and methods. The target region of the transgene 
specific primers used for genotyping can be seen in figure 4.3. Examples of 
genotyping results can be seen in figure 4.5. 
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Figure 4.4. Diagramatic representation of the strategy for generating wasted 
mice carrying the NSE-EEF1A2 transgene (+/tg wst/wst). 
Transgenic founders (+/tg,+/+) were initially mated to non-transgenic wasted 
heterozygotes (+/+,+/wst). One in four offspring were expected to be wasted 
heterozygotes carrying the transgene (+/tg,+/wst). Wasted heterozygotes carrying the 
transgene (+/tg,+/wst) were then mated to wasted heterozygotes without the 
transgene (+/+,+/wst). One in 8 of the offspring from these matings are expected to 
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Figure 4.5. Genotyping of transgenic NSE-EEF1A2 animals. 
Examples of genotyping results from NSE-EEF1A2 transgenic (TG) animals and 
non-transgenic controls (Non-TG). PCR results from a non transgenic and a 
transgenic wildtype (+/+), heterozygote (+/wst) and wasted (wst/wst) animals. Gel 
(a) shows PCR products that correspond to the wildtype Eef1a2 (WT) allele 
(expected size of product: 452bp). Gel (b) shows PCR products that correspond to 
the wasted Eef1a2 (WST) allele (expected size of product: 200bp). Gels (c) and (d) 
show PCR products from 2 sets of NSE-EEF1A2 transgene specific primers: TG1 
(NSE-EEF1A2 F1 and NSE-EEF1A2 –R1 (expected size 671bp)) and TG2 (NSE-
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4.3.4. Analysis of transgenic mice 
4.3.4.1. NSE-EEF1A2-A 
Wasted mice (wst/wst) usually begin to develop symptoms of neuromuscular disease 
at around 21 days. Wasted mice carrying the transgene (+/tg, wst/wst) in the NSE-
EEF1A2-A line showed symptoms of neuromuscular disease including weight loss 
and tremors at a similar age to wasted mice without the transgene (+/+, wst/wst).  
 
Body weight 
As wasted mice show a dramatic decrease in body weight from 21 days until death, 
mice from the NSE-EEF1A2-A line were weighed at 25 days (end stage) to assess 
whether this disease phenotype was corrected. Wasted mice carrying the transgene 
(+/tg, wst/wst) showed no significant difference in body weight compared to wasted 
animals without the transgene (+/+, wst/wst). Wasted mice, both with and without the 
transgene, weighed significantly less than wildtype littermates (figure 4.6, table 4.2). 
This indicates that this aspect of the disease phenotype is not corrected in these 
animals. 
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Figure 4.6. Body weights of 25 day old mice from the NSE-EEF1A2-A line. 
Body weights of wildtype animals (+/+,+/+), wasted animals without the transgene 
(+/+, wst/wst) and wasted animals with the transgene (+/tg, wst/wst) are shown. 
Animals were weighed at 25 days (end stage).  *** indicates a p value <0.001 
 
 
Table 4.2. Body weights of 25 day old mice from the NSE-EEF1A2-A line. 
Statistical analysis of body weights from wildtype animals (+/+,+/+), wasted 
animals without the transgene (+/+, wst/wst) and wasted animals with the transgene 
(+/tg, wst/wst) are shown. Animals were weighed at 25 days (end stage). Number of 
animals (N), mean, minimum (Min) and maximum (Max) bodyweight for each 
genotype are shown. S.D indicates the standard deviation across each genotype and 
S.E.M is a measure of the standard error of the mean. 
 
 
Genotype N Mean Min Max S.D S.E.M 
+/+ +/+ 3 10.1 9.1 11.3 1.1 0.6 
+/+ wst/wst 3 7.3 6.5 7.9 0.7 0.4 
+/tg wst/wst 3 6.6 6.1 7.0 0.5 0.3 
Line NSE-EEF1A2-A
Body weight
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Grip strength analysis 
Wasted mice demonstrate poor grip strength from around 20 days (Chapter 3). At 25 
days of age, analysis of both forelimb and all four limb grip strength showed that 
wasted mice carrying the transgene (+/tg, wst/wst) were indistinguishable from 
wasted mice without the transgene (+/+, wst/wst). It therefore appears that the 
transgene does not rescue the poor grip strength phenotype of wasted mice (figure 
4.7, Table 4.3). 
 
Figure 4.7. Grip strength analysis of 25 day old mice from the NSE-EEF1A2-A 
line. 
Mean grip strength analysis from 25 day old wildtype animals (+/+,+/+), wasted 
animals without the transgene (+/+, wst/wst) and wasted animals with the transgene 
(+/tg, wst/wst) from the NSE-EEF1A2 line A are shown. Forelimb (left graph) and 
all four limb (right graph)  grip strength readings from 3 tests (measured in Newtons) 
were normalised to body weight (measured in grams). ** indicates a p value <0.01 







Grip strength - Forelimbs only






































Grip strength - All four limbs
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(a) Forelimbs only 
Genotype N Mean Min Max S.D S.E.M 
(+/+, +/+) 3 0.050 0.044 0.054 0.005 0.003 
(+/+, wst/wst) 3 0.031 0.021 0.042 0.011 0.006 
(+/tg, wst/wst) 3 0.020 0.014 0.030 0.009 0.005 
(b) All four limbs 
Genotype N Mean Min Max S.D S.E.M 
(+/+, +/+) 3 0.088 0.083 0.091 0.005 0.003 
(+/+, wst/wst) 3 0.065 0.062 0.068 0.003 0.002 
(+/tg, wst/wst) 3 0.056 0.045 0.062 0.009 0.005 
 
Table 4.3. Grip strength analysis of 25 day old mice from the NSE-EEF1A2-A 
line. 
Statistical analysis of grip strength measurements from 25 day old wildtype animals 
(+/+,+/+), wasted animals without the transgene (+/+, wst/wst) and wasted animals 
with the transgene (+/tg, wst/wst) from the NSE-EEF1A2 line A. Animals were 
tested three times at 25 days (end stage) and an average per animal calculated. 
Number of animals (N), mean, minimum (Min) and maximum (Max) bodyweight for 
each genotype are shown. S.D indicates the standard deviation across each genotype 
and S.E.M is a measure of the standard error of the mean. 
 
Protein expression. 
Whilst it was shown that the founder of NSE-EEF1A2-A successfully transmitted the 
transgene through the germline, Western blot analysis of wasted mice carrying the 
transgene (+/tg wst/wst) indicated that the transgene was not being expressed at the 
protein level (figure 4.8). Brain, spinal cord and muscle tissues were analysed for 
protein expression from three wildtype animals (+/+, +/+), three wildtype mice 
carrying the trangene (+/tg, +/+), three wasted animals (+/+, wst/wst) and three 
wasted animals carrying the transgene (+/tg, wst/wst), all at 25 days of age. Wasted 
mice carrying the transgene showed no expression of eEF1A2 in any of the tissues 
examined. As it appears the transgene is not expressed in these animals, no further 
analysis was carried out on the NSE-EEF1A2-A line.  
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Figure 4.8. eEF1A2 protein expression in tissues from NSE-EEF1A2-A line 
animals. 
Western blots showing expression of eEF1A2 and GAPDH (as a loading control) of 
animal tissue from the transgenic line NSE-EEF1A2-A. Expression from three  
animals from each group (wildtype (+/+,+/+), wildtype with the transgene (+/tg, 
+/+,) wasted animals without the transgene (+/+, wst/wst) and wasted animals with 
the transgene (+/tg, wst/wst)) are shown. M indicates a muscle sample (as an 
eEF1A2 positive control) and L indicates a liver sample (an eEF1A2 negative 
control).   
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4.3.4.2. NSE-EEF1A2-B  
Unlike the NSE-EEF1A2-A line, wasted mice carrying the transgene (+/tg, wst/wst) 
from the NSE-EEF1A2-B line showed no observable signs of neuromuscular disease 
at 25 days. Wasted mice carrying the transgene were indistinguishable from wildtype 
mice at 25 days of age (figure 4.9 panels (a) and (b)). At the anatomical level, tissues 
from wasted mice carrying the transgene (+/tg, wst/wst) were also indistinguishable 
from wildtype littermate controls. The splenic and thymic atrophy (figure 4.9) 
normally seen in wasted mice (+/+, wst/wst) was not observed in wasted mice 
carrying the transgene (+/tg, wst/wst). It therefore appears that some aspects of the 
wasted phenotype have been corrected by the NSE-EEF1A2 transgene in this line. 
 
Body weight 
As wasted mice show a dramatic decrease in body weight from 21 days until death, 
mice from the NSE-EEF1A2-B line were weighed at 25 days (end stage) to assess 
whether this aspect of the disease phenotype was corrected (figure 4.10). As 
expected wasted mice showed a significant decrease in body weight compared to 
littermate controls. Wasted mice carrying the transgene (+/tg, wst/wst) showed a 
significant increase in body weight compared to the wasted animals without the 
transgene (+/+, wst/wst). No significant difference was observed between wasted 
mice with the transgene and the wildtype and heterozygote controls. It would 
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Figure 4.9. Photographs of animals from the NSE-EEF1A2-B line. 
Photographs of animals from the NSE-EEF1A2-B line. Panels (a) and (b) show a 
wildtype animal (+/+,+/+) a wasted animal (+/+, wst/wst) and a wasted animal 
carrying the transgene (+/tg, wst/wst). Panels (c) (spleen) and (d) (thymus) show 
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Figure 4.10. Body weights of 25 day old mice from the NSE-EEF1A2-B line. 
Body weight measurements (in grams) from wildtype animals (+/+,+/+), wildtype 
animals with the transgene (+/tg, +/+), heterozygote animals without the transgene 
(+/+, +/wst), heterozygote animals with the transgene (+/tg, +/wst) wasted animals 
without the transgene (+/+, wst/wst) and wasted animals with the transgene (+/tg, 
wst/wst) are shown. Animals were weighed at 25 days (end stage).  *** indicates a p 
value <0.01 
 
Genotype N Mean Min Max S.D S.E.M 
(+/+, +/+) 13 12.7 11.0 14.1 0.9 0.3 
(+/tg, +/+) 13 12.1 7.6 15.2 1.7 0.5 
(+/+, +/wst) 15 11.5 9.5 12.9 1.0 0.3 
(+/tg, +/wst) 9 11.6 9.9 13.9 1.3 0.4 
(+/+, wst/wst) 8 7.3 5.1 9.9 1.6 0.6 
(+/tg, wst/wst) 6 11.7 10.7 12.8 0.9 0.4 
Table 4.4. Body weights of 25 day old mice from the NSE-EEF1A2-B line. 
Statistical analysis of body weights from mice of the NSE-EEF1A2-B line. Animals 
were weighed at 25 days (end stage). Number of animals (N), mean, minimum (Min) 
and maximum (Max) bodyweight for each genotype are shown. S.D indicates the 
standard deviation across each genotype and S.E.M is a measure of the standard error 
of the mean. 
*** 
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Grip strength analysis 
At 25 days of age, analysis of grip strength in both forelimbs only and all four limbs 
showed that wasted mice carrying the transgene (+/tg, wst/wst) were 
indistuinguishable from wildtype animals (+/+,+/+) and had significantly higher grip 
strength than wasted mice without the transgene (+/+, wst/wst). It appears that the 
poor grip strength normally seen in wasted mice is therefore corrected upon 
expression of the transgene. 
 
NSE-EEF1A2-B






































































































































Figure 4.11. Grip strength analysis of 25 day old mice from the NSE-EEF1A2-B 
line. 
Mean grip strength analysis from 25 day old wildtype animals (+/+,+/+), wildtype 
animals with the transgene (+/tg, +/+), heterozygote animals without the transgene 
(+/+, +/wst), heterozygote animals with the transgene (+/tg, +/wst), wasted animals 
without the transgene (+/+, wst/wst) and wasted animals with the transgene (+/tg, 
wst/wst) from the NSE-EEF1A2 line B are shown. Forelimb (left graph) and all four 
limb (right graph)  grip strength readings from 3 tests (measured in Newtons) were 




(a)  (b)  
 **  ** 
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(a) Forelimbs only 
Genotype N Mean Min Max S.D S.E.M 
(+/+, +/+) 13 0.049 0.038 0.060 0.007 0.002 
(+/tg, +/+) 13 0.044 0.031 0.059 0.007 0.002 
(+/+, +/wst) 15 0.045 0.031 0.060 0.010 0.003 
(+/tg, +/wst) 9 0.049 0.032 0.060 0.010 0.003 
(+/+, wst/wst) 8 0.028 0.017 0.040 0.009 0.003 
(+/tg, wst/wst) 6 0.044 0.034 0.060 0.009 0.004 
(b) All four limbs 
Genotype N Mean Min Max S.D S.E.M 
(+/+, +/+) 13 0.083 0.062 0.121 0.015 0.004 
(+/tg, +/+) 13 0.083 0.065 0.112 0.016 0.004 
(+/+, +/wst) 15 0.075 0.055 0.095 0.010 0.003 
(+/tg, +/wst) 9 0.084 0.073 0.101 0.009 0.003 
(+/+, wst/wst) 8 0.061 0.046 0.085 0.013 0.004 
(+/tg, wst/wst) 6 0.086 0.076 0.097 0.008 0.003 
 
Table 4.5. Grip strength analysis of 25 day old mice from the NSE-EEF1A2-B 
line. 
Statistical analysis of grip strength from 25 day old wildtype animals (+/+,+/+), 
wildtype animals with the transgene (+/tg, +/+), heterozygote animals without the 
transgene (+/+, +/wst), heterozygote animals with the transgene (+/tg, +/wst) wasted 
animals without the transgene (+/+, wst/wst) and wasted animals with the transgene 
(+/tg, wst/wst) from the NSE-EEF1A2 line B. Animals were weighed at 25 days 
(wasted end stage). Number of animals (N), mean, minimum (Min) and maximum 
(Max) grip strength reading for each genotype are shown. S.D indicates the standard 
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Protein expression 
Western blots indicate that the transgene is expressed at the protein level in animals 
from NSE-EEF1A2 line B (Figure 4.12). Expression is not however restricted to the 
central nervous system. Brain, spinal cord, muscle, heart and liver samples were 
analysed for protein expression from 25 day old animals. Three wildtype animals 
(+/+, +/+), three wildtype animals carrying the transgene (+/tg, +/+), three wasted 
animals (+/+, wst/wst) and three wasted animals carrying the transgene (+/tg, 
wst/wst) were analysed. Results show that the transgene is expressed in brain and 
spinal cord as expected but also in muscle and heart tissue (figure 4.12). Panels of 
tissues from six week old wasted animals carrying the transgene were also examined 
(an example can be seen in figure 4.13). No expression of eEF1A2 was seen in any 
other tissues examined.    The protein expression pattern in wasted animals carrying 
the transgene (+/tg, wst/wst) is therefore as is seen in wildtype animals at the level of 
detection of the whole tissue by Western blotting.  
 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 4: Investigating the primary cause of the pathology in wasted mice 118 
Western blots showing expression of eEF1A2 and GAPDH (as a loading control) of animals 
from the transgenic line NSE-EEF1A2-B. Expression from three animals from each group 
(wildtype (+/+,+/+), wildtype with the transgene (+/+, +/tg,) wasted animals without the 
transgene (+/+, wst/wst) and wasted animals with the transgene (+/tg, wst/wst)) are shown. 
M indicates a muscle sample (as an eEF1A2 positive control) and L indicates a liver sample 
(an eEF1A2 negative control).   
 
Figure 4.12. eEF1A2 protein expression in tissues from NSE-EEF1A2-B line 
animals. 
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Figure 4.13. eEF1A2 protein expression in a panel of  tissues from NSE-
EEF1A2-B line animals. 
Western blots showing expression of eEF1A2 and GAPDH (as a loading control) on 
an expanded panel of tissues from a wasted animal carrying the transgene (+/tg, 
wst/wst) from the transgenic line NSE-EEF1A2-B. M=Muscle, H=Heart, Br=Brain, 
SC= Spinal cord, Li=Liver, K=Kidney, Sp = Spleen, P=Pancreas, C=Colon, 
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Immunohistochemistry 
Spinal cord and brain sections of animals from the NSE-EEF1A2 line B were stained 
by immunohistochemistry using an eEF1A2 specific antibody. This was to 
investigate whether the same patterns of eEF1A2 expression was seen at the cellular 
level between wildtype mice (+/+, +/+) and wasted animals carrying the transgene 
(+/tg, wst/wst). In the spinal cord, wasted animals carrying the transgene showed 
similar staining patterns compared to wildtype controls (figure 4.14). Staining was 
observed in the motor neurons as expected but also some additional staining was 
seen in non-motor neuron cells in the white matter. This ectopic expression of 
eEF1A2 in smaller neurons appears not be deleterious in terms of survival but may 
warrant further examination. 
Brain expression of eEF1A2  was again similar between wildtype animals (+/+, +/+) 
and wasted animals carrying the transgene (+/tg, wst/wst) including positive staining 
of the Purkinjie cells of the cerebellum (figure 4.15) and also in the cells of the 
hippocampus (figure 4.16). This is the same expression pattern as that seen in 
wildtype mice.  
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Figure 4.14. eEF1A2 expression in the spinal cord of animals from NSE-
EEF1A2 line B.  
Cervical spinal cord sections from animals from the NSE-EEF1A2-B line stained 
with an antibody recognising eEF1A2. Panels (a) and (b) are from a wildtype animal 
(+/+, +/+), panels (c) and (d) are from a wasted animal (+/+, wst/wst) and panels (e) 
and (f) are from a wasted animal carrying the transgene (+/tg, wst/wst).  Panels (a), 
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Figure 4.15.  eEF1A2 expression in the cerebellum of animals from NSE-
EEF1A2 line B.  
Cerebella sections of animals from the NSE-EEF1A2-B line stained with an antibody 
recognising eEF1A2. Panels (a) and (b) are from a wildtype animal (+/+, +/+), panels 
(c) and (d) are from a wasted animal (+/+, wst/wst) and panels (e) and (f) are from a 
wasted animal carrying the transgene (+/tg, wst/wst).  Panels (a), (c) and (e) are at 4x 
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Figure 4.16. eEF1A2 expression in the hippocampus of animals from NSE-
EEF1A2 line B.  
Hippocampal sections from animals from the NSE-EEF1A2-B line stained with an 
antibody recognising eEF1A2. Panels (a) and (b) are from a wildtype animal (+/+, 
+/+), panels (c) and (d) are from a wasted animal (+/+, wst/wst) and panels (e) and (f) 
are from a wasted animal carrying the transgene (+/tg, wst/wst).  Panels (a), (c) and 
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eEF1A2 expression in the pancreas 
Wasted animals with the transgene (+/tg, wst/wst) appear indistinguishable from 
wildtype mice at the protein level in all tissue and the cellular level in brain and 
spinal cord. Previously, immunohistochemistry experiments have revealed that 
eEF1A2 is also expressed in specialised cells in other tissues (not detected by 
Western blotting) including cells within the Islets of Langerhans in the pancreas 
(Newbery et al., 2007). 
Immunohistochemistry was performed on sections of pancreas from NSE-EEF1A2-B 
animals at 6 weeks of age to investigate eEF1A2 expression. Unlike wildtype 
animals no expression of eEF1A2 was observed in the islet cells of wasted animals 
carrying the transgene (+/tg, wst/wst). In conclusion wasted animals carrying the 
transgene (+/tg, wst/wst) from NSE-EEF1A2 line B are indistinguishable from 
wildtype animals in terms of protein expression at the level of whole tissue but 
maybe not at the level of specific cell types. 
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Figure 4.17. eEF1A2 expression in the pancreas of animals from NSE-EEF1A2 
line B.  
Pancreas sections of animals from the NSE-EEF1A2-B line stained with an antibody 
recognising eEF1A2. Panels (a) and (b) are from a wildtype animal (+/+, +/+), panels 
(c) and (d) are from a wasted animal (+/+, wst/wst) and panels (e) and (f) are from a 
wasted animal carrying the transgene (+/tg, wst/wst).  Panels (a), (c) and (e) are at 
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4.3.4.3. NSE-EEF1A2-C 
As with the NSE-EEF1A2 line B, the NSE-EEF1A2-C line wasted mice carrying the 
transgene (+/tg, wst/wst) showed no observable signs of neuromuscular disease at 25 
days. Wasted mice carrying the transgene (+/tg, wst/wst) were indistinguishable from 
wildtype mice (+/+, +/+) at 25 days of age (figure 4.18). The splenic and thymic 
atrophy normally seen in wasted mice (+/+, wst/wst) was not observed in wasted 
mice carrying the transgene (+/tg, wst/wst). It therefore appears that the NSE-
EEF1A2 transgene has corrected some aspects of the wasted phenotype in line C.  
 
Body weight 
As wasted mice show a dramatic decrease in body weight from 21 days until death, 
mice from the NSE-EEF1A2-C line were weighed at 25 days (end stage) to assess 
whether this disease phenotype was corrected (figure 4.19, Table 4.6). Wasted mice 
carrying the transgene (+/tg, wst/wst) showed a significant difference in body weight 
compared to wasted animals without the transgene (+/+, wst/wst). No significant 
difference was observed between wasted mice with the transgene and wildtype 
controls. As expected wasted mice showed a significant decrease in body weight 
compared to littermate controls. It would appear that the transgene has therefore 
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Figure 4.18. Photographs of animals from the NSE-EEF1A2-C line. 
Photographs of animals from the NSE-EEF1A2-C line. Panels (a) and (b) show a 
wildtype animal (+/+,+/+) a wasted animal (+/+, wst/wst) and a wasted animal 
carrying the transgene (+/tg, wst/wst). Panels C (spleen) and D (thymus) show 









  +/+               +/+              +/tg   
wst/wst           +/+            wst/wst  
(d) Thymus (c) Spleen 
  +/+                   +/+              +/tg   
wst/wst               +/+            wst/wst  
+/tg 
wst/wst 
(b)  (a)  
                              Investigating the role of eEF1A2 in motor neuron degeneration 

























































Figure 4.19. Body weights of 25 day old mice from the NSE-EEF1A2-C line. 
Body weight measurements from wildtype animals (+/+,+/+), wildtype animals with 
the transgene (+/tg, +/+), heterozygote animals without the transgene (+/+, +/wst), 
heterozygote animlas with the transgene (+/tg, +/wst), wasted animals without the 
transgene (+/+, wst/wst) and wasted animals with the transgene (+/tg, wst/wst) are 
shown. Animals were weighed at 25 days (end stage). *** indicates a p value <0.01  
 
Genotype N Mean Min Max S.D S.E.M 
(+/+, +/+) 6 13 10.9 14.6 1.7 0.7 
(+/tg, +/+) 5 11.2 9 15.4 2.6 1.2 
(+/+, +/wst) 8 11.5 10.1 14.6 1.4 0.5 
(+/tg, +/wst) 6 11.1 10.4 11.7 0.4 0.2 
(+/+, wst/wst) 9 7.6 6.6 8.9 0.9 0.3 
(+/tg, wst/wst) 10 11.3 8 14.6 2.4 0.8 
Table 4.6. Body weights of 25 day old mice from the NSE-EEF1A2-C line. 
Statistical analysis of body weights of mice from the NSE-EEF1A2-C line. Animals 
were weighed at 25 days (disease end stage). Number of animals (N), mean, 
minimum (Min) and maximum (Max) bodyweight for each genotype are shown. S.D 
indicates the standard deviation across each genotype and S.E.M is a measure of the 
standard error of the mean. 
 
*** 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 4: Investigating the primary cause of the pathology in wasted mice 129 
Grip strength analysis 
Analysis of both forelimb and all four limb grip strength (figure 4.20, table 4.7) 
showed that wasted mice carrying the transgene (+/tg, wst/wst) were 
indistinguishable from wildtype animals (+/+,+/+) and had significantly higher grip 
strength than wasted mice without the transgene (+/+, wst/wst). It appears that the 
poor grip strength normally seen in wasted mice is therefore corrected by the 
expression of the transgene in this line. 
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Figure 4.20. Grip strength analysis of 25 day old mice from the NSE-EEF1A2-C 
line. 
Mean grip strength analysis from 25 day old wildtype animals (+/+,+/+), wildtype 
animals with the transgene (+/tg, +/+), heterozygote animals without the transgene 
(+/+, +/wst), heterozygote animals with the transgene (+/tg, +/wst), wasted animals 
without the transgene (+/+, wst/wst) and wasted animals with the transgene (+/tg, 
wst/wst) from the NSE-EEF1A2 line C are shown. Forelimb (left graph) and all four 
limb (right graph)  grip strength readings from 3 tests (measured in Newtons) were 
normalised to body weight (measured in grams). *** indicates a p value <0.001 and 
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 (a) Forelimbs only 
 (b) All four limbs 
Genotype N Mean Min Max S.D S.E.M 
(+/+, +/+) 6 0.080 0.063 0.097 0.012 0.005 
(+/tg, +/+) 5 0.094 0.069 0.107 0.016 0.007 
(+/+, +/wst) 8 0.092 0.075 0.114 0.013 0.004 
(+/tg, +/wst) 6 0.085 0.060 0.115 0.020 0.008 
(+/+, wst/wst) 9 0.060 0.040 0.091 0.017 0.006 
(+/tg, wst/wst) 10 0.048 0.032 0.064 0.009 0.003 
 
Table 4.7. Grip strength analysis of 25 day old mice from the NSE-EEF1A2-C 
line. 
Statistical analysis of grip strength from 25 day old wildtype animals (+/+,+/+), 
wildtype animals with the transgene (+/tg, +/+), heterozygote animals without the 
transgene (+/+, +/wst), heterozygote animals with the transgene (+/tg, +/wst) wasted 
animals without the transgene (+/+, wst/wst) and wasted animals with the transgene 
(+/tg, wst/wst) from the NSE-EEF1A2 line C. Animals were tested at 25 days 
(wasted end stage). Number of animals (N), mean, minimum (Min) and maximum 
(Max) bodyweight for each genotype are shown. S.D indicates the standard deviation 




Genotype N Mean Min Max S.D S.E.M 
(+/+, +/+) 6 0.044 0.033 0.052 0.007 0.003 
(+/tg, +/+) 5 0.047 0.041 0.058 0.007 0.003 
(+/+, +/wst) 8 0.050 0.034 0.061 0.010 0.003 
(+/tg, +/wst) 6 0.047 0.040 0.054 0.005 0.002 
(+/+, wst/wst) 9 0.029 0.014 0.044 0.010 0.003 
(+/tg, wst/wst) 10 0.048 0.032 0.064 0.009 0.003 
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Protein expression 
Western blots indicate that the transgene is expressed at the protein level. As in The 
NSE-EEF1A2-B line, expression is not restricted to the central nervous system 
(figure 4.21). Brain, spinal cord, muscle, heart and liver samples were analysed for 
protein expression from 25 day old animals. Three wildtype animals (+/+, +/+), three 
wildtypes carrying the transgene (+/tg, +/+), three wasted animals (+/+, wst/wst) and 
three wasted animals carrying the transgene (+/tg, wst/wst) were analysed. Results 
show that the transgene is expressed in brain and spinal cord as expected but again 
also in muscle (figure 4.21). Unlike NSE-EEF1A2-B however, it initially appeared 
that there was no eEF1A2 expression in heart (figure 4.21 panel (d)). Further 
investigation of the hearts of more animals actually showed variable expression of 
eEF1A2 (figure 4.26, table 4.8).  Panels of tissues from six week old wasted animals 
carrying the transgene were also examined (an example can be seen in figure 4.22). 
No expression of eEF1A2 was seen in any other tissues examined.  
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Western blots showing expression of eEF1A2 and GAPDH (as a loading control) of 
animals from the transgenic line NSE-EEF1A2-C. Expression from three  animals 
from each group (wildtype (+/+,+/+), wildtype with the transgene (+/+, +/tg), 
wasted animals without the transgene (+/+, wst/wst) and wasted animals with the 
transgene (+/tg, wst/wst)) are shown. M indicates a muscle sample (as an eEF1A2 
positive control) and L indicates a liver sample (an eEF1A2 negative control).  
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Figure 4.22. eEF1A2 protein expression in a panel of  tissues from NSE-
EEF1A2-C line animals. 
Western blots showing expression of eEF1A2 and GAPDH (as a loading control) on 
an extended tissue panel from a wasted animal carrying the transgene (+/tg, wst/wst) 
from the transgenic line NSE-EEF1A2-B. M=Muscle, H=Heart, Br=Brain, SC= 
Spinal cord, Li=Liver, K=Kidney, Sp = Spleen, P=Pancreas, C=Colon, Lu=Lung. 






Spinal cord and brain sections of animals from the NSE-EEF1A2 line C were stained 
by immunohistochemistry using an eEF1A2 specific antibody. This was to 
investigate whether the same patterns of eEF1A2 expression was seen at the cellular 
level between wildtype mice (+/+, +/+) and wasted animals carrying the transgene 
(+/tg, wst/wst). The staining pattern in the spinal cord from wasted animals carrying 
the transgene was indistinguishable from that seen in wildtype controls (figure 4.23). 
Brain expression of eEF1A2  was again similar between wildtype animals (+/+, +/+) 
and wasted animals carrying the transgene (+/tg, wst/wst) including positive staining 
of the Purkinjie cells of the cerebellum (figure 4.24) and also in the cells of the 
hippocampus (figure 4.25), in keeping with wildtype expression. 
GAPDH 37KDa 
  M         H         Br        SC        Li        K        Sp         P         C         T        Lu 
eEF1A2 50KDa 
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Figure 4.23. eEF1A2 expression in the spinal cord of animals from NSE-
EEF1A2 line C.  
Cervical spinal cord sections from animals from the NSE-EEF1A2-C line stained 
with an antibody recognising eEF1A2. Panels (a) and (b) are from a wildtype animal 
(+/+, +/+), panels (c) and (d) are from a wasted animal (+/+, wst/wst) and panels (e) 
and (f) are from a wasted animal carrying the transgene (+/tg, wst/wst).  Panels (a), 
(c) and (e) are at 4x magnification while panels (b), (d) and (f) are at 10x 
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Figure 4.24. eEF1A2 expression in the cerebellum of animals from NSE-
EEF1A2 line C.  
Cerebella sections from animals from the NSE-EEF1A2-C line stained with an 
antibody recognising eEF1A2. Panels (a) and (b) are from a wildtype animal (+/+, 
+/+), panels (c) and (d) are from a wasted animal (+/+, wst/wst) and panels (e) and (f) 
are from a wasted animal carrying the transgene (+/tg, wst/wst).  Panels (a), (c) and 
(e) are at 4x magnification while panels (b), (d) and (f) are at 10x magnification. 
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Figure 4.25. eEF1A2 expression in the hippocampus of animals from NSE-
EEF1A2 line C.  
Hippocampal sections from animals from the NSE-EEF1A2-C line stained with an 
antibody recognising eEF1A2. Panels (a) and (b) are from a wildtype animal (+/+, 
+/+), panels (c) and (d) are from a wasted animal (+/+, wst/wst) and panels (e) and (f) 
are from a wasted animal carrying the transgene (+/tg, wst/wst).  Panels (a), (c) and 
(e) are at 4x magnification while panels (b), (d) and (f) are at 10x magnification. 
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A possible heart phenotype. 
Prior to the knowledge of the variable expression of eEF1A2 in heart, a cohort of 
animals from the NSE-EEF1A2 line C were aged to six months to further investigate 
any phenotype caused by this transgene in animals of adult mice. A proportion ( 5 
out of 9) of the wasted animals with the transgene in this ageing cohort failed to 
survive to 6 months. Animals would die suddenly between 6 weeks and  4 months of 
age. On observation of two of these animals,  hearts appeared enlarged. This initiated 
a further study into the heart phenotype of these animals.  
Initially it appeared that wasted mice carrying the transgene from line C had no 
expression of eEF1A2 in heart (even though it was expressed everywhere else that 
eEF1A2 would be seen in wildtype animals) on a Western blot as shown in figure 
4.21, but this was not the case for all animals (figure 4.26). Further wasted animals 
carrying the transgene (+/tg, wst/wst) of around 6 weeks of age were analysed for 
heart eEF1A2 expression by Western blotting (figure 4.26). As can be seen in figure 
4.26 expression was highly variable. Table 4.8 displays data from all animals so far 
investigated for heart eEF1A2 expression to attempt to identify any correlations 
between heart eEF1A2 expression and sex and/or genetic lineage. No obvious 
correlation was seen but this is further elaborated on in the discussion section of this 
chapter. 
In the animals where no eEF1A2 expression was observed in the heart (figure 4.21), 
eEF1A1 expression was also investigated in the hearts of these animals to identify 
whether a compensatory mechanism was in place. As is shown in figure 4.27, no 
expression of eEF1A1 was observed in these samples thus eEF1A1 is not 
compensating for the loss of eEF1A2 in these animals.  
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Figure 4.26. eEF1A2 expression in heart tissue of wasted animals carrying the 
transgene from the NSE-EEF1A2 line C.  
eEF1A2 and GAPDH expression in heart tissue from 12 wasted animals carrying the 
transgene (+/tg, wst/wst).  
 
 
Table 4.8. eEF1A2 expression in heart tissue of wasted animals carrying the 
transgene from the NSE-EEF1A2 line C.  
Details of 12 wasted animals carrying the transgene (+/tg, wst/wst) including age and 
cause of death, sex, the degree of eEF1A2 expression (as shown in figure 4.26), 
breeding pair (to display which mice are from the same parental line) and an 











1 4 weeks Culled Female Yes (weak) Two Male 
2 4 weeks Culled Female No Two Male 
3 6 weeks Culled Male No Two Male 
4 6 weeks Unknown Male No Two Male 
5 7 weeks Unknown Male No Two Male 
6 6 weeks Culled Male Yes (strong) Four Female 
7 6 weeks Culled Male Yes (weak) Four Female 
8 6 weeks Culled Male Yes (weak) Four Female 
9 7 weeks Culled Female Yes (strong) Four Female 
10 7 weeks Culled Male Yes (weak) Four Female 
11 6 weeks Culled Female Yes (strong) Six Male 







   1      2      3      4     5      6     7    8     9     10    11    12       
GAPDH 37KDa 
eEF1A2 50KDa 
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Figure 4.27. eEF1A1 expression in heart tissue of animals from the  NSE-
EEF1A2-C line 
Western blots showing expression of eEF1A1 and GAPDH (as a loading control) of 
animals from the transgenic line NSE-EEF1A2-C. Expression from three  animals 
from each group ( wildtype (+/+,+/+), wildtype with the transgene (+/+, 
+/tg,}wasted animals without the transgene (+/+, wst/wst) and wasted animals with 
the transgene (+/tg, wst/wst)) are shown. M indicates a muscle sample (as an 









+/+, +/+         +/tg, +/+       +/+, wst/wst    +/tg, wst/wst 
GAPDH 37KDa 
eEF1A1 50KDa 
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4.4. Discussion 
The nature of the primary cause of the pathology of wasted mice is still to be 
confirmed. It remains to be established whether the loss of eEF1A2 in muscle 
leading to a primary muscle myopathy is the primary cause of the muscle pathology, 
or whether it is the loss of neuronal eEF1A2 causing denervation of muscle that leads 
to muscle atrophy. 
As mentioned, Permphan Dharmasaroja’s work addressed one half of this important 
question. It was shown that expression of eEF1A2 exclusively in muscle, did not 
appear to rescue the wasted phenotype, despite significant levels of eEF1A2 protein 
expression in muscle tissue. Only one transgenic line that expressed muscle specific 
eEF1A2 was generated. Further lines should be investigated, to eliminate the 
possibility of the results observed being due solely to the integration site of the 
transgene. Four additional transgenic lines were generated within this project by 
microinjection of the construct used previously (Dharmasaroja 2007). Unfortunately 
restrictions in animal movements imposed by the Biological Research Facility 
resulted in the generation of wasted mice carrying the transgene being significantly 
delayed. This in turn prevented expression analysis from being conducted on wasted 
mice carrying the muscle specific transgene within the time scale of the project. 
Preliminary results generated by Jennifer Doig suggests that two of the four lines 
express eEF1A2 specifically in muscle tissue and this expression does not correct the 
wasted phenotype (unpublished data). These results are consistent with those of the 
previous line generated (Dharmasaroja 2007) and as such further support the notion 
that the loss of neuronal eEF1A2 is the primary cause of the muscle pathology. To 
complete the picture, rescue by neuronal eEF1A2 only, needs to be demonstrated, 
which was the primary aim of this study.    
To directly compare the two halves of this experiment, the same methodology was 
used in this study as was used by Permphan (Dharmasaroja 2007). The same eEF1A2 
construct was used to isolate the gene and the same restriction sites were used to 
insert the promoter (neuronal specific enolase (NSE) promoter) as was used in the 
generation of the muscle specific promoter used previously. One deviation from the 
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previous protocol was required; the method of purification of the eEF1A2 fragment. 
In his thesis Permphan describes how using gel purification he was able to separate 
the unwanted eEF1A2 promoter region from the required fragment (Dharmasaroja 
2007). Although the same protocol was followed here, the gel purification protocol 
appeared to hinder ligation. Thus it was deemed necessary to simply purify the entire 
digest with a purification kit (rather than separate out the fragments on a gel) and 
then add promoter at a higher ratio than was used previously. This resulted in an 
increased number of colonies requiring screening due to the competition between the 
EEF1A2 promoter and the new NSE promoter. Positive colonies were eventually 
identified by PCR and confirmed by restriction digest, however this did result in a 
delay in the cloning of the construct. 
As previously described, three transgenic lines were generated in the first round of 
injection of which all three transmitted through the germline. It quickly became 
apparent that two of the three transgenic lines were rescuing the wasted phenotype. 
The third line NSE-EEF1A2-A failed to rescue any aspect of the wasted phenotype. 
Expression analysis quickly showed that although the construct was present in the 
genomic DNA, it was not being expressed at the protein level or the RNA level (data 
not shown). The reason for this is undetermined however it is likely to be due to the 
site of integration. For example  the transgene may have integrated into an area of the 
genome which is transcriptionally inactive or is strongly repressed.  
At first it appeared the other two lines (NSE-EEF1A2-B and NSE-EEF1A2-C) were 
completely rescuing the wasted phenotype. Unfortunately expression analysis 
showed undesired, non-specific expression in muscle tissue. As a result the aims of 
the project could not be addressed, as expression was not exclusively neuronal.  
NSE-EEF1A2-B showed the same expression pattern on a Western blot as is seen in 
wildtype animals. In wasted animals carrying the transgene (+/tg, wst/wst) eEF1A2 
expression was observed in brain, spinal cord, muscle and heart but in no other tissue 
examined. Non-specific promoter expression of  transgenes is commonly seen and is 
often due to the site of integration. One possibility in this study is that the transgene 
has integrated into the genome adjacent to a muscle specific promoter/enhancer 
element, resulting in non-specific muscle expression. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 4: Investigating the primary cause of the pathology in wasted mice 143 
This is not the first study using this promoter to see non-specific expression. In Shim 
et al expression of the transgene was found to be expressed at high levels in the brain 
and lower levels of expression was observed in kidney and liver but none in muscle 
(Shim et al., 2007). Hwang et al (Hwang et al., 2002) also used this promoter and 
presented two transgenic lines, one of which had very non-specific expression across 
multiple tissue types and the other showed expression in brain, muscle and heart (like 
our study). Many investigations using the rat NSE promoter region described by 
Forss-Petter et al (Forss-Petter et al., 1990) had directly received a plasmid 
containing the promoter from the authors of the paper. It is possible that there may be 
slight discrepancies between the sequence of the promoter cloned here and the one 
cloned in other studies. The NSE promoter-containing-plasmid was therefore kindly 
donated by Dr Forss-Petter. This promoter was sequenced and compared to that 
obtained from the RAT2 cell line that was used in this study. A single discrepancy 
was identified; the promoter used in this study contained an additional 20bp 
upstream of the NSE promoter. This additional sequence was investigated and the 
only sequence found to match this 20bp region was that of NSE. It is therefore 
unlikely that this additional 20bp is the cause of the non-specific muscle expression 
seen in this study. To remove any doubt, in future studies a direct PCR of the 
promoter construct received from the Forss-Petter lab should be used to correspond 
exactly with the experiments previously reported. Other neuronal specific promoters 
such as the Thy1.2 expression cassette (Caroni 1997) should also be investigated.  
The cell specific expression of eEF1A2 in pancreas of NSE-EEF1A2-B wasted mice 
carrying the transgene (+/tg, wst/wst) was also investigated. In addition to expression 
of eEF1A2 in the CNS and muscle tissue, some specialized cell types in other tissues 
also express eEF1A2. The Islets of Langerhan cells, some neuroendocrine cells in the 
base of the gut and retinal ganglion cells are examples (Newbery et al., 2007). The 
Islets of Langerhans were investigated in these transgenic animals to assess whether 
there is any difference in expression between wildtype animals (+/+, +/+)  and 
wasted animals carrying the transgene (+/tg, wst/wst). Results showed no eEF1A2 
expression in the Islets of Langerhans in wasted mice carrying the transgene (+/tg, 
wst/wst). While this loss appears not to influence any of the observable symptoms in 
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wasted mice, it will be interesting to investigate whether these animals display any 
abnormalities in the pancreas because of this lack of eEF1A2 in the islets. A cohort 
of animals were aged to >6months of age to examine this. Pathological analysis of 
the pancreas showed no observable differences between wasted mice carrying the 
transgene (+/tg, wst/wst) and wildtype controls (data not shown). However, the 
pancreas should be analysed biochemically in these animals, to elucidate whether 
eEF1A2 is required for nomal pancreatic function. At the time of completion of the 
project the necessary licence was not in place to conduct such experiments but these 
will be conducted in the future.  
The non-specific expression of eEF1A2 has prevented the aims of this project from 
being addressed, however overexpression of eEF1A2 in muscle is of interest to Dr 
Bernard Jasmin’s group (Miura et al., 2010). They are now investigating tissue 
samples from wildtype animals carrying the transgene as they appear to express 
eEF1A2 above the level observed in wildtype animals. Any results from this 
investigation have yet to be reported. 
Inititally, NSE-EEF1A2 line C appeared to have the same limitations as the NSE-
EEF1A2-B line. Like in NSE-EEF1A2 line B,  wasted mice carrying the transgene 
(+/tg, wst/wst) in NSE-EEF1A2 line C showed no observable signs of neuromuscular 
disease. Initial expression analysis suggested that protein expression in the NSE-
EEF1A2-C line was again not restricted to the central nervous system (CNS). In the 
panel of  mice investigated, expression was observed in brain, spinal cord and muscle 
of wasted mice carrying the transgene (+/tg, wst/wst). Unlike in the NSE-EEF1A2-B 
line no expression of EEF1A2 was initially observed in hearts of wasted mice 
carrying the transgene (+/tg, wst/wst). Thus it appeared that eEEF1A2 expression 
had been corrected in the CNS and muscle but not heart. At this time a cohort of 
mice were being aged to 6 months to undertake similar studies as the NSE-EEF1A2-
B line. Many mice in the cohort however, didn’t survive to six months of age. Of the 
9 wasted mice carrying the transgene (+/tg, wst/wst) in this cohort only 4 survived to 
6 months of age. The mice appeared to die spontaneously between 6 weeks and 4 
months of age. Two mice were examined after death and on observation appeared to 
have enlarged hearts. These two mice also showed no expression of eEF1A2 in heart 
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tissue (figure 4.26, animals 4 and 5). The mice that did survive to 6 months were 
sacrificed and either sent for pathological analysis (conducted by David Brownstein) 
or tested for heart eEF1A2 expression. No abnormal pathology was observed in the 
hearts of any of the animals investigated. The hearts of the remaining animals were 
examined by Western blot for eEF1A2 expression. eEF1A2 expression was observed 
in the hearts of these animals. Thus it appears the phenotype of these animals is 
highly variable. To attempt to address this issue the hearts of more wasted animals 
carrying the transgene (+/tg, wst/wst) were investigated. Results were highly 
variable. Some mice expressed no eEF1A2 in heart and others expressed varying 
levels. Many possibilities could account for this outcome and multiple factors were 
considered while attempting to solve this complex issue. No correlation was 
observed between eEF1A2 expression and the sex of the animals suggesting the 
variability was not linked to a single variant on a sex chromosome. Imprinting may 
play a role i.e. the variation could be linked to sex of the transmitting parent, 
however this also appears not to be the case. Multiple integration sites remain one of 
the more likely possibilities.  It is possible that an expressing variant and a non-
expressing variant exist within this line. One variant may have integrated into a site 
where heart expression is inhibited for example. Copy number analysis by Real-Time 
PCR could be used to attempt to address whether there are more than one integration 
sites, or better still Fluorescence In Situ Hybridisation (FISH) could be used to 
identify the integration site/s of the transgene. Generating mouse lines and the 
subsequent breeding steps required to generate sufficient mice of the desired 
phenotype involves unavoidable delays. As such the complex inheritance of the 
transgene remains unresolved. Current studies are focusing on trying to determine 
the inheritance pattern but this is proving very complex. Wasted transgenic males 
(+/tg, wst/wst) are being mated to heterozygous females (+/+, +/wst) to attempt to 
increase the numbers of wasted animals carrying the transgene (+/tg, wst/wst). As 
wasted mice carrying the transgene (+/tg,wst/wst) potentially suffer from a heart-
related disorder, female wasted mice carrying the transgene (+/tg,wst/wst) are not 
being used for breeding because pregnancy may put too much pressure on the heart. 
One breeding pair in particular, breeding pair two, produced the most wasted mice 
carrying the transgene (+/tg, wst/wst) without eEF1A2 expression in the heart. 
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However not all wasted transgenic animals from this pair  have no eEF1A2 
expression in the heart. Offspring of this breeding pair are the main focus of current 
breeding strategies. At the time of submitting this thesis this issue had not been 
resolved. An additional point to be considered is that in the work by Permphan 
Dharmasroja on the muscle specific transgenic line, some wasted mice carrying the 
muscle specific transgene had expression in both heart and muscle and some only in 
muscle. In the data shown (Dharmasaroja 2007), two animals that express eEF1A2 in 
heart are females and the two animals that only express eEF1A2 in muscle are male. 
The significance of this is unclear with such small numbers but the new muscle 
specific lines may further help to clarify the significance of these findings.  
While the NSE-EEF1A2 line C cannot be used to address the initial aims of this 
experiment they still may prove to be a very interesting model for future studies 
investigating the loss of eEF1A2 in the hearts of wasted mice. Once the inheritance 
of the transgene can be confirmed, a line expressing eEF1A2 in all tissues where it is 
normally expressed with the exception of the heart could be generated. An alternative 
strategy would be to produce a heart-specific conditional knockout of eEF1A2. Such 
lines could address many important questions regarding the pathology of wasted 
mice. An important question that needs to be addressed is how animals with no 
expression of eEF1A2 in heart can survive to at least 6 weeks of age (the earliest age 
at which sudden death occurred in wasted mice carrying the transgene). In wasted 
mice, eEF1A1 expression is observed in heart until 21 days (Khalyfa et al., 2001) 
after which time, in wildtype animals, expression of eEF1A2 takes over. Therefore in 
mice from line C where no expression of eEF1A2 is seen in heart it is presumed that 
by 21 days the hearts of these animals will express neither eEF1A1 or eEF1A2. This 
has been shown in some of these animals (figures 4.21 and 4.27). The crucial 
question is how these animals survive without this essential translation factor. An 
interesting avenue of investigation is to assess how much protein synthesis is taking 
place in the hearts of these animals before and after the eEF1A variant switch.. A 
recently publish technique named SUnSET (Surface Sensing of Translation) uses an 
analogue of aminoacyl tRNAs, (puromycin) to achieve this (Schmidt et al., 2009).  
The incorporation of puromycin into proteins directly reflects the rate of mRNA 
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translation. Antibodies to puromycin are then used to directly monitor translation 
using immunofluorescence. This non-radioactive method is currently being 
investigated by our lab. 
 
4.5. Conclusion 
In conclusion the main aim of this project could not be achieved due to the non-
specific expression of the transgene. However  interesting transgenic lines have been 
generated which with some further work could; potentially yield a line suitable for 
investigating the pathology of the hearts of wasted animals (NSE-EEF1A2-C) and 
investigate the role of eEF1A2 in the pancreas (NSE-EEF1A2-B). The questions that 
were intended to be addressed are still of crucial importance for our understanding of 
the wasted phenotype. These experiments should certainly be pursued, with some 
modification.  Injection of a modified construct will hopefully yield wasted animals 
with transgenic expression of eEF1A2 exclusively in the CNS which will be able to 
answer the questions set out in this project.  
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5. Chapter 5: Investigating the role of eEF1A2 in 
motor neuron degeneration 
5.1. Aim 
The first aim of this study was to investigate whether eEF1A2 has a role in human 
motor neuron degeneration. The second aim was to investigate whether recently 
identified candidate genes in human motor neuron disease have disrupted protein 
expression in the wasted mouse model. These data could further validate the wasted 
mouse model as a model for human motor neuron degeneration. 
 
5.2. Introduction 
5.2.1. Animal models of motor neuron degeneration 
Identifying links between animal models and human disease is essential to increase 
our understanding of various diseases and to aid in the development of appropriate 
disease treatments. Animal models are crucial for increasing our understanding of 
diseases as they give a whole biological system with which to work. The links 
between mouse models and human disease are usually uncovered in one of two 
ways. Often studies use information from human disease patients to identify 
candidate genes that are then used to develop animal models to further investigate the 
role of said genes. An example of this is seen with the discovery of SOD1 as a gene 
involved in familial amyotrophic lateral sclerosis (ALS) by linkage analysis (Rosen 
et al., 1993).  This discovery has resulted in the generation of numerous SOD1 
mutant animal models. Alternatively, existing animal models or models generated by 
spontaneous mutation sometimes illuminate genes or biological pathways that are 
then investigated in human disease cases.    
For many years mutations in SOD1 and the subsequent SOD1 mutant models have 
dominated research in ALS. However in recent years numerous new candidate genes 
have come to light as having important roles in the disease. The most prominent of 
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these is the 43KDa TAR DNA binding protein TDP-43. TDP-43 was identified in 
2006 as the major component of ubiquitinated inclusions in the motor neurons of 
sporadic ALS patients (Neumann et al., 2006).  
Since the identification of  TDP-43 as a component of motor neuron inclusions in 
ALS, TDP-43 expression has been thoroughly investigated in numerous models of 
ALS and other neurodegenerative diseases to attempt to find further associations 
between mouse models and human disease. In this project TDP-43 expression is 
investigated in the wasted mouse model. 
The wasted mouse model is an example of a spontaneous mutation in a gene 
(Eef1a2)  leading to a neuromuscular disorder in mice. The wasted mouse model was 
initially thought to be a model for ataxia telangiectasia (Shultz et al., 1982), but on 
further investigation of the pathology of wasted mice it became apparent that it was 
more appropriate as a model for early onset motor neuron degeneration. Wasted mice 
show many similar pathological features of the human disease including vacuolar 
degeneration of motor neurons, reactive gliosis as shown by enhanced GFAP 
expression, neurofilament accumulation in neuronal cell bodies and loss of anterior 
horn motor neurons (Lutsep and Rodriguez 1989; Newbery 2003; Newbery et al., 
2005).  
 
5.2.2. eEF1A2 in human disease 
Positional cloning identified Eef1a2 as the mutated gene in the wasted mouse model 
(Chambers et al., 1998), however little is known about the role of eEF1A2 in human 
disease. To date eEF1A2 has not been identified in any screens such as genome wide 
association studies for genes involved in ALS. In 2009 however a genome wide 
association study identified eEF1D (otherwise known as eEF1Bδ) as a new locus 
demonstrating ALS specific copy number variation (Wain et al., 2009). eEF1B is 
thought to be the guanine exchange factor for eEF1A and thus this finding has very 
interesting implications for understanding the role of eEF1A2 in human motor 
neuron degeneration. 
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In 2006 Bakay et al used microarray technology to analyse gene expression in 
several muscle disorders including nine cases of ALS (Bakay et al., 2006). eEF1A2 
was shown to be downregulated in muscle samples from ALS patients as shown in 
figure 5.1. Groups of samples from other muscle disorders including Duchenne 
muscular dystrophy and Becker muscular dystrophy among others were also 
investigated. Of the disorders analysed eEF1A2 was most significantly decreased in 
samples from ALS patients. This is the first evidence of eEF1A2 being disrupted in 
human motor neuron disease. To our knowledge, eEF1A2 has never been 
investigated in the spinal cord of motor neuron disease patients and so this was the 








Figure 5.1. eEF1A2 is downregulated in muscle samples from patients with ALS.  
A snapshot of expression profiling of eEF1A2 in muscle biopsies from ALS patients (and other muscle disorders) compared to healthy 
controls. The image was prepared using “Genome expression omnibus profiles” on NCBI http://www.ncbi.nlm.nih.gov/sites/geo. The red 
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5.3. Results 
5.3.1. Tissue samples 
Spinal cord sections from ten motor neuron disease (MND) patients and ten controls 
without any known neurological disease were investigated in this study.  Samples 
were kindly provided by Dr Colin Smith from the Edinburgh Brain Bank. Details of 
the samples can be seen in table 5.1.  
Spinal cord samples from low copy number G93A SOD1 mutant mice were also 
examined in this study. These samples were kindly donated by Dr Abraham 
Acevedo-Arozena of  MRC Harwell. Spinal cords from three end-stage (33 weeks of 
age) SOD1 mutant mice were received together with spinal cords from three age-
matched controls, all of which were investigated in this study.  
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ID Age Duration Family 
history 
Diagnosis 
MND-1 72 6 months No MND 
MND-2 77 Months (respiratory illness only) No MND 
MND-3 71 Unknown,  clinically PSP No MND 
MND-4 81 Less than 12 months No MND 
MND-5 77 12 months No MND 
MND-6 70 Unknown No Distal neuropathy 
MND-7 52 3-4 years Yes MND 
MND-8 72 6 months No MND 
MND-9 70 unknown No MND 
MND-10 58 12 months ? MND 
 
 
ID Age Cause of death 
Control-1 55 Ischaemic heart disease 
Control-2 37 Internal haemorrhage 
Control-3 35 Unascertained 
Control-4 53 Ischaemic heart disease 
Control-5 53 Ischaemic heart disease 
Control-6 78 Bronchopneumonia 
Control-7 89 Perforated duodenal ulcer 
Control-8 24 Acute alcohol poisoning 
Control-9 28 Hanging 
Control-10 43 Ischaemic heart disease 
 
Table 5.1. Patient data from MND patients and controls 
Diagnosis, age of onset, disease duration and family history of MND patient samples 
used in this study (table (a)). Cause of death and age at death of control samples used 
in this study (b).   
 
 
(a) MND cases 
(b) Controls 
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5.3.2. eEF1A2 expression in motor neurons 
Expression of eEFIA2 was examined in the human sections by 
immunohistochemistry (IHC) using an eEF1A2-specific antibody, generated by 
Helen Newbery in our laboratory (Newbery 2003). Results showed that in the spinal 
cord sections from all ten of the control samples examined, all showed consistently 
high levels of eEF1A2 expression in the motor neurons (an example is shown in 
figure 5.2 panel (c)). The spinal cord sections from MND patients showed varying 
results. Of the ten MND patient samples examined only two sections showed levels 
of eEF1A2 expression in motor neurons similar to the levels seen in control samples 
(an example is shown in figure 5.1 panel (d)). Four out of the ten displayed variable 
degrees of staining between motor neurons (an example is shown in figure 5.1 panel 
(e)), although overall staining was weaker than control samples. The remaining four 
samples showed no eEF1A2 expression in motor neurons (an example is shown in 
figure 5.1 panel (f)). This is the first evidence of eEF1A2 downregulation in motor 
neurons in MND patients and thus warrants further investigation. To assess whether 
this downregulation in eEF1A2 was simply a result of dying motor neurons, eEF1A2 
expression was also examined in spinal cord sections from end stage SOD1 mutant 
mice. This model has no known mutation in eEF1A2 but mutant mice display severe 
motor neuron pathology, comparable to that seen in human MND patients. As seen in 
figure 5.3. results show that eEF1A2 is not downregulated in motor neurons from the 
SOD1 mutant mice spinal cords. This would suggest that the downregulation of 
eEF1A2 in human MND patients is not simply the result of damaged motor neurons.  
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Figure 5.2. eEF1A2 expression in human MND spinal cords. 
Examples of spinal cord sections from human MND patients and controls stained 
with an antibody recognising eEF1A2. Panel (a) shows a section from a wildtype 
mouse (positive control) and panel (b) shows a section from a wasted (wst/wst) 
mouse (negative control). Panel (c) is an example of a human control section and 
panels (d), (e) and (f) are examples from MND patients. All images were taken at 
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Figure 5.3. eEF1A2 expression in mutant SOD1 mice 
Examples of a cervical spinal cord section from a wildtype (a) and a mutant SOD1 
(b) mouse stained with an antibody recognising eEF1A2. Images were taken at 10x 
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5.3.3. eEF2 expression in motor neurons. 
To confirm the results from the expression analysis of eEF1A2 in spinal cord 
sections of MND patients, it was necessary to find a suitable control that would stain 
motor neurons in both MND patient and control samples equally. Such a control 
would confirm that the downregulation of eEF1A2 is specific to this protein, and not 
a more general decrease in overall protein expression in damaged motor neurons. 
The first of those investigated was the eukaryotic elongation factor 2 (eEF2). As can 
be seen in figure 5.4 the expression of eEF2 was weaker in MND patient samples (an 
example is seen in panel (b)) than control samples (an example is seen in panel (a)). 
Another control was therefore required as this data suggests that perhaps the 
downregulation observed in eEF1A2 may not be specific, and it was possible that a 
general downregulation of either elongation factors or factors involved in protein 
synthesis was being observed. Figure 5.4 also shows that a decrease in expression of 
eEF2 was also seen in SOD1 mutant mice (an example is seen in panel (d)) 
compared to age matched wildtype controls (as example is seen in panel (c)) and also 
in wasted (wst/wst) mice (an example is seen in panel (f)) compared to wildtype 
controls. eEF2 was therefore deemed an unsuitable control for this experiment but 
yielded some potentially interesting results. 
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Figure 5.4. eEF2 expression in human and mouse spinal cord sections 
Examples of spinal cord sections from human MND patients and controls stained 
with an antibody recognising eEF2. Panel (a) and (b) show human spinal cord 
sections from an MND patient (b) and a control (a). Panels (c)-(f) show cervical 
spinal cord sections from a SOD1 (d) mutant mouse along with  an age matched 
control (c) and a wasted (wst/wst) mouse (f) along with an age matched control (e). 
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5.3.4. NeuN expression in motor neurons 
The next control to be investigated was an antibody that detects the neuron specific 
protein NeuN (Neuronal Nuclei). As can be seen in figure 5.5 this antibody has 
proved to be a useful marker of neuronal cells in spinal cords from wildtype (panels 
(c) and (e)), wasted (panel (f)) and SOD1 (panel (d)) mice. However no NeuN 
expression was observed in neuronal cells in the spinal cords of MND patients. Some 
detection was observed in human control samples but staining was highly variable 
and sometimes undetectable thus it was also deemed an unsuitable control antibody 
for this investigation. 
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Figure 5.5. NeuN expression in human and mouse spinal cord sections 
Examples of spinal cord sections from human MND patients and controls stained 
with an antibody recognising NeuN. Panel (a) and (b) show human spinal cord 
sections from an MND patient (b) and a control (a). Panels (c)-(f) show cervical 
spinal cord sections from a SOD1(d) mutant mouse along with  an age matched 
control (c) and a wasted (wst/wst) mouse (f) along with an age matched control (e). 
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5.3.5. GRP78 expression in motor neurons 
The next question was to address whether there may be a more fundamental problem 
with the sections from the MND patient samples, which may explain why motor 
neurons in these samples remain largely unstained with multiple antibodies. All 
samples, while processed on different occasions, were all processed using exactly the 
same protocol. Thus in order to establish whether staining in the motor neurons from 
these MND patient samples could be achieved a protein which has previously shown 
to be overexpressed in motor neurons from MND patients was next examined. The 
protein selected was the stress response chaperone Glucose Regulated Protein 78 
(GRP78). Using an antibody that binds a protein overexpressed in motor neurons 
from ALS patients should indicate whether the motor neurons in these sections are 
capable of staining. If no staining is observed in the patient samples this would 
indicate a more fundamental problem with the sections.  
Motor neurons in spinal cord sections from all ten MND patient samples showed 
strong staining for GRP78, an example is shown in figure 5.6 panel (b). This 
indicates that immunolabelling of motor neurons is achievable in these samples and 
there is no apparent problem with the MND patient samples. The level of staining in 
the MND patients was indistinguishable from the control samples. This therefore 
supports the finding that eEF1A2 expression is truly downregulated in motor neurons 
from some MND patients.  
As can be seen in figure 5.6 no overexpression of GRP78 was observed in spinal 
cords from wasted mice (panel (f)) or SOD1 (panel(d)) mutant mice compared to 
wildtype controls (panels (c) and (e)). 
Identifying a suitable control antibody that detects protein in motor neurons from 
both ALS patient samples and control samples equally is still important. Whilst 
GRP78 appears to stain both ALS patient and control samples equally in this study 
GRP78 has been shown previously to be upregulated in motor neurons from ALS 
patients and as such is not an ideal control.  
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Figure 5.6. GRP78 expression in human and mouse spinal cord sections 
Examples of spinal cord sections from a human MND patient and controls stained 
with an antibody recognising GRP78. Panel (a) and (b) show human spinal cord 
sections from an MND patient (b) and a control (a). Panels (c)-(f) show cervical 
spinal cord sections from a SOD1(d) mutant mouse along with  an age matched 
control (c) and a wasted (wst/wst) mouse (f) along with an age matched control (e). 
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5.3.6. eEF1Bδ expression in motor neurons 
As eEF1Bδ has recently been implicated in ALS, the expression of eEF1Bδ was also 
examined in the spinal cord sections from MND patients. All control samples 
showed similar expression levels of  eEF1Bδ, an example is shown in figure 5.7 
panel (b). Eight of the ten MND patients showed a similar level of  eEF1Bδ 
expression in the motor neurons compared to control samples (an example is shown 
in figure 5.7 (d)). The remaining two samples showed a decrease in eEF1Bδ 
expression in motor neurons although this was variable between cells as shown in 
figure 5.7 panel (c). Therefore overall there was no significant decrease in eEF1Bδ 
expression between spinal cord sections from controls and MND patients although 
this was not the case for all samples. 
eEF1Bδ expression was also examined in spinal cord sections of SOD1 mutant mice. 
Results show that there is no significant difference in the expression of eEF1Bδ 
between control animals (figure 5.7 panel (e)) and SOD1 mutant animals (figure 5.7 
panel (f)). 
 
5.3.6.1. eEF1A2 and eEF1Bδ 
The expression of eEF1A2 and eEF1Bδ is summarised in table 5.2. Data shows some 
correlation between these two translation factors. Whilst a decrease in eEF1A2 does 
not consistently result in a decrease in eEF1Bδ expression, it appears that those 
samples with lower expression of eEF1Bδ have little or no expression of eEF1A2. 
 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 5: Investigating the role of eEF1A2 in motor neuron degeneration 164 
Examples of spinal cord sections from human and mouse spinal cord stained with 
an antibody recognising eEF1Bδ. Panel (a) shows a section from a wildtype 
mouse (positive control), panel (b) is an example of a human control section and 
panels (c) and (d) are examples from MND patients. Sections from the cervical 
spinal cord of a SOD1(f) mouse and an age matched control (e) are also shown.  
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Table 5.2. Analysis of eEF1A2 and eEF1Bδ  expression in motor neurons of ALS patients. 
Expression levels of  eEF1A2 and eEF1Bδ in motor neurons from spinal cord sections of ALS patients. ** indicates strong antibody 
staining throughout the section (similar to control samples), * indicates weak and variable staining and       indicates no observable staining.  
ID Age Duration Family 
history 
Diagnosis eEF1A2 eEF1Bδ 
MND-1 72 6 months No MND  * 
MND-2 77 Months (respiratory illness only) No MND * ** 
MND-3 71 Unknown,  clinically PSP No MND ** ** 
MND-4 81 Less than 12 months No MND * ** 
MND-5 77 12 months No MND  ** 
MND-6 70 Unknown No Distal neuropathy  ** 
MND-7 52 3-4 years Yes MND  ** 
MND-8 72 6 months No MND * ** 
MND-9 70 unknown No MND * * 
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5.3.7. From human disease to wasted mice: TDP-43 
As previously mentioned many new genes have recently come to light as having 
roles in human motor neuron degeneration. The most prominent of these is the 
43KDa Tar DNA binding Protein (TDP-43). In human disease the normally nuclear 
TDP-43 expression is disrupted and the protein accumulates in ubiquitinated 
inclusions in the cell body (Neumann et al., 2006). An example of such inclusions 
can be seen in the motor neuron from an MND patient in figure 5.9 panel (b). Of the 
ten MND samples examined here, seven showed evidence of TDP-43 inclusions. 
Spinal cords from wasted mice together with age matched controls were investigated 
for any abnormal TDP-43 protein localisation. Sections from post-symptomatic 
wasted mice (25 days – 28 day old) and pre-symptomatic (15 day old) mice together 
with age matched controls were examined. Immunohistochemistry results showed 
that in spinal cords from control animals, TDP-43 protein is found as expected in the 
nucleus of motor neurons (as shown in figure 5.10 panel (a), (c) and (e)). In spinal 
cords from both pre-symptomatic and post-symptomatic wasted (wst/wst) animals, 
the normal nuclear TDP-43 staining pattern appears disrupted in motor neurons. The 
cytoplasm of some motor neurons appears to show diffuse staining with the TDP-43 
antibody and no nuclear staining. No inclusions were observed in the cell body of the 
motor neuron as is seen in human disease.  SOD1 mice show no disrupted TDP-43 
expression which supports previous investigations of TDP-43 expression in SOD1 
mice (Robertson et al., 2007; Turner et al., 2008). 
 
 
5.3.7.1. eEF1A2 and TDP-43 
There appears to be no direct correlation between the level of expression of eEF1A2 
and the presence of TDP-43 inclusions (table 5.3).  
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Figure 5.8. TDP-43 expression in human spinal cord. 
Examples of spinal cord sections from a human MND patient (panel (b)) and a 
control (panel (a)) stained with an antibody recognising TDP-43. TDP-43 inclusions 
are seen in motor neurons of the MND patient (indicated by the black arrow). Images 
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Figure 5.9. TDP-43 expression in wasted and SOD1 mouse spinal cord.          
Examples of spinal cord sections from wasted (panel (d) and (f)), SOD1 (panel b) 
and age matched control mice ((a), (c), (e)). Panels (c) and (d) show cervical sections 
from 15 day old, pre-symptomatic mice while panels (e) and (f) show cervical 
sections from 24 day old, symptomatic mice. Arrows show examples of motor 
neurons with either strong nuclear staining (controls and SOD1 sections) or disrupted 
TDP-43 expression as indicated by the presence of a blue nucleus (wasted mice). 
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Table 5.3. Analysis of eEF1A2 and TDP-43 expression in motor neurons of ALS patients. 
Expression of eEF1A2 together with TDP-43 inclusion analysis in spinal cord sections from ALS patients.  ** indicates strong 
antibody staining throughout the section (similar to control samples), * indicates weak and variable staining and       indicates no 
observable staining. The presence of any observable TDP-43 inclusions is also noted. 
ID Age Duration Family 
history 
Diagnosis eEF1A2 TDP-43 
MND-1 72 6 months No MND  Inclusions 
MND-2 77 Months (respiratory illness only) No MND * Inclusions 
MND-3 71 Unknown,  clinically PSP No MND ** Inclusions 
MND-4 81 Less than 12 months No MND * Inclusions 
MND-5 77 12 months No MND  Inclusions 
MND-6 70 Unknown No Distal neuropathy  No inclusions 
MND-7 52 3-4 years Yes MND  Inclusions 
MND-8 72 6 months No MND * Inclusions 
MND-9 70 unknown No MND  Inclusions 
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5.4. Discussion 
Here is shown the first study investigating eEF1A2 in spinal cords from MND 
patients and controls (with no known neurological disease). The results indicate that 
eEF1A2 is downregulated to varying degrees in the motor neurons of eight out of the 
ten patient samples examined. The key to determining if this downregulation is 
specific to eEF1A2 is finding a suitable control antibody that detects neuronal 
proteins in motor neurons of ALS patients and normal controls equally. Various 
antibodies were tested in this project, however only the GRP78 antibody (which has 
previously been shown to be upregulated in motor neurons from ALS patients 
(Sasaki 2010) detected equal protein levels in motor neurons from all ALS patients 
and normal controls.  
eEF2 was downregulated in spinal cord sections from ALS patients, SOD1 mutant 
mice and wasted mice compared to healthy controls. This suggests that damaged 
motor neurons fail to express eEF2. It was therefore necessary to investigate a 
protein with no known role in translation such as Neuronal Nuclei (NeuN). NeuN 
expression is observed in the nuclei of neurons (Mullen et al., 1992) and has been 
shown to be a useful neuronal marker for diagnostic histopathology (Wolf et al., 
1996). This antibody however showed variable staining in both MND patient 
samples and normal controls. This indicates that this antibody is not suitable for use 
on these human spinal cord sections despite appearing to work effectively on mouse 
spinal cord sections.  As the NeuN antibody was raised in mouse it is possible that 
the antibody is detecting some other neuronal protein in mouse tissue which makes it 
appear to be working effectively on mouse but not on human tissue. The observation 
that neuron cytoplasm as well as the nucleus is also stained in mouse spinal cord 
supports this. Other NeuN antibodies could perhaps be investigated to see if this is a 
specific antibody problem. 
Immunohistochemistry using an antibody to detect proteins that are overexpressed in 
motor neurons from MND patients such as GRP78 showed motor neuron staining in 
MND patient samples. This showed that the samples themselves could be stained 
with some antibodies and therefore remain suitable for the project. Unusually GRP78 
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expression was also observed in all control samples. This contradicts previous data 
from a study investigating GRP78 in ALS patients and controls which showed very 
little expression of GRP78 in the motor neurons of control sample (Sasaki 2010). No 
observable difference in GRP78 expression was observed between spinal cord 
sections from MND patients and controls. Ideally a control antibody that should 
detect protein in motor neurons from both MND patient samples and controls equally 
should continue to be investigated i.e. a protein unaffected by neuronal degeneration. 
This could prove difficult as findings suggest that some neuronal proteins such as 
NeuN and Neuronal specific enolase (NSE) may decrease during neurodegenerative 
disease (Sarnat and Trevenen 2007). Perhaps staining motor neurons from MND 
patients will always be problematic due to motor neuron damage. An antibody to 
another protein upregulated in ALS should also be tested such as calcium binding 
protein S100β (Migheli et al., 1999) to confirm that the motor neurons in the MND 
patient samples can stain with multiple proteins.  
Expression of the delta subunit of the eEF1B complex (eEF1Bδ) was also examined. 
eEF1Bδ showed similar expression between motor neurons from MND patients and 
controls. Only two MND patient samples showed any obvious decrease in eEF1Bδ 
expression in motor neurons, thus eEF1Bδ could be involved in a subset of ALS 
cases. This is in agreement with study the by Wain et al who implicating copy 
number variation of eEF1Bδ  in ALS samples (Wain et al., 2009). Little difference 
was observed in eEF1Bδ expression between motor neurons in SOD1 mutant mice 
and wildtype controls. Determining eEF1Bδ expression in wasted mice is now 
crucial and is currently being investigated by another PhD student in the lab.   
 
In recent years numerous new genes have been found to have roles in human motor 
neuron degeneration. The most intensely studied of these is TDP-43.  Studies 
investigating TDP-43 expression in ALS and Frontotemporal Lobar Dementia 
(FTLD) have found ubiquitinated TDP-43 inclusions in nearly all sporadic and 
SOD1-negative familial ALS samples (Neumann et al., 2006; Mackenzie et al., 
2007; Tan et al., 2007).  TDP-43 expression has been investigated in numerous 
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mouse models of motor neuron degeneration with varying results. SOD1 mutant 
animals show no abnormal distribution of TDP-43 (Robertson et al., 2007; Turner et 
al., 2008) as is confirmed here. This supports the data from human ALS samples 
which suggests that motor neurons cases with SOD1 mutations have ubiquitin 
positive but TDP-43 negative inclusions, (Mackenzie et al., 2007). Other models 
however such as the wobbler mouse model (Dennis and Citron 2009) and the mutant 
Vesicle-Associated Membrane Protein-associated ProteinB (VAPB) model (Tudor et 
al., 2010) both show mislocalisation of TDP-43. TDP-43 positive inclusions are also 
found in the motor neurons of mutant animals. It was therefore important to 
investigate whether any changes in TDP-43 expression are observed in wasted  mice 
compared to controls. In human disease the normal neuronal localisation of TDP-43 
is disrupted resulting in the formation of inclusions in motor neurons. Wasted mice 
showed little neuronal TDP-43 in motor neurons of the spinal cord and some diffuse 
cytoplasmic staining, however no inclusions were observed in any sample. A change 
in the localisation of TDP-43 from its normal nuclear location to the cytoplasm has 
been described in motor neurons in tissue sections from patients with ALS 
(Brandmeir et al., 2008) and these are thought to be “pre-inclusion” motor neurons. 
The absence of inclusions in wasted mice was unsurprising as motor neurons from 
wasted mice do not develop ubiquitinated inclusions (Newbery 2003). This could be 
due to the rapid disease progression and early age of death in these animals resulting 
in little time for inclusion development. Wasted mice could therefore provide a 
useful model for investigating neuronal degeneration prior to inclusion development.  
Interestingly TDP-43 has been shown to interact with SMN (Wang et al., 2002)  
which is also known to form a complex with eEF1A (Gangwani et al., 1998; 
Gangwani et al., 2001). Disruption of TDP-43 could therefore affect eEF1A2 protein 
expression and vice-versa. In addition eEF1A has been implicated in the nuclear 
export pathway (Khacho et al., 2008).  An attractive hypothesis would be that 
disruption of eEF1A could lead to a disruption in transport across the nuclear 
membrane which may account for the mislocalisation of proteins such as TDP-43. 
Firstly however, distinguishing the separate roles of eEF1A1 and eEF1A2 in nuclear 
transport would need to be addressed.  
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This is the first account of spinal cord eEF1A2 expression being altered in human 
motor neuron degeneration. Further analysis with increased sample numbers (and 
more closely age-matched controls) should be performed to confirm this finding. In 
addition the expression of the eEF1A1 variant should also be examined in these 
sections. Unfortunately problems with the specificity of the eEF1A1 antibodies for 
IHC prevented this from being addressed in this study. Previous studies have shown 
that in injured rat muscle there is a switch in the expression of eEF1A variants. 
eEF1A2 expression is downregulated and eEF1A1 expression is upregulated until 
recovery at which time the expression is switched back (Carlson et al., 2002; Khalyfa 
et al., 2003). It would therefore be very interesting to investigate if this also happens 
in damaged motor neurons. While problems were encountered with the specificity of 
the eEF1A1 antibody using IHC the antibody has proven to be variant specific on 
Western blots therefore looking at variant specific expression from tissues on a 
Western blot could be investigated should samples become available. Also 
examining levels of RNA expression by Real-Time PCR in spinal cord samples from 
MND patients would be beneficial to asses whether changes seen in eEF1A2 
expression are at the RNA level as well as the protein level.  
If eEF1A2 is truly downregulated in a proportion of MND patients further 
investigation into the cause of this will be required. In her PhD thesis, Helen 
Newbery analysed 40 familial ALS and 64 sporadic cases of MND for mutations in 
the exons of eEF1A2 (Newbery 2003). No MND specific mutations were found  in 
the protein coding regions of EEF1A2. It is therefore unlikely that mutations in 
EEF1A2 are responsible for common cases of MND. Only seven of the eight exons 
of EEF1A2 were investigated as exon 8 is a particularly GC rich region and thus 
amplifying the region by PCR is extremely problematic. Therefore mutations in exon 
8 of EEF1A2 have not been currently detectable. At the time this initial sequencing 
was undertaken it was not deemed practical or cost effective to sequence the 
promoter region, however given the results of this study, this should now be 
thoroughly investigated. Examples of the importance of variability in promoter 
regions of various genes have been implicated in motor neuron degeneration. A 
mutation in the  promoter region of Vascular Endothelial Growth Factor (VEGF), for 
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example leads to late onset motor neuron degeneration in an ALS mouse model 
(Oosthuyse et al., 2001). An ALS specific promoter haplotype in the paraoxonase 1 
(PON1) gene has also been identified (Landers et al., 2008). Copy number variation 
in EEF1A2 should also be investigated in MND patients and controls to try and 
determine if a decrease in copy number is the cause of the decrease in protein 
expression of eEF1A2.  
eEF1A2 expression should also be analysed in samples from patients with other 
neurodegenerative conditions such as Spinal Muscular Atrophy (SMA) or 
Frontotemporal dementia (FTD). SMA is caused by mutations in the Survival Motor 
Neuron (SMN) gene resulting in decreased full length SMN protein (Lefebvre et al., 
1995; Lefebvre et al., 1997). Given that SMN and eEF1A both interact with ZPR1 
(Gangwani et al., 1998; Gangwani et al., 2001) it would be interesting to observe if 
levels of eEF1A are changed in samples from patients with SMA. Significant overlap 
is observed between ALS and FTD and therefore investigating whether 
downregulation of eEF1A2 is common to both disorders, could possibly identify 
another pathological similarity between the two.  
In addition, other mouse models of motor neurodegeneration such as the wobbler 
mouse model, Legs at odd angles (Loa) and other SOD1 mutant models should also 
be investigated for eEF1A2 expression in the spinal cord. While the spinal cords 
from SOD1 mutant mice investigated here show little change in eEF1A2 this may 
not be the case for all models. Investigating other models may help to uncover 
whether the loss of eEF1A2 observed in the patient samples in this study is an early 
onset and possible contributory event to motor neuron degeneration or  if it is simply 
a result of motor neuron degeneration. Such information is crucial in identifying 
potential therapeutic targets. 
The initial findings shown here indicating that TDP-43 is disrupted in the wasted 
model without the development of inclusions requires further investigation. A 
thorough time course experiment with increased numbers of samples at each age 
should now be investigated to confirm these initial findings. Ideally counting the 
number of motor neurons with nuclear and with cytoplasmic staining should also be 
conducted. Immunofluorescence should also be considered as a clearer method of 
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identifying motor neurons with mislocalisation of TDP-43. TDP-43 RNA expression 
in the spinal cords of wasted mice and wildtype controls of various ages could be 
investigated to see if expression increases (as in seen with the wobbler mouse model 
(Dennis and Citron 2009)). In addition to immunohistochemistry, TDP-43 expression 
in the spinal cord from protein extracts of nuclear and cytoplasmic fractions could be  
measured by Western blotting. This would aid in confirming whether TDP-43 
localisation is truly disrupted in the wasted mouse model. A phosphorylated TDP-43 
antibody should also be investigated as it is thought that the inclusions seen in ALS 
patients contain phosphorylated TDP-43. An antibody specific for phosphorylated 
TDP-43, which has been shown to detect inclusions present in ALS samples, and not 
normal nuclear TDP-43 (Hasegawa et al., 2008; Inukai et al., 2008) may result in a 
clearer indication of TDP-43 pathology in sections from wasted mice spinal cord. 
This would confirm whether wasted mice are positive for TDP-43 inclusions in 
addition to purely mislocalised TDP-43. 
An interesting avenue of future research would be to identify whether eEF1A2 has a 
role in nuclear export and also to investigate whether eEF1A2 interacts with TDP-43 
as this could have important implications for our understanding of the mislocalisation 
of TDP-43.  
The wasted mouse model has been shown to be a useful model for motor neuron 
degeneration. As such, continuing to investigate whether protein expression of other, 
recently identified candidate genes in ALS, are disrupted in wasted mice is 
important. In her thesis Helen Newbery searched for ubiquitinated incusions and also 
for decreased expression of Microtubule Associated Protein MAP2 in wasted mice, 
both of which are pathological features observed in the spinal cord from ALS 
patients (Leigh et al., 1988; Leigh et al., 1991; Kikuchi et al., 1999). No 
ubiquitinated inclusions were observed in wasted mice and no difference in MAP2 
protein expression between spinal cord sections of wasted mice and controls was 
seen. Other recently identified ALS candidates could also be considered for future 
investigation such as Fused in Sarcoma (FUS) or Translocation in Liposarcoma 
(TLS), which like TDP-43, display a shift in expression of protein from the nucleus 
to cytoplasmic inclusions (Kwiatkowski et al., 2009; Vance et al., 2009). It is to be 
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expected that not all candidate genes will have an effect in the wasted model, but 
identifying ones that do increases our knowledge of commonly disrupted proteins 




These data show for the first time that downregulation of eEF1A2 is observed in 
motor neurons from patients with motor neuron disease. This interesting finding 
should now be expanded to include increased sample numbers and further expression 
analysis. This could result in eEF1A2 being investigated as a therapeutic target in 
motor neuron degeneration. The data presented also show abnormal distribution of 
the TDP-43 protein in wasted mice without the formation of inclusions. Given the 
high incidence of TDP-43 pathology in ALS, additional  investigation of TDP-43 
expression in the wasted mouse model may further validate it as a useful model for 
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6. Chapter 6: Investigating the role of eEF1A in the 
heat shock response 
6.1. Aim 
The aim of this project was to determine if eEF1A1 and eEF1A2 have similar or 
different roles in the heat shock response. To attempt to address this aim, the 
intention was to knock down eEF1A1 and eEF1A2 separately in cells and to assess 
the effect this has on the cells ability to mount a heat shock response.  The different 
abilities of eEF1A1 and eEF1A2 to participate in the heat shock response could show 
a key difference between the two variants. A difference in their roles in the heat 
shock response may explain in part why motor neurons, which only express eEF1A2, 
are vulnerable to heat shock.  
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6.2. Introduction 
Many examples of the diverse roles of eEF1A have been documented, but in almost 
all cases the specific variant involved is not identified. This is largely due to 
commercially available eEF1A antibodies recognizing both variants equally. One 
example of a proposed non-canonical function for eEF1A was published by 
Shamovsky et al in 2006. This study found that eEF1A  is involved in the heat shock 
response (or stress response) by its interaction with heat-shock transcription factor 1 
(HSF1, (Kugel and Goodrich 2006; Shamovsky et al., 2006).  
Heat shock proteins (or stress proteins) produced during a heat shock response are 
part of the cells integral repair mechanism. Their levels are increased in response to 
numerous environmental stresses including (but not limited to) elevated temperature, 
oxygen deprivation and exposure to toxins. They act as molecular chaperones aiding 
in refolding proteins that have misfolded during the stress period.  
While the exact role of eEF1A in the heat shock response is unclear, a model (shown 
in figure 6.1) has been proposed (Kugel and Goodrich 2006).
 
 It is thought that 
following heat shock, HSF1 monomers are released from their inactive conformation 
and localise in the nucleus as a homotrimer (Shi et al., 1998). These trimers then 
bind heat shock elements (HSEs), found in the promoter regions of genes up-
regulated during the heat shock response (Morimoto 1998; Voellmy 2004; Kugel and 
Goodrich 2006).  
Shamovsky et al  searched for factors in mammalian cell extracts that associate with 
HSF1 and found eEF1A (Shamovsky et al., 2006). It was also shown that heat shock 
enhanced the association between these two proteins. It is believed that eEF1A 
together with a previously unknown RNA named heat shock RNA 1 (HSR1) are 
involved in the trimerisation of HSF1, although their exact mechanism of action is 
unknown. eEF1A purified from rat liver was shown to activate HSF1 in this study 
and this must therefore be eEF1A1, as eEF1A2 is not expressed in liver. The study 
failed to address directly whether eEF1A2 can also play a part in the heat-shock 
response.  
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Figure 6.1. A model for the role of eEF1A in the heat shock response.   
The current model as suggested by Kugel and Goodrich (Kugel and Goodrich 2006). 
On heat shock HSF1 is released from its inhibitors. These monomeric HSF1 
molecules trimerise in the presence of eEF1A and HSF1. The HSF1 trimers bind 
promoter regions of heat shock proteins and function in transcriptional activation. 
Figure taken from Kugel and Goodrich 2006. 
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Distinguishing the roles of these two variants in the heat shock response is 
particularly relevant to the study of motor neuron degeneration. As motor neurons 
have been shown to express eEF1A2 and not eEF1A1 (Newbery et al., 2007) and 
have a poor heat shock response (Batulan et al., 2003).  
Numerous examples of the important neuroprotective roles of heat shock proteins 
have been reported (Brown 2007), for example SOD-1 toxicity has been shown to be 
delayed by gene transfer of HSP70 in cultured motor neurons (Bruening et al., 1999). 
Overexpression studies of HSP70, HSP40 and HSP27 in animal models of 
neurodegenerative disease have also demonstrated their neuroprotective properties 
(Muchowski and Wacker 2005). For example, crossing mice overexpressing HSP27 
to mice overexpressing mutant SOD1 results in a decrease in disease severity, 
including a reduced rate of motor deterioration and increased motor neuron survival 
(Sharp et al., 2008). These investigations suggest that an insufficient stress response 
in motor neurons increases their vulnerability to toxic insult.  
Batulan et al demonstrated that while heat shock failed to induce HSP70 expression 
in cultured motor neurons, injection of a constituitively active form of HSF1 resulted 
in high levels of HSP70 (Batulan et al., 2003). This suggests  that the most likely 
cause of failure of motor neurons to induce a stress response involves the HSF1 
activation pathway, a key player of which has now be shown to be eEF1A1 (Kugel 
and Goodrich 2006; Shamovsky et al., 2006). As motor neurons express eEF1A2 and 
not eEF1A1, addressing whether eEF1A2 also has an important role in the heat 
shock response, and can substitute for eEF1A1 is now vital.  
The availability of eEF1A1 and eEF1A2 specific antibodies, which have been 
generated and optimised in our lab, has allowed experiments to be conducted to 
address this question. Dr Vicky Tomlison (Tomlinson 2007)  began investigating this 
question by studying the roles of eEF1A1 and eEF1A2 in the heat shock response 
using HeLa cells. HeLa cells are known to express both eEF1A1 and eEF1A2. 
siRNAs designed to target human eEF1A1 and eEF1A2 were used to knockdown 
eEF1A1 and eEF1A2 respectively in HeLa cells. Cells were heat shocked following  
transfection and the protein expression of the heat shock protein HSP70 was 
measured as a readout of the heat shock response. HSP70 (or HSP72) is one of the 
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inducible HSPs i.e. it should only be present under cell stress.  While successful 
knockdown was achieved for eEF1A1 and eEF1A2, HeLa cells proved unsatisfactory 
for the addressing the aims of this project because this cell line was found to express 
HSP70 constitutively. They are therefore an inappropriate cell line for the 
investigation of the induction of heat shock due to their already disrupted heat shock 
response.  
Following this work the baby hamster kidney (BHK) cell line was investigated as 
this cell line was used successfully by Shamovsky et al (Shamovsky et al., 2006).  
This work formed part of a MSc by research rotation project conducted by myself in 
the Abbott group. During this project siRNAs were designed to target hamster 
eEF1A1. At this time the complete hamster genome sequence including the sequence 
for eEF1A2 was unavailable. 
The results of this project showed that BHK cells express both eEF1A1 and eEF1A2 
but not constitutive HSP70, making them an ideal candidate cell line to address this 
research question. Two siRNAs for eEF1A1 were designed based on homologous 
regions between hamster, mouse and human eEF1A1 that were different from mouse 
and human eEF1A2. The results of this project showed that ablating eEF1A1 in BHK 
cells inhibited the induction of the heat shock response. This preliminary data 
required further validation and as such was the starting point of this project. 
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6.3. Results 
6.3.1. RNAi: BHK cells 
The first aim of this project was to replicate the RNAi experiments conducted 
previously in BHK cells and to test the specificity of the eEF1A1 siRNAs used. The 
two hamster eEF1A1 (Ham1a1-1 and Ham1a1-2) siRNAs were transfected 
separately into BHK cells using a Nucleofector (Lonza). The effect of decreasing 
eEF1A1 expression on the heat shock response was determined by measuring protein 
expression of HSP70. Samples were transfected, and allowed to recover for 24hrs 
before being subjected to heat shock. Some samples were pelleted immediately 
following heat shock and some were left to recover overnight at 37
o
C (approximately 
16 hours) before pelleting. This recovery period proved essential to allow protein 
synthesis to occur, resulting in the expression of measurable HSP70 protein. Protein 
extracts from cells that had not had a recovery period following heat shock expressed 
no observable HSP70 protein (figure 6.2). Both Western blots in figure 6.2 represent 
samples from the same experiment. The “Untransfected ” samples have the same 
protein extracts used in both Westerns so that both blots are directly comparable. As 
can be seen in figure 6.2, both eEF1A1 siRNAs successfully decreased levels of 
eEF1A1. Due to the large degree of homology between eEF1A1 and eEF1A2 it is 
critical to test that the siRNA’s are specific for one variant. These samples were 
therefore also examined for the expression of eEF1A2 protein to test the specificity 
of the RNA interference. As can be seen in figure 6.2, eEF1A2 expression is also 
decreased in cells transfected with both  eEF1A1 targetting siRNAs. These siRNAs 
are therefore unsuitable to address the aims of this project as they disrupt both 
eEF1A1 and eEF1A2 expression. Although the siRNAs are not specific for eEF1A1, 
the Western blots show that this decrease in eEF1A completely ablates the heat 
shock response (indicated by red stars in figure 6.2). This highlights the crucial role 
that eEF1A plays in the heat shock response, as without it no HSP70 is induced. As 
can be seen in figure 6.2 panel (a), the presence of a scrambled non-targetting siRNA 
also appears to have disrupted the heat shock response and so it is possible that the 
transfection of any siRNA is enough to block HSP70 induction. However this aliquot 
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of scrambled siRNA was very old and when other scrambled non-targetting controls 
were tested they had no effect on the induction of HSP70 (data not shown). Thus an 
alternative scrambled siRNA was used in all future experiments.  
As previously mentioned designing specific eEF1A1 siRNAs was difficult due to the 
hamster eEF1A2 sequence being unavailable. Numerous attempts were made to 
sequence regions of hamster eEF1A2 from BHK cells. RT-PCR primers based on 
homologous regions of eEF1A2 from mouse and human (but that were different from 
hamster eEF1A1) were designed to amplify a region of hamster eEF1A2 for 
sequencing. A region of approximately 500bp of  hamster eEF1A2 was sequenced 
from RNA extracted from BHK cells. Sequencing of this fragment confirmed it to be 
eEF1A2. 
Two hamster eEF1A2 specific siRNAs were designed to target this region however 
following transfection by Nucleofector neither siRNA resulted in any observable 
knockdown of eEF1A2 protein (data not shown). The numerous problems 
encountered as a result of not knowing the sequence of hamster eEF1A2 led to the 
investigation of other candidate cell lines. 
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Western blots showing protein expression from BHK cells transfected with 
eEF1A1 siRNAs; HAM1A1-1 (panel (a)) and HAM1A1-2 (panel (b)), and also a 
non-targeting scrambled control (panel (a)). NO indicates untreated cells, HS 
indicates heat shock with no recovery, HSR indicates heat shock followed by 
recovery, MOCK indicates a mock transfection, MUS indicates mouse muscle 
(negative for eEF1A1), HELA indicates HeLa cells (positive control for eEF1A 
and HSP70). Red stars mark samples that were heat shocked and allowed to 
recover, highlighting the dfference in HSP70 expression between control cells and 




Figure 6.2. Knocking down eEF1A in BHK cells inhibits HSP70 induction.  
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6.3.2. RNAi: NSC-34 cells 
Whilst trying to overcome the problems encountered while investigating BHK cells, 
another cell line was investigated. NSC-34 (Neuroblastoma Spinal Cord) is a hybrid 
cell line produced by fusion of motor neuron enriched, embryonic mouse spinal cord 
cells and mouse neuroblastoma (Cashman et al., 1992). A project student in our lab, 
Corinne Krommer, showed that NSC-34 cells express both eEF1A1 and eEF1A2 and 
thus satisfy some of the criteria required for this experiment. The cells were 
subsequently tested for constitutive HSP70 expression. Initially NSC-34 cells were 
subjected to 42
o
C heat shock for two hours (as was sufficient for BHK cells) 
followed by a 16 hour recovery at 37
o
C. However, as can be seen from figure 6.3 
panel (a), 2 hours at 42
o
C followed by a 16 hour recovery period was not sufficient to 
induce HSP70 expression in NSC-34 cells. Subjecting cells to 43
o
C heat shock for 
two hours was then tested. As can be seen in figure 6.3 panel (b), HSP70 expression 
was detectable following two hours at 43
o
C and 16 hours recovery at 37
o
C. 
Therefore HSP70 expression is only detectable in NSC-34 cells following heat shock 
at 43
o
C. At this point it was decided in future experiments, all heat shocked cells 
would be placed at 37
o
C for 16 hours following heat shock, therefore all other 
experiments described in this chapter do not include samples that were heat shocked 
and pelleted immediately.  
In addition to being a far more biologically relevant cell line for this investigation 
than BHK cells, NSC-34 cells express both eEF1A variants and show no constitutive 
HSP70 expression and are therefore an ideal candidate for these experiments. Since 
NSC-34 cells are derived from mouse, and mouse eEF1A1 and eEF1A2 sequences 
are readily available, designing variant specific siRNAs was less problematic than 
for BHKs.  
Mouse specific siRNAs were designed to target mouse eEF1A1 and eEF1A2 
separately. Two eEF1A1  specific siRNAs (named m1A1-a and m1A1-b) and two 
eEF1A2 specific siRNAs (named m1A2-a and m1A2-b) were investigated. Similarly 
to the BHK cell line experiments, a Nucleofector was used initially to transfect the 
siRNAs into NSC-34 cells. This technique proved very difficult with this cell line; 
the procedure resulted in high levels of cell death in NSC-34 cells.  
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Figure 6.3. NSC-34 cells do not constitutively express HSP70.  
Western blots showing the expression of HSP70 in NSC-34 cells following heat 
shock. Panel (a) shows heat shock at 42
o
C and panel (b) shows heat shock at 43
o
C. 
HELA indicates HeLa cells which are a positive control for HSP70 expression. NO 
indicates no heat shock (cells remained at 37
o
C), HS indicates cells were subjected to 
heat shock and not allowed to recover, HSR indicates cells were subjected to heat 
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Numerous attempts were made to optimise the procedure but these were 
unsuccessful. Lipid transfection using siLentFect (Biorad)  was therefore tested. 
Preliminary mock transfection reactions resulted in little cell death in NSC-34 cells 
and therefore siLentFect was deemed a suitable reagent for transfection of these 
cells. Experiments to assess the affect of knocking down eEF1A1 and eEF1A2 could 
now commence. Cells were transfected with the separate siRNAs, allowed to recover 
for 24 hours, incubated at 43
o
C for 2 hours and allowed to recover overnight. Control 
cells remained at 37
o
C for the duration of the experiment. 
Preliminary results indicate that decreasing eEF1A1 disrupts the cells’ ability to 
mount a heat shock response, as measured by HSP70 expression (figure 6.4). Both 
eEF1A1 siRNAs decreased the level of eEF1A1 expression and subsequently 
blocked HSP70 induction. The eEF1A2 siRNAs decreased eEF1A2 protein 
expression, however this did not dramatically reduce the level of HSP70 in heat 
shocked cells (figure 6.5). These preliminary data suggests that eEF1A1 is necessary 
for the induction of the heat shock response whereas eEF1A2 has a less important 
role. The graphs in figures 6.4 and 6.5 display the expression of eEF1A1 (figure 6.4), 
eEF1A2 (figure 6.5) and HSP70 in the samples subjected to heat shock normalised to 
GAPDH (as a loading control). These are compared to the cells transfected with the 
non-targeting scrambled siRNA and subjected to heat shock. This control is the most 
appropriate for comparison given that experimental conditions are identical between 
the samples transfected with a non-targetting siRNA and those transfected with the 
eEF1A siRNAs. This ensures that any knockdown is due to the specific siRNA and 
not to the presence of any siRNA molecule. The expression of each protein was 
measured using the GeneGnome image analysis software.   
These experiments were replicated numerous times. The level of knockdown of 
eEF1A1 and eEF1A2 varied dramatically between and within experiments.  Due to 
this variability, data from multiple experiments was combined in the following way. 
For the eEF1A1 knockdown experiments, levels of eEF1A1 expression was first 
normalised to GAPDH in all samples where cells had been subjected to heat shock. 
To measure the amount of knockdown, the levels of eEF1A1 expression (normalised 
to GAPDH) from cells transfected with siRNAs and heat shocked were then 
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normalised to the cells transfected with scrambled siRNA and subjected to heat 
shock. This gave a measurement for knockdown for each well with an siRNA and 
subjected to heat shock as compared to the non-targetting scrambled control. If the 
expression of the eEF1A1 was reduced by 10% or more compared to the scrambled 
control, this sample was counted in the analysis.  
For each experiment, the expression data from all wells with a knockdown of greater 
than 10% were pooled. The mean of these pooled samples gave a mean knockdown 
of eEF1A1 by eEF1A1 siRNAs (compared to transfection with a scrambled control) 
for that experiment. As seen in the table in figure 6.6. the combined results of three 
separate experiments were then pooled to give a combined knockdown measurement 
of eEF1A1 in all three experiments. HSP70 expression was measured in the same 
selected samples in the same way i.e. normalised to scrambled then pooled. The 
same method was also used to measure eEF1A2 knockdown and subsequent HSP70 
expression in the eEF1A2 siRNA experiments. 
The specificity of the siRNAs was confirmed by examining protein expression of the 
variant not being targeted by the siRNA; i.e eEF1A1 expression was checked in 
samples with eEF1A2 siRNAs and vice versa. No significant problems with 
specificity were observed as shown in figures 6.4 and 6.5. While it may appear in 
figure 6.4 that cells transfected with the eEF1A1 siRNA m1a1-a and then heat 
shocked have decreased levels of eEF1A2, this is not the case. The Western blot 
showing eEF1A1 and eEF1A2 are in fact from different gels and GAPDH was 
undetectable in this lane also (data not shown) and this result is thus thought to be 
due to a loading error. All four siRNAs have been shown to be specific for their 
target variant in multiple experiments (data not shown).  
The results of multiple RNAi experiments are represented by graphs in figure 6.6. 
These combined data indicate that significantly reducing eEF1A1 by approximately 
50% results in a significant decrease of around 60% in the expression of HSP70. The 
results also suggest that significantly reducing levels of eEF1A2 by approximately 
70% has no significant efffect on HSP70 expression.   
Taken together these data suggest a crucial role for eEF1A1 and not eEF1A2 in the 
heat shock response.    
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Protein expression from NSC-34 cells transfected with eEF1A1 siRNAs.  Western 
blots showing expression of eEF1A1, eEF1A2,  HSP70 and GAPDH (loading 
control) in cells transfected with two eEF1A1 siRNAs (m1a1-a and m1a1-b). 
Scram indicates a scrambled non-targeting negative control, Mock indicates a 
mock transfection (no siRNA).  Red arrows highlight lanes with samples 
subjected to heat shock. Red stars highlight samples used in the analysis (graph). 
The graph indicates expression of eEF1A1 and HSP70 normalised to GAPDH in 
heat shocked samples transfected with eEF1A1 siRNAs and the scrambled non-
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Protein expression from NSC-34 cells transfected with eEF1A2 siRNAs.  Western 
blots showing expression of eEF1A2, eEF1A1, HSP70 and GAPDH (as a loading 
control) in cells transfected with two eEF1A2 siRNAs (m1a2-a and m1a2-b). 
Scram indicates a scrambled non-targeting negative control, Mock indicates a 
mock transfection (no siRNA). Red arrows highlight lanes with samples subjected 
to heat shock. Red stars highlight samples used in the analysis (graph). The graph 
indicates expression of eEF1A2 and HSP70 normalised to GAPDH in heat shocked 
samples transfected with eEF1A2 siRNAs and the scrambled non-targeting 











































Untransfected  m1A2-a 
Heat shock 
eEF1A1 50KDa 













                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 6: Investigating the role of eEF1A in the heat shock response  191 
Figure 6.6. Combined RNAi data.  
(a) Expression of eEF1A1 and HSP70 from heat shocked cells transfected with 
eEF1A1 siRNAs, normalised to heat shocked cells transfected with a scrambled non-
targetting siRNA. (b) Expression of eEF1A2 and HSP70 from heat shocked cells 
transfected with eEF1A2 siRNAs , normalised to heat shocked cells transfected with 
a scrambled non-targetting siRNA. * indicates a  p value<0.05. 
 
 
Table 6.1. Combined RNAi data.  
(a) Expression of eEF1A1 and HSP70 from heat shocked cells transfected with 
eEF1A1 siRNAs, normalised to heat shocked cells transfected with a scrambled non-
targetting siRNA. (b) Expression of eEF1A2 and HSP70 from heat shocked cells 
transfected with eEF1A2 siRNAs , normalised to heat shocked cells transfected with 
a scrambled non-targetting siRNA. S.D indicates standard deviation, S.E.M indicates 









Mean S.D S.E.M 
eEF1A1  0.56 0.50 0.74 0.60 0.13 0.07 









Mean S.D S.E.M 
eEF1A2  0.06 0.43 0.35 0.28 0.20 0.11 
HSP70  1.45 0.63 0.84 0.97 0.43 0.25 
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6.4. Discussion 
Although the importance of the trimerisation of heat shock factor 1(HSF1) in the heat 
shock response has been known for some time, the importance of the co-operation of 
eEF1A and a previously unknown RNA named heat shock RNA 1 (HSR1) in this 
chain of events has only recently been found (Shamovsky et al., 2006). We know 
that eEF1A1 can fulfil this role from the previous study (Shamovsky et al., 2006) as 
they found eEF1A purified from liver is involved in HSF1 activation. Liver only 
expresses eEF1A1 and not eEF1A2. We hypothesised that eEF1A2 is not able to 
fulfil the same role in the heat shock response as eEF1A1.  
In this project, RNAi in various cell lines was used to investigate the separate rolls of 
eEF1A1 and eEF1A2 in the heat shock response. The criteria for a cell line to be 
suitable for this project, was firstly that the cells express both eEF1A1 and eEF1A2 
and second that cells do not constitutively express the inducible heat shock protein 
HSP70. The first cell line to be investigated was the baby hamster kidney (BHK) cell 
line. This cell line expresses eEF1A1 and eEF1A2 and only expresses HSP70 when 
subjected to heat shock at 42
o
C, thus making it an ideal candidate for this 
experiment. The hamster eEF1A2 sequence is currently unavailable which made 
designing variant specific siRNAs very difficult. While it appeared initially as 
though knocking down eEF1A1 ablates the heat shock response in BHK cells, 
analysis of eEF1A2 in these same samples showed a similar pattern of protein 
expression. The two most logical explanations for this are firstly that the siRNAs are 
not specific and second that one or both of the variant specific antibodies are not 
specific in hamster. Given that the panel of antibodies used have been shown to be 
variant specific in mouse, human and also xenopus, it is unlikely that this is the cause 
of the problem. It is therefore more likely that the problem lies with the specificity of 
the siRNAs. More efforts could have been spent attempting to further sequence 
hamster eEF1A2 and designing more siRNAs however it was deemed more practical 
to investigate an alternative cell line. The mouse NSC-34 cell line was investigated 
as an alternative and proved to be a more suitable and convenient cell line to work 
with than BHK cells. NSC-34 cells also express both eEF1A variants and don’t 
constitutively express HSP70. Interestingly, here is shown that NSC-34 cells have a 
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slightly higher threshold for heat shock than BHKs. This is shown by the fact that 
42
o
C is not enough to induce the heat shock response as in BHK cells and that a 
minimum temperature of 43
o
C is required to induce HSP70 expression in NSC-34 
cells.  This may be due to NSC-34 cells being a neuronal cell line as neurons are 
thought to have a higher threshold for heat shock than other cell types  
Preliminary data from RNAi in NSC-34 cells suggests that ablating eEF1A1 results 
in the inhibition of heat shock induction while ablating eEF1A2 has little effect on 
the cells ability to mount a heat shock response. However the RNAi experiments 
have been very problematic and as such some replication and optimisation is still 
required to confirm these findings.  
The first problem faced was an unreliable negative control. A scrambled control from 
Ambion was used alongside the eEF1A1 siRNAs in the initial experiments in BHK 
cells. Western blots showed that although the scrambled siRNA was not affecting the 
expression of eEF1A1 in the cells, the level of HSP70 was reduced by the presence 
of this apparent negative control (Figure 6.2). It was therefore possible that the 
presence of any siRNA would reduce HSP70 expression. Other scrambled controls 
were investigated and it transpired that only this aliquot of the Ambion scrambled 
control affected HSP70 expression. A new scrambled control was used in all future 
experiments thus eliminating this problem. A positive actin siRNA was also tested in 
BHK cells which had no observable affect on eEF1A1, eEF1A2 or HSP70 
expression. In NSC-34 cells the actin siRNA had little effect on the expression of 
eEF1A1, eEF1A2 or HSP70. However problems with the actin antibody prohibited 
the effect of the actin siRNA on the levels of actin from being confirmed in NSC-34 
cells. While scrambled is used as a negative control its efficiency as a positive 
control cannot be measured. An siRNA with a known target which has no influence 
on the gene of interest is thus more useful as its functional capabilities can be 
confirmed. An actin siRNA may not be ideal for this as actin has been shown to 
interact with eEF1A (Ejiri 2002). This should be investigated in future experiments. 
The nucleofection procedure also proved problematic for NSC-34 cells (although not 
for BHK cells). Numerous attempts were made to transfect siRNAs into NSC-34 
cells using a Nucelofector but these often resulted in large amounts of cell death. 
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Various experimental conditions as recommended by the manufacturer were tested 
but all were unsuccessful. SiLentFect was then tested, which resulted in very little 
cell death. There are multiple reagents available for transfection of siRNAs and these 
should be thoroughly investigated to try and optimise knockdown of the eEF1A 
variants in NSC-34 cells. For these experiments a GFP plasmid was transfected into 
cells to measure transfection efficiency but this is of limited use as a plasmid is very 
different from an siRNA. Confirmation of effective transfection should be 
determined using a fluorescently labelled siRNA in future experiments which may 
help with the optimisation procedures. 
The siRNAs produced variable results both within and between experiments. The 
eEF1A1 siRNAs in particular resulted in often poor knockdown. The effectiveness of 
the eEF1A1 siRNAs appeared to decrease with time and usage. This could simply be 
a result of degradation of the siRNAs which in the past have proved to be vulnerable 
to repetitive freeze-thawing. Ordering new siRNAs and aliquoting on arrival may 
eliminate this problem from future experiments. However numerous attempts in the 
past to reduce eEF1A1 expression have also proved unsuccessful or not reproducible. 
Attempts have been made in our laboratory by multiple researchers using multiple 
methods, all of which have been problematic. This could be due to the importance of 
eEF1A1 for cell survival. Important compensatory mechanisms could be in place to 
prohibit reduction of this crucial elongation factor. Using eEF1A2 siRNAs was less 
problematic. Successful knockdown of eEF1A2 was achieved consistently on 
multiple occasions.  
For future experiments many replicate wells for each siRNA and also for the 
scrambled controls should be used to try to reduce the variability between 
experiments.  
As mentioned, numerous technical problems were encountered in this project and 
much work is still required to eliminate these difficulties and optimise experimental 
conditions. In addition many other avenues of research have become apparent of 
which time restraints prohibited these from being investigated in this project. 
One important aspect of this research area that has yet to be fully addressed is 
whether heat shock itself has any affect on levels of expression eEF1A1 and 
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eEF1A2. Shamovsky et al suggest that the shut down of translation caused by heat 
shock releases eEF1A from its translational role so that it is freely available to 
participate in the heat shock response (Shamovsky et al., 2006). This suggests no 
change in the total expression of eEF1A. Lucy Mallins (under my supervision) began 
to investigate whether eEF1A1 and/or eEF1A2 expression levels changed during 
heat shock. Lucy showed that heat shock has no significant affect on eEF1A1 
expression in NSC-34, PC12 (dervived from a rat pheochromocytoma (Greene and 
Tischler 1976)) and SHY5Y (derived from a neuroblastoma (Biedler et al., 1973; 
Biedler et al., 1978) cells. However it was observed that eEF1A2 protein expression 
was sometimes decreased upon heat shock in these cell lines. This can also be 
observed in figure 6.2 where eEF1A2 levels in untransfected cells appear reduced in 
cells that were subjected to heat shock and recovery compared to cells that were not 
heat shocked. This result however is variable between experiments and a more 
detailed time course investigation is required to confirm these findings.     
Lucy also investigated other cell lines as potential candidates for the RNAi 
experiments. It was shown that SHY5Y and PC12 cells express both eEF1A1 and 
eEF1A2 however only PC12 cells showed no constitutive HSP70. At the beginning 
of the project only BHK cells had shown expression of both eEF1A1 and eEF1A2 
without constitutive expression of HSP70. It has now been shown that NSC-34 cells 
and PC12 cells both also meet these criteria. Other cell lines such as SHY5Y, HeLa, 
COS7, OVCAR5 and MO6 all have constitutive HSP70 (data not shown) but there 
may be other cell lines yet to be investigated that would be appropriate for the 
experiments. Stable cell lines expressing both variants could also be studied.  
The differentiation state of neuronal cell lines has also been shown to affect heat 
shock induction. The ability of the rat neuronal PC12 cell line to induce HSP70 on 
heat shock is diminished when differentiated (Hatayama et al., 1997). While the 
NSC-34 cells in these experiments were all undifferentiated, it is possible to 
differentiate them to a more neuronal state (Cashman et al., 1992). It would be 
interesting to assess the affect of differentiating these cells and other neuronal cell 
lines on the heat shock response and to investigate whether any changes are observed 
in eEF1A1 and eEF1A2 expression between undifferentiated and differentiated cells. 
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Other heat shock proteins should also be investigated , as a possible compensatory 
role in the absence of HSP70 cannot be ruled out. These could include HSP25/27 
which has been shown to rescue motor neurons following nerve injury (Sharp et al., 
2006) and also has been found to be up-regulated in cell lines with mutant SOD1 
(Batulan et al., 2003).  
Differences in the protein interactions of eEF1A1 and eEF1A2 with HSF1 during 
heat shock should also be investigated. To address this, methods such as 
Biomolecular florescence complementation (BiFC) or Proximity ligation assay 
(PLA) could be attempted. BiFC is a relatively new method, which is used to directly 
visualise protein-protein interactions in living cells (Hu et al., 2002). Two fragments 
of a split fluorescent protein are fused to the two proteins of interest. An interaction 
between these proteins of interest allows association between the two fragments of 
the fluorescent protein to produce a biomolecular fluorescent complex. This has been 
used by a group here in Edinburgh (Gkogkas et al., 2008). Another method which is 
currently being optimised in our lab is PLA. In brief, this technique involves the use 
of two PLA probes which consist of a secondary antibody with an attached 
oligonucleotide. When two proteins and thus their primary antibodies are in close 
proximity, these PLA probes bind and the oligonucleotides attached to them come 
into close enough proximity to be amplified by PCR. This results in a fluorescent 
PCR product that can be visualised down the microscope as a dot (Gustafsdottir et 
al., 2005). This technique can be used to assess protein-protein interactions in cells 
and also in tissue sections. 
If the preliminary data from this study is validated and shows that only eEF1A1 has a 
role in the heat shock response, the effect of transfecting an eEF1A1 expression 
construct into cultured motor neurons could be assessed. This would address whether 
the ability of the motor neurons to respond to stress is improved by the presence of 
eEF1A1. This study in itself would be problematic as motor neurons have shown to 
be very difficult to culture.  
This question could also be addressed at the whole animal level. Transgenic studies 
in our laboratory are currently investigating the affect of expressing eEF1A1 under 
the control of the eEF1A2 promoter in mice. These animals will be crossed to the 
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wasted line to generate wasted mice (wst/wst, which lack eEF1A2 expression) with 
the eEF1A1 transgene to assess whether eEF1A1 under the control of the eEF1A2 
promoter can rescue the wasted phenotype. If this proved to be the case, these 
animals expressing neuronal eEF1A1 could also be crossed to other models of motor 
neuron degeneration such as a mutant SOD1 line to see if the presence of neuronal 




The results of this project suggest a crucial role for eEF1A1 in the heat shock 
response, specifically by its effect on HSP70 expression. eEF1A2 appears to have a 
less crucial role and is unable to compensate for the loss of eEF1A1 in the heat shock 
response. The different abilities of eEF1A1 and eEF1A2 in participating in the heat 
shock response show a key difference between the two and may explain in part why 
motor neurons are vulnerable to heat shock
 
(Batulan et al., 2003). This is important 
not only for our understanding of the selective vulnerability of motor neurons in 
motor neuron disease/amyotrophic lateral sclerosis but also in other 
neurodegenerative disorders  such as Alzheimers and Parkinsons disease. Disrupted 
stress pathways in these neurodegenerative diseases are thought to lead to aggregate 
formation in neurons. Once confirmed, these results could lead to the investigation of 
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7. Chapter 7: Discussion 
7.1. Project aims 
In this project the role of eEF1A in motor neuron degeneration was studied. The 
main aims of this project were to increase our understanding of the importance of 
this crucial elongation factor by further studying the wasted (wst) mouse model and 
also by investigating what role it has (if any) in human motor neuron disease. Within 
this research area there were four main aims. Firstly, to ascertain whether there is a 
gene dosage effect of eEF1A2 by examining ageing heterozygote animals for any 
signs of motor neuron degeneration. Secondly, to understand further the pathology of 
wasted mice, tissue specific transgenic animals were examined. Thirdly, human 
spinal cord sections from ALS patients were examined for any changes in eEF1A2, 
which would further validate the wasted mouse model as a model of human motor 
neuron degeneration. Finally, a possible role of eEF1A in the heat shock response 
was investigated. Together, these four projects aimed to improve our understanding 
of the wasted mouse model and to increase our knowledge of the mechanisms 
involved in motor neuron degeneration both in mouse and human disease.    
 
7.2. Gene dosage of eEF1A2 
Ageing mice heterozygous for a mutation in the ZPR1 gene have shown to be a 
useful model for studying motor neuron degeneration (Doran et al., 2006). This, 
combined with the finding that eEF1A (the specific variant was not identified) is 
found in a complex with ZPR1 and SMN (Gangwani et al., 1998), led to the 
investigation of wasted heterozygotes (+/wst) as a possible model for motor neuron 
degeneration. This study is the first to examine ageing heterozygote wasted mice 
(+/wst) for signs of motor neuron degeneration. The grip strength meter proved to be 
an effective tool for measuring disease in wasted mice and so was used in 
combination with the accelerating rotarod to assess any physical differences in the 
ageing cohort. The study showed no statistical difference between wildtype (+/+) 
and heterozygote (+/wst) animals in either male or female mice. However there was 
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a trend for female heterozygous (+/wst) animals to perform slightly worse than 
female wildtype animals (+/+) on the accelerating rotarod. In addition no significant 
pathological differences were observed between the groups. These results suggest 
that ageing heterozygote wasted mice (+/wst) are not a useful model for studying 
motor neuron degeneration, and that 50% of wild-type levels of eEF1A2 are 
sufficient for normal function. This study does however raise some interesting issues 
regarding the impact of gender, age and also exercise/training regimes on the results 
of behavioural studies (as dicussed in chapter 3).  
Although wasted heterozygotes may not be a valuable model for studying motor 
neuron degeneration the important link between eEF1A and ZPR1 should however 
continue to be investigated. The main aim in this regard should be to establish which 
of the eEF1A variants is found to complex with ZPR1. The observation that wasted 
mice have reduced ZPRI (Murray et al., 2008), leads to the possibility that shared 
disease pathways may exist between the wasted model and models of spinal 
muscular atrophy. Results from this study however should be viewed with caution as 
it is possible that ZPR1 may simply be reduced due to disrupted protein synthesis 
resulting from the loss of eEF1A2. Further investigating the function of ZPR1 in 
wasted mice may therefore shed light on our understanding of common pathologies 
between models of motor neuron degeneration and thus improve our understanding 
of the vulnerability of motor neurons in these conditions.  
 
7.3. Tissue specific eEF1A2 expression 
A key question yet to be answered in the wasted mouse is whether the reduction of 
eEF1A2 in muscle has a direct effect on muscle pathology, or whether muscle 
pathology occurs indirectly due to the loss of eEF1A2 in motor neurons. The aim of 
this part of the project was to investigate whether it is the loss of neuronal eEF1A2 
leading to denervation of muscle or the loss of eEF1A2 in muscle, is the primary 
cause of the muscle atrophy in wasted animals. Unfortunately, this could not be fully 
addressed in this study due to the common problem of non-specific transgene 
expression. Transgenic animals expressing only neuronal eEF1A2 were therefore not 
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achieved. The study did, however uncover some potentially interesting findings. The 
generation of a mouse line with normal expression of eEF1A2 in all tissues except 
the heart will allow the role of eEF1A2 in the heart to be studied. The transgenic 
animals generated also offer the opportunity to investigate the so-far unknown role of 
eEF1A2 in other tissues such as the pancreas. While no gross pancreatic dysfunction  
has yet been seen in wasted mice, this may take longer than 28 days (the approximate 
lifespan of a wasted mouse) to manifest. Transgenic animals which survive beyond 
the 28 day stage (such as the NSE-EEF1A2 line B described in this study) may 
therefore be of interest. A diabetes susceptibility locus has been mapped to 20q13.3 
(Rotimi et al., 2004) which is in a similar region to EEF1A2. Expression of eEF1A1 
in the eEF1A2 positive cells should first be investigated, as co-expression cannot yet 
be ruled out which may reduce the impact of the loss of eEF1A2. 
The investigation of mice expressing only neuronal eEF1A2 (i.e no muscle eEF1A2) 
together with the mice expressing only muscle eEF1A2 (i.e. no neuronal eEF1A2 - 
currently under investigation) will increase our understanding of the primary cause of 
the muscle pathology seen in wasted mice. Transgenic animals could also be used to 
investigate the role of eEF1A2 in the heart of wasted mice. In addition to using the 
transgenic line created here (line C), conditional knockouts of eEF1A2 could also be 
generated. These could potentially address the crucial timing of the loss of eEF1A2 
in all tissues and also whether the pathology caused by the loss of eEF1A2 is 
reversible.  This may also aid in our understanding of the ultimate cause of death of 
wasted mice. Likely hypotheses for the cause of death currently centre around the 
loss of eEF1A2 in muscle. The lack of eEF1A in skeletal muscle of wasted animals 
for example may eventually lead to respiratory failure. The transgenic animals 
generated in our lab, which show that muscle specific eEF1A2 do not rescue the 
wasted phenotype begin to contradict this opinion. Alternatively the loss of eEF1A in 
heart may ultimately lead to a cardiac failure. Further tissue specific transgenic 
models together with an investigation into de-novo protein synthesis in the affected 
tissues in wasted mice may help us to address these hypotheses.     
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7.4. eEF1A2 in human disease 
While animal models provide a relatively easy way to investigate the roles of protein 
in human disease, they are limited in their use. Continuing to investigate human 
samples is therefore of fundamental importance. This study highlights a possible role 
for eEF1A2 in human motor neuron disease and is the first (to our knowledge) of 
eEF1A2 being investigated in human spinal cord of patients with motor neuron 
disease. 80% of spinal cords from MND patients studied here showed a decrease in 
the expression of eEF1A2 in their motor neurons. This, combined with previous 
findings (Bakay et al., 2006) showing decreased eEF1A2 expression in muscle 
samples from MND patients highlights the need to further investigate the role of 
eEF1A2 in human motor neuron degeneration. Expanding the findings shown here to 
include larger sample numbers is crucial to gain a more accurate understanding of the 
extent to which eEF1A2 is involved in human disease. Collaborations are currently 
underway to expand this study.  
The recently identified role of TDP-43 (Arai et al., 2006; Neumann et al., 2006) in 
ALS demonstrates the importance of studying pathological samples from human 
disease patients. Animal models are currently being developed to further understand 
its role in the disease process. While these are being developed, mouse models which 
show abnormal TDP-43 expression are now key for furthering our understanding of 
its role in motor neuron degeneration. As shown here wasted mice may be one such 
model. A detailed understanding of TDP-43 in the wasted mouse model should now 
be investigated. While studying inclusions is not possible in the wasted model due to 
the absence of ubiquitinated inclusions, wasted mice may offer insights into the role 
of TDP-43 prior to the formation of inclusions.  Understanding the role of eEF1A 
variants in nuclear transport may also strengthen this study.  
To begin to understand the function of eEF1A2 in human disease copy number 
variation could be investigated in MND patients. In addition the promoter region of 
eEF1A2 should be sequenced, to assess whether any rare mutations in the promoter 
region may be responsible for any ALS cases.  Investigating eEF1A2 in other animal 
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models of motor neuron degeneration and also possibly other neurodegenerative 
diseases may uncover whether eEF1A2 has roles in these.   
The results of this study further emphasise the importance of the wasted mouse 
model for studying human disease. In addition it demonstrates the necessity for 
investigating all possible models of motor neuron degeneration and not just those 
with known mutations in human disease. Collectively information from sporadic 
mouse models may uncover common pathogenic pathways and previously unknown 
factors in human disease. This study has also highlighted some of the difficulties of 
analysing degenerating motor neurons and the importance of understanding how 
protein expression in motor neurons changes during degeneration.   
 
7.5. eEF1A in the heat shock response 
One possible mechanism for the involvement of eEF1A variants in motor neuron 
disease could be through the stress response pathways as shown here in the 
investigation of eEF1A1 and eEF1A2 in the heat shock response. Results show that 
eEF1A1 has a crucial role in the heat shock response and that eEF1A2 does not fully 
share this role. Ablating eEF1A1 disrupted the heat shock response in NSC-34 cells 
while the remaining eEF1A2 was unable to compensate for this loss. This study has 
therefore potentially identified a functional difference between the two variants 
which further expands on our understanding of why we have two variants with 
almost indistinguishable roles in translation. One possible hypothesis might be that 
the role of eEF1A1 in cytoskeletal remodelling is detrimental to motor neurons. They 
therefore express eEF1A2, with the shortcoming of having a poor heat shock 
response as a result. The expression of eEF1A2 rather than eEF1A1 in motor neurons 
may in part explain the vulnerability of motor neurons to heat shock (Batulan et al., 
2003) and may also prove an interesting link between eEF1A and motor neuron 
degeneration.  
The potential therapeutic benefit of eEF1A1 should be investigated further. Ideally 
eEF1A1 would be introduced into cell lines expressing only eEF1A2, to assess for 
any changes in the cells ability to mount a heat shock response. Motor neurons have 
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proven to be very difficult to culture, and to our knowledge, no cell lines expressing 
only eEF1A2 and no eEF1A1 have yet been identified. Many labs are attempting to 
generate motor neuron-like cell lines which, once validated, could be considered for 
this study. For example subsets of motor neurons have been generated from human 
embryonic stem cells in a recent study by Patani et al (Patani et al., 2011). Cells such 
as these could be investigated to determine the expression pattern of eEF1A variants 
to determine if they may be utilised for studies investigating the functional differnces 
between the two variants. 
Further animal models may be also be considered for this investigation. Current work 
in the laboratory is attempting to generate transgenic animals expressing eEF1A1 
under the control of the eEF1A2 promoter which will investigate the potential of 
eEF1A1 (in motor neurons and muscle) to rescue the wasted phenotype.  
Pharmacological compounds which induce the expression of heat shock proteins are 
being investigated as potential therapeutic agents for neurodegenerative disease. 
Arimolcolol, a co-inducer of the heat shock response has been shown to delay 
disease progression and reduce both neuronal loss and aggregate formation in SOD1 
transgenic mice (Kieran et al., 2004; Kalmar et al., 2008). It would be beneficial to 
test compounds such as these on other mouse models that do not arise from SOD1 
mutations, to observe what affect (if any) they may have. It has also been shown that 
targeting multiple HSPs has a greater effect on the reduction in aggregate formation 
in cells (Takeuchi et al., 2002) and has a greater effect on the rescue of SOD1 mutant 
mice than individual HSPs (Patel et al., 2005). Thus targeting factors which may be 
involved in the regulation of multiple HSPs such as HSF1 might be of more 
therapeutic benefit and might also reduce the detrimental side affects of 
overexpression of individual HSPs such as alterations in cell cycle regulation and 
cancer (Mosser and Morimoto 2004). Manipulating the entire heat shock pathway as 
opposed to individual HSPs may therefore achieve greater neuroprotection. 
Arimochol for example acts by prolonging the activity of HSF1 (Kieran et al., 2004), 
resulting in the upregulation of HSP70 and HSP90  resulting in prolonged survival. 
Transgenic expression of HSP70 alone however, does not slow disease progression 
in these mice (Liu et al., 2005). Given that eEF1A1 appears to act on HSF1 which 
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then regulates multiple heat shock factors, it now warrants further investigation as a 
possible therapeutic target for motor neuron degeneration.  
7.6. Conclusion 
The main aim of the project has been achieved; it has improved our understanding of 
the role of eEF1A2 in motor neuron degeneration and has uncovered multiple 
avenues for future research. 
On of the key questions that remain to be answered is; why is eEF1A2 only 
expressed in terminally differentiated cells such as motor neurons. Many functions of 
eEF1A1 have been previously uncovered including cytoskeletal rearrangement and 
nuclear transport. Studies examining the differing roles of the two variants are 
therefore key to an understanding of the parts they may play in disease processes.  
The separate roles of the two variants in nuclear transport for example is of particular 
interest. Findings that eEF1A has been found in a complex with SMN which in turn 
has been found to complex with TDP-43 may provide a link between eEF1A and 
TDP-43. Investigating which variant/s complex with SMN and are involved in 
nuclear transport may therefore be important for our understanding of eEF1A in 
motor neuron degeneration. The wasted mouse is therefore crucial for not only 
improving our understanding of the biology of eEF1A but also the various pathways 
involved in motor neuron degeneration.  
In order to fully understand theses disease processes, multiple avenues of research 
including mouse models, cell models and human samples should be fully 
investigated. All three have been utilised in this study and together are essential for 
the progression of the field. While human tissue shows us the most accurate portrayal 
of what is occurring in tissues of the body during disease, this is usually at the end-
stage of disease. It therefore offers us little insight into the early stages of disease 
progression, where therapeutic intervention may still be a possibility. Models of 
disease are therefore essential for our understanding of the initiation and 
development of disease processes.  
                              Investigating the role of eEF1A2 in motor neuron degeneration 
Chapter 7: Discussion 205 
Cell models provide us with an inexpensive view into proteins of interest. Findings 
in cells can then be extended to the whole animal models to investigate their role in a 
whole biological system. In the past, animal models have allowed further 
investigation of factors identified in human disease and (as demonstrated here) they 
also have the potential to uncover new factors and pathways that may be involved in 
human disease which have yet to be examined. They are of utmost importance in 
multifactorial diseases such as ALS as they allow us to tease apart the complex 
network of events and to investigate the roles of single factors and pathways of 
interest. They also offer the opportunity to investigate and test therapeutic agents. 
With the development of high throughput, detailed genetic analysis such as next 
generation sequencing which in time may uncover a plethora of disease associated 
genes, animal models will be crucial in teasing apart the individual roles of these 
genes. Continuing to investigate and improve animal models is therefore paramount 
for our understanding of neurodegenerative conditions.   
With the prevalence of neurodegenerative disease on the rise, it is now more 
important than ever to understand these conditions. Even with the recent discovery of 
some key players in ALS, the cause of the vast majority of ALS remains unknown. 
There are still many crucial unanswered questions such as; why ubiquitously 
expressed proteins such as SOD1 and TDP-43 cause selective vulnerability of motor 
neurons, and what role do protein aggregates play in disease processes? To address 
these fundamental questions, investigating common features of different 
neurodegenerative disease such as aggregate formation, RNA processing and the 
stress response is crucial. Understanding the normal functions of proteins involved in 
ALS and the identification of shared pathological pathways is vital for the 
development of effective treatments for these debilitating conditions.   
 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 206 
8. References 
Abbott, C., et al. (1994). Linkage mapping around the ragged (Ra) and wasted (wst) 
loci on distal mouse chromosome 2. Genomics 20(1): 94-8. 
Abbott, C. M. and C. G. Proud (2004). Translation factors: in sickness and in health. 
Trends Biochem Sci 29(1): 25-31. 
Aghajanian, G. K. and F. E. Bloom (1967). The formation of synaptic junctions in 
developing rat brain: a quantitative electron microscopic study. Brain Res 
6(4): 716-27. 
Anand, N., et al. (2002). Protein elongation factor EEF1A2 is a putative oncogene in 
ovarian cancer. Nat Genet 31(3): 301-5. 
Ann, D. K., et al. (1991). Isolation and characterization of the rat chromosomal gene 
for a polypeptide (pS1) antigenically related to statin. J Biol Chem 266(16): 
10429-37. 
Arai, T., et al. (2006). TDP-43 is a component of ubiquitin-positive tau-negative 
inclusions in frontotemporal lobar degeneration and amyotrophic lateral 
sclerosis. Biochem Biophys Res Commun 351(3): 602-11. 
Ayala, Y. M., et al. (2008). Structural determinants of the cellular localization and 
shuttling of TDP-43. J Cell Sci 121(Pt 22): 3778-85. 
Bakay, M., et al. (2006). Nuclear envelope dystrophies show a transcriptional 
fingerprint suggesting disruption of Rb-MyoD pathways in muscle 
regeneration. Brain 129(Pt 4): 996-1013. 
Barneoud, P., et al. (1997). Quantitative motor assessment in FALS mice: a 
longitudinal study. Neuroreport 8(13): 2861-5. 
Batulan, Z., et al. (2003). High threshold for induction of the stress response in motor 
neurons is associated with failure to activate HSF1. J Neurosci 23(13): 5789-
98. 
Bechtold, D. A., et al. (2000). Localization of the heat-shock protein Hsp70 to the 
synapse following hyperthermic stress in the brain. J Neurochem 74(2): 641-
6. 
Biedler, J. L., et al. (1973). Morphology and growth, tumorigenicity, and 
cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 
33(11): 2643-52. 
Biedler, J. L., et al. (1978). Multiple neurotransmitter synthesis by human 
neuroblastoma cell lines and clones. Cancer Res 38(11 Pt 1): 3751-7. 
Boillee, S., et al. (2006). ALS: a disease of motor neurons and their nonneuronal 
neighbors. Neuron 52(1): 39-59. 
Brandmeir, N. J., et al. (2008). Severe subcortical TDP-43 pathology in sporadic 
frontotemporal lobar degeneration with motor neuron disease. Acta 
Neuropathol 115(1): 123-31. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 207 
Brown, I. R. (2007). Heat shock proteins and protection of the nervous system. Ann 
N Y Acad Sci 1113: 147-58. 
Bruening, W., et al. (1999). Up-regulation of protein chaperones preserves viability 
of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated 
with amyotrophic lateral sclerosis. J Neurochem 72(2): 693-9. 
Bruijn, L. I., et al. (1997). ALS-linked SOD1 mutant G85R mediates damage to 
astrocytes and promotes rapidly progressive disease with SOD1-containing 
inclusions. Neuron 18(2): 327-38. 
Bruijn, L. I., et al. (2004). Unraveling the mechanisms involved in motor neuron 
degeneration in ALS. Annu Rev Neurosci 27: 723-49. 
Buratti, E., et al. (2004). Nuclear factor TDP-43 binds to the polymorphic TG repeats 
in CFTR intron 8 and causes skipping of exon 9: a functional link with 
disease penetrance. Am J Hum Genet 74(6): 1322-5. 
Buratti, E., et al. (2001). Nuclear factor TDP-43 and SR proteins promote in vitro 
and in vivo CFTR exon 9 skipping. Embo J 20(7): 1774-84. 
Cai, H., et al. (2005). Loss of ALS2 function is insufficient to trigger motor neuron 
degeneration in knock-out mice but predisposes neurons to oxidative stress. J 
Neurosci 25(33): 7567-74. 
Carlson, B. M., et al. (2002). Effects of long-term denervation on skeletal muscle in 
old rats. J Gerontol A Biol Sci Med Sci 57(10): B366-74. 
Caroni, P. (1997). Overexpression of growth-associated proteins in the neurons of 
adult transgenic mice. J Neurosci Methods 71(1): 3-9. 
Cashman, N. R., et al. (1992). Neuroblastoma x spinal cord (NSC) hybrid cell lines 
resemble developing motor neurons. Dev Dyn 194(3): 209-21. 
Chambers, D. M., et al. (1998). The lethal mutation of the mouse wasted (wst) is a 
deletion that abolishes expression of a tissue-specific isoform of translation 
elongation factor 1alpha, encoded by the Eef1a2 gene. Proc Natl Acad Sci U 
S A 95(8): 4463-8. 
Chen, Y. Z., et al. (2004). DNA/RNA helicase gene mutations in a form of juvenile 
amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 74(6): 1128-35. 
Choi, C. I., et al. (2008). Effects of estrogen on lifespan and motor functions in 
female hSOD1 G93A transgenic mice. J Neurol Sci 268(1-2): 40-7. 
Chuang, S. M., et al. (2005). Proteasome-mediated degradation of cotranslationally 
damaged proteins involves translation elongation factor 1A. Mol Cell Biol 
25(1): 403-13. 
Condeelis, J. (1995). Elongation factor 1 alpha, translation and the cytoskeleton. 
Trends Biochem Sci 20(5): 169-70. 
Coovert, D. D., et al. (1997). The survival motor neuron protein in spinal muscular 
atrophy. Hum Mol Genet 6(8): 1205-14. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 208 
Cottrelle, P., et al. (1985). Either one of the two yeast EF-1 alpha genes is required 
for cell viability. Curr Genet 9(8): 693-7. 
Cozzolino, M., et al. (2008). Amyotrophic lateral sclerosis: from current 
developments in the laboratory to clinical implications. Antioxid Redox 
Signal 10(3): 405-43. 
Dal Canto, M. C. and M. E. Gurney (1995). Neuropathological changes in two lines 
of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice 
overexpressing wild type human SOD: a model of familial amyotrophic 
lateral sclerosis (FALS). Brain Res 676(1): 25-40. 
Dalbello-Haas, V., et al. (2008). Therapeutic exercise for people with amyotrophic 
lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev(2): 
CD005229. 
de Luca, C., et al. (2005). Complete rescue of obesity, diabetes, and infertility in 
db/db mice by neuron-specific LEPR-B transgenes. J Clin Invest 115(12): 
3484-93. 
Dennis, J. S. and B. A. Citron (2009). Wobbler mice modeling motor neuron disease 
display elevated transactive response DNA binding protein. Neuroscience 
158(2): 745-50. 
Derventzi, A., et al. (1993). Phorbol ester PMA stimulates protein synthesis and 
increases the levels of active elongation factors EF-1 alpha and EF-2 in 
ageing human fibroblasts. Mech Ageing Dev 69(3): 193-205. 
Dharmasaroja, P. (2007). The Role of eEF1A2 in the Pathogenesis of Motor Neurone 
Disease in Wasted Mice. PhD Thesis. 
DiBernardo, A. B. and M. E. Cudkowicz (2006). Translating preclinical insights into 
effective human trials in ALS. Biochim Biophys Acta 1762(11-12): 1139-49. 
Dion, P. A., et al. (2009). Genetics of motor neuron disorders: new insights into 
pathogenic mechanisms. Nat Rev Genet 10(11): 769-82. 
Doran, B., et al. (2006). Deficiency of the zinc finger protein ZPR1 causes 
neurodegeneration. Proc Natl Acad Sci U S A 103(19): 7471-5. 
Duttaroy, A., et al. (1998). Apoptosis rate can be accelerated or decelerated by 
overexpression or reduction of the level of elongation factor-1 alpha. Exp 
Cell Res 238(1): 168-76. 
Ejiri, S. (2002). Moonlighting functions of polypeptide elongation factor 1: from 
actin bundling to zinc finger protein R1-associated nuclear localization. 
Biosci Biotechnol Biochem 66(1): 1-21. 
Evgrafov, O. V., et al. (2004). Mutant small heat-shock protein 27 causes axonal 
Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat 
Genet 36(6): 602-6. 
Fischer, L. R., et al. (2004). Amyotrophic lateral sclerosis is a distal axonopathy: 
evidence in mice and man. Exp Neurol 185(2): 232-40. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 209 
Forss-Petter, S., et al. (1990). Transgenic mice expressing beta-galactosidase in 
mature neurons under neuron-specific enolase promoter control. Neuron 5(2): 
187-97. 
Fujita, K., et al. (1998). Increases in fragmented glial fibrillary acidic protein levels 
in the spinal cords of patients with amyotrophic lateral sclerosis. Neurochem 
Res 23(2): 169-74. 
Gangwani, L., et al. (1998). Interaction of ZPR1 with translation elongation factor-
1alpha in proliferating cells. J Cell Biol 143(6): 1471-84. 
Gangwani, L., et al. (2001). Spinal muscular atrophy disrupts the interaction of ZPR1 
with the SMN protein. Nat Cell Biol 3(4): 376-83. 
Gkogkas, C., et al. (2008). VAPB interacts with and modulates the activity of ATF6. 
Hum Mol Genet 17(11): 1517-26. 
Greene, L. A. and A. S. Tischler (1976). Establishment of a noradrenergic clonal line 
of rat adrenal pheochromocytoma cells which respond to nerve growth factor. 
Proc Natl Acad Sci U S A 73(7): 2424-8. 
Greenway, M. J., et al. (2006). ANG mutations segregate with familial and 'sporadic' 
amyotrophic lateral sclerosis. Nat Genet 38(4): 411-3. 
Groeneveld, G. J., et al. (2004). Ovariectomy and 17beta-estradiol modulate disease 
progression of a mouse model of ALS. Brain Res 1021(1): 128-31. 
Gurney, M. E., et al. (1994). Motor neuron degeneration in mice that express a 
human Cu,Zn superoxide dismutase mutation. Science 264(5166): 1772-5. 
Gustafsdottir, S. M., et al. (2005). Proximity ligation assays for sensitive and specific 
protein analyses. Anal Biochem 345(1): 2-9. 
Hadano, S., et al. (2001). A gene encoding a putative GTPase regulator is mutated in 
familial amyotrophic lateral sclerosis 2. Nat Genet 29(2): 166-73. 
Hall, T. A. (1999). BioEdit: a user-friendly biological sequence alignment editor and 
analysis program for Windows 95/98/NT Nucleic Acids Symposium Series 
41: 95-98. 
Hartman, T. K., et al. (2007). Mutant mice with small amounts of BubR1 display 
accelerated age-related gliosis. Neurobiol Aging 28(6): 921-7. 
Hasegawa, M., et al. (2008). Phosphorylated TDP-43 in frontotemporal lobar 
degeneration and amyotrophic lateral sclerosis. Ann Neurol 64(1): 60-70. 
Hatayama, T., et al. (1997). Reduced induction of HSP70 in PC12 cells during 
neuronal differentiation. J Biochem 122(5): 904-10. 
Heiman-Patterson, T. D., et al. (2005). Background and gender effects on survival in 
the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci 236(1-2): 1-
7. 
Helmken, C., et al. (2003). Evidence for a modifying pathway in SMA discordant 
families: reduced SMN level decreases the amount of its interacting partners 
and Htra2-beta1. Hum Genet 114(1): 11-21. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 210 
Hershey, J. W. (1991). Translational control in mammalian cells. Annu Rev Biochem 
60: 717-55. 
Hu, C. D., et al. (2002). Visualization of interactions among bZIP and Rel family 
proteins in living cells using bimolecular fluorescence complementation. Mol 
Cell 9(4): 789-98. 
Hwang, D. Y., et al. (2002). Alterations in behavior, amyloid beta-42, caspase-3, and 
Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. Faseb 
J 16(8): 805-13. 
Inukai, Y., et al. (2008). Abnormal phosphorylation of Ser409/410 of TDP-43 in 
FTLD-U and ALS. FEBS Lett 582(19): 2899-904. 
Irobi, J., et al. (2004). Hot-spot residue in small heat-shock protein 22 causes distal 
motor neuropathy. Nat Genet 36(6): 597-601. 
Kahns, S., et al. (1998). The elongation factor 1 A-2 isoform from rabbit: cloning of 
the cDNA and characterization of the protein. Nucleic Acids Res 26(8): 1884-
90. 
Kalmar, B., et al. (2008). Late stage treatment with arimoclomol delays disease 
progression and prevents protein aggregation in the SOD1 mouse model of 
ALS. J Neurochem 107(2): 339-50. 
Khacho, M., et al. (2008). eEF1A is a novel component of the mammalian nuclear 
protein export machinery. Mol Biol Cell 19(12): 5296-308. 
Khalyfa, A., et al. (2001). Characterization of elongation factor-1A (eEF1A-1) and 
eEF1A-2/S1 protein expression in normal and wasted mice. J Biol Chem 
276(25): 22915-22. 
Khalyfa, A., et al. (2003). Changes in protein levels of elongation factors, eEF1A-1 
and eEF1A-2/S1, in long-term denervated rat muscle. Restor Neurol Neurosci 
21(1-2): 47-53. 
Kieran, D., et al. (2004). Treatment with arimoclomol, a coinducer of heat shock 
proteins, delays disease progression in ALS mice. Nat Med 10(4): 402-5. 
Kirkinezos, I. G., et al. (2003). Regular exercise is beneficial to a mouse model of 
amyotrophic lateral sclerosis. Ann Neurol 53(6): 804-7. 
Knippenberg, S., et al. (2010). Significance of behavioural tests in a transgenic 
mouse model of amyotrophic lateral sclerosis (ALS). Behav Brain Res. 
Knudsen, S. M., et al. (1993). Tissue-dependent variation in the expression of 
elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA 
encoding a novel variant of human elongation-factor 1 alpha. Eur J Biochem 
215(3): 549-54. 
Kohama, S. G., et al. (1995). Increases of glial fibrillary acidic protein in the aging 
female mouse brain. Neurobiol Aging 16(1): 59-67. 
Kugel, J. F. and J. A. Goodrich (2006). Beating the heat: A translation factor and an 
RNA mobilize the heat shock transcription factor HSF1. Mol Cell 22(2): 153-
4. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 211 
Kunst, C. B., et al. (2000). Genetic mapping of a mouse modifier gene that can 
prevent ALS onset. Genomics 70(2): 181-9. 
Kwiatkowski, T. J., Jr., et al. (2009). Mutations in the FUS/TLS gene on 
chromosome 16 cause familial amyotrophic lateral sclerosis. Science 
323(5918): 1205-8. 
Lagier-Tourenne, C. and D. W. Cleveland (2009). Rethinking ALS: the FUS about 
TDP-43. Cell 136(6): 1001-4. 
Laird, F. M., et al. (2008). Motor neuron disease occurring in a mutant dynactin 
mouse model is characterized by defects in vesicular trafficking. J Neurosci 
28(9): 1997-2005. 
Landers, J. E., et al. (2008). A common haplotype within the PON1 promoter region 
is associated with sporadic ALS. Amyotroph Lateral Scler 9(5): 306-14. 
Larsen, J. O., et al. (2000). Does long-term physical exercise counteract age-related 
Purkinje cell loss? A stereological study of rat cerebellum. J Comp Neurol 
428(2): 213-22. 
Le Sourd, F., et al. (2006). Cellular coexistence of two high molecular subsets of 
eEF1B complex. FEBS Lett 580(11): 2755-60. 
Lee, S., et al. (1994). Cloning of human and mouse brain cDNAs coding for S1, the 
second member of the mammalian elongation factor-1 alpha gene family: 
analysis of a possible evolutionary pathway. Biochem Biophys Res Commun 
203(3): 1371-7. 
Lee, S., et al. (1992). Tissue-specific expression in mammalian brain, heart, and 
muscle of S1, a member of the elongation factor-1 alpha gene family. J Biol 
Chem 267(33): 24064-8. 
Lee, S., et al. (1995). Terminal differentiation-dependent alteration in the expression 
of translation elongation factor-1 alpha and its sister gene, S1, in neurons. 
Exp Cell Res 219(2): 589-97. 
Lee, S., et al. (1993). Differential expression of S1 and elongation factor-1 alpha 
during rat development. J Biol Chem 268(32): 24453-9. 
Leegwater, P. A., et al. (2001). Subunits of the translation initiation factor eIF2B are 
mutant in leukoencephalopathy with vanishing white matter. Nat Genet 
29(4): 383-8. 
Lefebvre, S., et al. (1995). Identification and characterization of a spinal muscular 
atrophy-determining gene. Cell 80(1): 155-65. 
Lefebvre, S., et al. (1997). Correlation between severity and SMN protein level in 
spinal muscular atrophy. Nat Genet 16(3): 265-9. 
Leigh, P. N., et al. (1988). Ubiquitin deposits in anterior horn cells in motor neurone 
disease. Neurosci Lett 93(2-3): 197-203. 
Leigh, P. N., et al. (1991). Ubiquitin-immunoreactive intraneuronal inclusions in 
amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 
114 ( Pt 2): 775-88. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 212 
Li, X., et al. (2009). Mutant copper-zinc superoxide dismutase associated with 
amyotrophic lateral sclerosis binds to adenine/uridine-rich stability elements 
in the vascular endothelial growth factor 3'-untranslated region. J Neurochem 
108(4): 1032-44. 
Liu, J., et al. (2005). Elevation of the Hsp70 chaperone does not effect toxicity in 
mouse models of familial amyotrophic lateral sclerosis. J Neurochem 93(4): 
875-82. 
Loh, D. (2003). Analysis of the role of eukaryotic elongation factor 1 alpha-2 
(eEF1A-2) in the Wasted mouse mutant. PhD Thesis. 
Lowenstein, D. H., et al. (1991). The stress protein response in cultured neurons: 
characterization and evidence for a protective role in excitotoxicity. Neuron 
7(6): 1053-60. 
Lu, L., et al. (2007). Mutant Cu/Zn-superoxide dismutase associated with 
amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor 
mRNA and downregulates its expression. J Neurosci 27(30): 7929-38. 
Ludolph, A. C., et al. (2010). Guidelines for preclinical animal research in 
ALS/MND: A consensus meeting. Amyotroph Lateral Scler 11(1-2): 38-45. 
Ludolph, A. C. and A. D. Sperfeld (2005). Preclinical trials--an update on 
translational research in ALS. Neurodegener Dis 2(3-4): 215-9. 
Lund, A., et al. (1996). Assignment of human elongation factor 1alpha genes: 
EEF1A maps to chromosome 6q14 and EEF1A2 to 20q13.3. Genomics 36(2): 
359-61. 
Lutsep, H. L. and M. Rodriguez (1989). Ultrastructural, morphometric, and 
immunocytochemical study of anterior horn cells in mice with "wasted" 
mutation. J Neuropathol Exp Neurol 48(5): 519-33. 
Mackenzie, I. R., et al. (2007). Pathological TDP-43 distinguishes sporadic 
amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 
mutations. Ann Neurol 61(5): 427-34. 
Maddatu, T. P., et al. (2004). Transgenic rescue of neurogenic atrophy in the nmd 
mouse reveals a role for Ighmbp2 in dilated cardiomyopathy. Hum Mol Genet 
13(11): 1105-15. 
Mansilla, F., et al. (2002). Mapping the human translation elongation factor eEF1H 
complex using the yeast two-hybrid system. Biochem J 365(Pt 3): 669-76. 
Markowitz, J. A., et al. (2004). Spinal muscular atrophy in the neonate. J Obstet 
Gynecol Neonatal Nurs 33(1): 12-20. 
Mercado, P. A., et al. (2005). Depletion of TDP 43 overrides the need for exonic and 
intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res 
33(18): 6000-10. 
Merrick, W. C., Nyborg, J. (2000). The protein biosynthesis elongation cycle. In 
Translational Control of Gene Expression. Cold Sping Harbor Laboratory 
Press, Cold Spring Harbor, NY.: 89-125. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 213 
Messer, A., et al. (1999). An early-onset congenic strain of the motor neuron 
degeneration (mnd) mouse. Mol Genet Metab 66(4): 393-7. 
Migheli, A., et al. (1999). S-100beta protein is upregulated in astrocytes and motor 
neurons in the spinal cord of patients with amyotrophic lateral sclerosis. 
Neurosci Lett 261(1-2): 25-8. 
Mishra, A. K., et al. (2007). Structural insights into the interaction of the 
evolutionarily conserved ZPR1 domain tandem with eukaryotic EF1A, 
receptors, and SMN complexes. Proc Natl Acad Sci U S A 104(35): 13930-5. 
Mitsumoto, H. and W. G. Bradley (1982). Murine motor neuron disease (the wobbler 
mouse): degeneration and regeneration of the lower motor neuron. Brain 105 
(Pt 4): 811-34. 
Miura, P., et al. (2010). The utrophin A 5'-UTR drives cap-independent translation 
exclusively in skeletal muscles of transgenic mice and interacts with eEF1A2. 
Hum Mol Genet 19(7): 1211-20. 
Moisse, K., et al. (2009a). Cytosolic TDP-43 expression following axotomy is 
associated with caspase 3 activation in NFL-/- mice: support for a role for 
TDP-43 in the physiological response to neuronal injury. Brain Res 1296: 
176-86. 
Moisse, K., et al. (2009b). Divergent patterns of cytosolic TDP-43 and neuronal 
progranulin expression following axotomy: implications for TDP-43 in the 
physiological response to neuronal injury. Brain Res 1249: 202-11. 
Morimoto, R. I. (1998). Regulation of the heat shock transcriptional response: cross 
talk between a family of heat shock factors, molecular chaperones, and 
negative regulators. Genes Dev 12(24): 3788-96. 
Mosser, D. D. and R. I. Morimoto (2004). Molecular chaperones and the stress of 
oncogenesis. Oncogene 23(16): 2907-18. 
Mouton, P. R., et al. (2002). Age and gender effects on microglia and astrocyte 
numbers in brains of mice. Brain Res 956(1): 30-5. 
Muchowski, P. J. and J. L. Wacker (2005). Modulation of neurodegeneration by 
molecular chaperones. Nat Rev Neurosci 6(1): 11-22. 
Mullen, R. J., et al. (1992). NeuN, a neuronal specific nuclear protein in vertebrates. 
Development 116(1): 201-11. 
Munoz, D. G., et al. (1988). Accumulation of phosphorylated neurofilaments in 
anterior horn motoneurons of amyotrophic lateral sclerosis patients. J 
Neuropathol Exp Neurol 47(1): 9-18. 
Murray, J. W., et al. (1996). Bundling of actin filaments by elongation factor 1 alpha 
inhibits polymerization at filament ends. J Cell Biol 135(5): 1309-21. 
Murray, L. M., et al. (2008). Loss of translation elongation factor (eEF1A2) 
expression in vivo differentiates between Wallerian degeneration and dying-
back neuronal pathology. J Anat 213(6): 633-45. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 214 
Nagy, D., et al. (1994). Reactive astrocytes are widespread in the cortical gray matter 
of amyotrophic lateral sclerosis. J Neurosci Res 38(3): 336-47. 
Neumann, M., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar 
degeneration and amyotrophic lateral sclerosis. Science 314(5796): 130-3. 
Newbery, H. J. (2003). The role of eEF1A-2 in the pathogenesis of Motor Neuron 
Disease. PhD Thesis. 
Newbery, H. J., et al. (2005). Progressive loss of motor neuron function in wasted 
mice: effects of a spontaneous null mutation in the gene for the eEF1 A2 
translation factor. J Neuropathol Exp Neurol 64(4): 295-303. 
Newbery, H. J., et al. (2007). Translation elongation factor eEF1A2 is essential for 
post-weaning survival in mice. J Biol Chem 282(39): 28951-9. 
Nishimura, A. L., et al. (2004). A mutation in the vesicle-trafficking protein VAPB 
causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. 
Am J Hum Genet 75(5): 822-31. 
O'Callaghan, J. P. and D. B. Miller (1991). The concentration of glial fibrillary acidic 
protein increases with age in the mouse and rat brain. Neurobiol Aging 12(2): 
171-4. 
Oosthuyse, B., et al. (2001). Deletion of the hypoxia-response element in the 
vascular endothelial growth factor promoter causes motor neuron 
degeneration. Nat Genet 28(2): 131-8. 
Ou, S. H., et al. (1995). Cloning and characterization of a novel cellular protein, 
TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA 
sequence motifs. J Virol 69(6): 3584-96. 
Pan, J., et al. (2004). Immuno-characterization of the switch of peptide elongation 
factors eEF1A-1/EF-1alpha and eEF1A-2/S1 in the central nervous system 
during mouse development. Brain Res Dev Brain Res 149(1): 1-8. 
Pape, T., et al. (1998). Complete kinetic mechanism of elongation factor Tu-
dependent binding of aminoacyl-tRNA to the A site of the E. coli ribosome. 
Embo J 17(24): 7490-7. 
Pasinelli, P. and R. H. Brown (2006). Molecular biology of amyotrophic lateral 
sclerosis: insights from genetics. Nat Rev Neurosci 7(9): 710-23. 
Patani, R., et al. (2011). Retinoid-independent motor neurogenesis from human 
embryonic stem cells reveals a medial columnar ground state. Nat Commun 
2: 214. 
Patel, Y. J., et al. (2005). Hsp27 and Hsp70 administered in combination have a 
potent protective effect against FALS-associated SOD1-mutant-induced cell 
death in mammalian neuronal cells. Brain Res Mol Brain Res 134(2): 256-74. 
Pellizzoni, L., et al. (1998). A novel function for SMN, the spinal muscular atrophy 
disease gene product, in pre-mRNA splicing. Cell 95(5): 615-24. 
Puls, I., et al. (2003). Mutant dynactin in motor neuron disease. Nat Genet 33(4): 
455-6. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 215 
Robertson, J., et al. (2007). Lack of TDP-43 abnormalities in mutant SOD1 
transgenic mice shows disparity with ALS. Neurosci Lett 420(2): 128-32. 
Rodnina, M. V., et al. (1997). Hydrolysis of GTP by elongation factor G drives 
tRNA movement on the ribosome. Nature 385(6611): 37-41. 
Rosen, D. R., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are 
associated with familial amyotrophic lateral sclerosis. Nature 362(6415): 59-
62. 
Rotimi, C. N., et al. (2004). A genome-wide search for type 2 diabetes susceptibility 
genes in West Africans: the Africa America Diabetes Mellitus (AADM) 
Study. Diabetes 53(3): 838-41. 
Ruest, L. B., et al. (2002). Peptide elongation factor eEF1A-2/S1 expression in 
cultured differentiated myotubes and its protective effect against caspase-3-
mediated apoptosis. J Biol Chem 277(7): 5418-25. 
Sasaki, S. (2010). Endoplasmic reticulum stress in motor neurons of the spinal cord 
in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 69(4): 
346-55. 
Saxena, S. K., et al. (1992). Angiogenin is a cytotoxic, tRNA-specific ribonuclease 
in the RNase A superfamily. J Biol Chem 267(30): 21982-6. 
Schmidt, E. K., et al. (2009). SUnSET, a nonradioactive method to monitor protein 
synthesis. Nat Methods 6(4): 275-7. 
Selkoe, D. J. (2001). Alzheimer's disease results from the cerebral accumulation and 
cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3(1): 75-80. 
Shamovsky, I., et al. (2006). RNA-mediated response to heat shock in mammalian 
cells. Nature 440(7083): 556-60. 
Sharp, P., et al. (2006). Heat shock protein 27 rescues motor neurons following nerve 
injury and preserves muscle function. Exp Neurol 198(2): 511-8. 
Sharp, P. S., et al. (2008). Protective effects of heat shock protein 27 in a model of 
ALS occur in the early stages of disease progression. Neurobiol Dis 30(1): 
42-55. 
Shaw, P. J. and C. J. Eggett (2000). Molecular factors underlying selective 
vulnerability of motor neurons to neurodegeneration in amyotrophic lateral 
sclerosis. J Neurol 247 Suppl 1: I17-27. 
Shi, Y., et al. (1998). Molecular chaperones as HSF1-specific transcriptional 
repressors. Genes Dev 12(5): 654-66. 
Shim, S. B., et al. (2007). Tau overexpression in transgenic mice induces glycogen 
synthase kinase 3beta and beta-catenin phosphorylation. Neuroscience 
146(2): 730-40. 
Shultz, L. D., et al. (1982). 'Wasted', a new mutant of the mouse with abnormalities 
characteristic to ataxia telangiectasia. Nature 297(5865): 402-4. 
Silver, L. M. (1995). Mouse genetics: concepts and applications. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 216 
Slobin, L. I. (1980). The role of eucaryotic factor Tu in protein synthesis. The 
measurement of the elongation factor Tu content of rabbit reticulocytes and 
other mammalian cells by a sensitive radioimmunoassay. Eur J Biochem 
110(2): 555-63. 
Smeitink, J. A., et al. (2006). Distinct clinical phenotypes associated with a mutation 
in the mitochondrial translation elongation factor EFTs. Am J Hum Genet 
79(5): 869-77. 
Spillantini, M. G., et al. (1997). Alpha-synuclein in Lewy bodies. Nature 388(6645): 
839-40. 
Strong, M. J., et al. (2007). TDP43 is a human low molecular weight neurofilament 
(hNFL) mRNA-binding protein. Mol Cell Neurosci 35(2): 320-7. 
Takeuchi, H., et al. (2002). Hsp70 and Hsp40 improve neurite outgrowth and 
suppress intracytoplasmic aggregate formation in cultured neuronal cells 
expressing mutant SOD1. Brain Res 949(1-2): 11-22. 
Tan, C. F., et al. (2007). TDP-43 immunoreactivity in neuronal inclusions in familial 
amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta 
Neuropathol 113(5): 535-42. 
Thompson, J. D., et al. (1994). CLUSTAL W: improving the sensitivity of 
progressive multiple sequence alignment through sequence weighting, 
position-specific gap penalties and weight matrix choice. Nucleic Acids Res 
22(22): 4673-80. 
Tomlinson, V. (2007). The putative oncogene EEF1A2 and its role in breast and 
ovarian cancer. PhD Thesis. 
Tomlinson, V. A., et al. (2005). Translation elongation factor eEF1A2 is a potential 
oncoprotein that is overexpressed in two-thirds of breast tumours. BMC 
Cancer 5: 113. 
Tovar, Y. R. L. B., et al. (2009). Experimental models for the study of 
neurodegeneration in amyotrophic lateral sclerosis. Mol Neurodegener 4: 31. 
Tudor, E. L., et al. (2010). Amyotrophic lateral sclerosis mutant vesicle-associated 
membrane protein-associated protein-B transgenic mice develop TAR-DNA-
binding protein-43 pathology. Neuroscience 167(3): 774-85. 
Turner, B. J., et al. (2008). TDP-43 expression in mouse models of amyotrophic 
lateral sclerosis and spinal muscular atrophy. BMC Neurosci 9: 104. 
van Praag, H., et al. (1999). Running increases cell proliferation and neurogenesis in 
the adult mouse dentate gyrus. Nat Neurosci 2(3): 266-70. 
Vance, C., et al. (2009). Mutations in FUS, an RNA processing protein, cause 
familial amyotrophic lateral sclerosis type 6. Science 323(5918): 1208-11. 
Veldink, J. H., et al. (2003). Sexual differences in onset of disease and response to 
exercise in a transgenic model of ALS. Neuromuscul Disord 13(9): 737-43. 
Voellmy, R. (2004). On mechanisms that control heat shock transcription factor 
activity in metazoan cells. Cell Stress Chaperones 9(2): 122-33. 
                              Investigating the role of eEF1A2 in motor neuron degeneration 
References 217 
Wain, L. V., et al. (2009). The role of copy number variation in susceptibility to 
amyotrophic lateral sclerosis: genome-wide association study and comparison 
with published loci. PLoS One 4(12): e8175. 
Wang, I. F., et al. (2002). Higher order arrangement of the eukaryotic nuclear bodies. 
Proc Natl Acad Sci U S A 99(21): 13583-8. 
Wang, I. F., et al. (2008a). TDP-43, the signature protein of FTLD-U, is a neuronal 
activity-responsive factor. J Neurochem 105(3): 797-806. 
Wang, X., et al. (2008b). Induced ncRNAs allosterically modify RNA-binding 
proteins in cis to inhibit transcription. Nature 454(7200): 126-30. 
Watanabe, M., et al. (2001). Histological evidence of protein aggregation in mutant 
SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. 
Neurobiol Dis 8(6): 933-41. 
Weber, U. J., et al. (1997). Total number and size distribution of motor neurons in 
the spinal cord of normal and EMC-virus infected mice--a stereological 
study. J Anat 191 ( Pt 3): 347-53. 
Wong, P. C., et al. (1995). An adverse property of a familial ALS-linked SOD1 
mutation causes motor neuron disease characterized by vacuolar degeneration 
of mitochondria. Neuron 14(6): 1105-16. 
Xu, Z. P., et al. (2002). The nuclear function of angiogenin in endothelial cells is 
related to rRNA production. Biochem Biophys Res Commun 294(2): 287-92. 
Yang, L., et al. (1998). Oncoprotein TLS interacts with serine-arginine proteins 
involved in RNA splicing. J Biol Chem 273(43): 27761-4. 
Yang, Y., et al. (2001). The gene encoding alsin, a protein with three guanine-
nucleotide exchange factor domains, is mutated in a form of recessive 
amyotrophic lateral sclerosis. Nat Genet 29(2): 160-5. 
Yeo, G., et al. (2004). Variation in alternative splicing across human tissues. Genome 
Biol 5(10): R74. 
Zinszner, H., et al. (1997). TLS (FUS) binds RNA in vivo and engages in nucleo-
cytoplasmic shuttling. J Cell Sci 110 ( Pt 15): 1741-50. 
 
 
 
 
